

71354

From: Chan, Christina
S nt: Thursday, July 18, 2002 4:21 PM
To: Sullivan, Daniel; STIC-Biotech/ChemLib
Subject: RE: CDB Search Request for 2 month amended

Pl ase rush. Thanks Chris

-----Original Message-----

From: Sullivan, Daniel
Sent: Thursday, July 18, 2002 4:06 PM
T : Chan, Christina
Subject: FW: CDB Search Request for 2 month amended
Imp rtance: High

Hi Chris,

Could you please approve this search request for me? Thanks.

Dan

-----Original Message-----

From: Sullivan, Daniel
Sent: Thursday, July 18, 2002 3:55 PM
T : STIC-Biotech/ChemLib
Subject: CDB Search Request for 2 month amended
Imp rtance: High

Please do a **RUSH** search for two month amended case **09/754014**, nucleic acids 1-9, 16-22, and 25-45 of SEQ ID NO: 10 against the commercial or interference nucleic acid databases or both. If possible, the search can be limited to noncoding sequences within plasmids.

Thanks very much.

Daniel M. Sullivan
 Examiner AU 1636
 Room: 12D12
 Mail Box: 11E12
 Tel: 703-305-4448

Point of Contact:
 Beverly Shears
 Technical Info. Specialist
 CM1 1E05 Tel: 308-4994

RECEIVED
 JUL 18 2002
 (STIC)

Searcher: _____
 Phone: _____
 Location: _____
 Date Picked Up: _____
 Date Completed: _____
 Searcher Prep/Review: _____
 Clerical: _____
 Online time: _____

TYPE OF SEARCH:

NA Sequences: _____
 AA Sequences: _____
 Structures: _____
 Bibliographic: _____
 Litigation: _____
 Full text: _____
 Patent Family: _____
 Other: _____

VENDOR/COST (where applic.)

STN: _____
 DIALOG: _____
 Questel/Orbit: _____
 DRLink: _____
 Lexis/Nexis: _____
 Sequence Sys.: _____
 WWW/Internet: _____
 Other (specify): _____

THIS PAGE BLANK (USPTO)

SEARCH REQUEST FORM

Requestor's Name: _____ Serial Number: _____
Date: _____ Phone: _____ Art Unit: _____

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

STAFF USE ONLY

Date completed: 07-22-02
Searcher: Beverly C 4994
Terminal time: 20
Elapsed time: _____
CPU time: _____
Total time: 25
Number of Searches: _____
Number of Databases: 1

Search Site

_____ STIC
_____ CM-1
_____ Pre-S

Type of Search

_____ N.A. Sequence
_____ A.A. Sequence
_____ Structure
_____ Bibliographic

Vendors

_____ IG
_____ STN
_____ Dialog
_____ APS
_____ Geninfo
_____ SDC
_____ DARC/Questel
☒ Other CGN

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 21, 2002, 09:45:13 ; Search time 2038.31 Seconds
(without alignments)
71.866 Million cell updates/sec

Title: US-09-754-014-10_COPY_16_22
Perfect score: 7
Sequence: 1 TACTAAC 7

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1797656 seqs, 10463268293 residues

Total number of hits satisfying chosen parameters: 3595312

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : GenEmbl.*

- 1: gb_ba.*
- 2: gb_htg.*
- 3: gb_in.*
- 4: gb_om.*
- 5: gb_ov.*
- 6: gb_pat.*
- 7: gb_ph.*
- 8: gb_pl.*
- 9: gb_pr.*
- 10: gb_ro.*
- 11: gb_sts.*
- 12: gb_sy.*
- 13: gb_un.*
- 14: gb_vl.*
- 15: em_ba.*
- 16: em_fun.*
- 17: em_hum.*
- 18: em_in.*
- 19: em_mu.*
- 20: em_om.*
- 21: em_or.*
- 22: em_ov.*
- 23: em_pat.*
- 24: em_ph.*
- 25: em_pl.*
- 26: em_ro.*
- 27: em_sts.*
- 28: em_un.*
- 29: em_vi.*
- 30: em_htg_hum.*
- 31: em_htg_inv.*
- 32: em_htg_other.*
- 33: em_htgo_inv.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
------------	-------	-------------	--------	----	-------------

1	7	100.0	7	AX203149	AX203149
2	7	100.0	11	AX175038	Sequence
3	7	100.0	11	AX175039	Sequence
4	7	100.0	12	AR121253	Sequence
5	7	100.0	13	AR037996	Sequence
6	7	100.0	13	AR039094	Sequence
7	7	100.0	13	AR050339	Sequence
8	7	100.0	13	AR062898	Sequence
9	7	100.0	14	I76088	Sequence 4
10	7	100.0	17	AR039499	Sequence
11	7	100.0	17	AR039501	Sequence
12	7	100.0	17	AR039503	Sequence
13	7	100.0	17	AR040467	Sequence
14	7	100.0	17	AR040469	Sequence
15	7	100.0	17	AR040471	Sequence
16	7	100.0	17	AR040473	Sequence
17	7	100.0	17	AX214703	Sequence
18	7	100.0	17	AX214704	Sequence
19	7	100.0	17	AX214705	Sequence
20	7	100.0	17	AX214706	Sequence
21	7	100.0	17	AX214707	Sequence
22	7	100.0	17	AX216434	Sequence
23	7	100.0	17	AX216435	Sequence
24	7	100.0	17	AX216696	Sequence
25	7	100.0	17	AX217512	Sequence
26	7	100.0	17	AX217513	Sequence
27	7	100.0	17	AX217514	Sequence
28	7	100.0	17	AX217873	Sequence
29	7	100.0	17	AX217874	Sequence
30	7	100.0	17	AX217875	Sequence
31	7	100.0	17	AX217876	Sequence
32	7	100.0	17	AX217877	Sequence
33	7	100.0	17	AX218189	Sequence
34	7	100.0	17	AX325433	Sequence
35	7	100.0	17	AX325434	Sequence
36	7	100.0	17	E01964	E01964 DNA encodin
37	7	100.0	17	E03611	E03611 DNA primer
38	7	100.0	17	I26214	I26214 Sequence 3
39	7	100.0	18	A68284	A68284 Sequence 5
40	7	100.0	18	AR062161	AR062161 Sequence
41	7	100.0	18	AR083039	AR083039 Sequence
42	7	100.0	18	AR108111	AR108111 Sequence
43	7	100.0	18	AR124377	AR124377 Sequence
44	7	100.0	18	AX003354	AX003354 Sequence
45	7	100.0	19	A22790	A22790 NCA HCV pro

ALIGNMENTS

RESULT 1	AX203149	AX203149	Sequence 2 from Patent WO0153529.	7 bp	mRNA	linear	PAT 30-AUG-2001
LOCUS	AX203149	Sequence 2 from Patent WO0153529.					
DEFINITION	AX203149	AX203149	GI:15392500				
ACCESSION	AX203149	AX203149	GI:15392500				
VERSION	AX203149.1	AX203149.1	GI:15392500				
KEYWORDS		synthetic construct.					
SOURCE		synthetic construct.					
ORGANISM		artificial sequence.					
REFERENCE		1 (bases 1 to 7)					
AUTHORS		Thomann,H.U. and Fitzgerald,M.S.					
TITLE		Rapid determination of gene structure using cdna sequence					
JOURNAL		Patent: WO 0153529-A 2 26-JUL-2001;					
FEATURES		Genome Therapeutics Corporation (US)					
		Location/Qualifiers					
		1..7					
		/organism="synthetic construct"					
		/db_xref="taxon:32630"					
		/note="Yeast consensus branch site"					
BASE COUNT		3 a	2 c	0 g			
ORIGIN							

```

Query Match      100.0%; Score 7; DB 6; Length 7;
Best Local Similarity 100.0%; Pred. No. 3e+09;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 1 TACTAAC 7

RESULT 2
AXI175038/c
LOCUS AXI175038 11 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 27 from Patent WO0142493.
ACCESSION AXI175038
VERSION AXI175038.2 GI:15142057
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 11)
AUTHORS Olek,A. and Piepenbrock,C.
TITLE Method for the parallel detection of the degree of methylation of
genomic dna
JOURNAL Patent: WO 0142493-A 27 14-JUN-2001;
COMMENT Epigenomics AG (DE)
FEATURES
    source
        Location/Qualifiers
            1..11
                /organism="synthetic construct"
                /db_xref="taxon:32630"
                /note="chemisch vorbehandelte Genom-DNA"
BASE COUNT 3 a 0 c 4 g 4 t
ORIGIN

Query Match      100.0%; Score 7; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 11 TACTAAC 5

RESULT 3
AXI175039
LOCUS AXI175039 11 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 28 from Patent WO0142493.
ACCESSION AXI175039
VERSION AXI175039.2 GI:15142058
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 11)
AUTHORS Olek,A. and Piepenbrock,C.
TITLE Method for the parallel detection of the degree of methylation of
genomic dna
JOURNAL Patent: WO 0142493-A 28 14-JUN-2001;
COMMENT Epigenomics AG (DE)
FEATURES
    source
        Location/Qualifiers
            1..11
                /organism="synthetic construct"
                /db_xref="taxon:32630"
                /note="chemisch vorbehandelte Genom-DNA"
BASE COUNT 4 a 4 c 0 g 3 t
ORIGIN

Query Match      100.0%; Score 7; DB 6; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 7 TACTAAC 1

RESULT 6
AR039094/c
LOCUS AR039094 13 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2 from patent US 5807738.
ACCESSION AR039094
VERSION AR039094.1 GI:5958457
FEATURES
    source
        Location/Qualifiers
            1..13
                /organism="unknown"
                /db_xref="taxon:32630"
                /note="chemisch vorbehandelte Genom-DNA"
BASE COUNT 4 a 1 c 2 g 6 t
ORIGIN

Query Match      100.0%; Score 7; DB 6; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 7 TACTAAC 1

RESULT 4
AR121253
LOCUS AR121253 12 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 33 from patent US 6159710.
ACCESSION AR121253
VERSION AR121253.1 GI:14104829
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 12)
AUTHORS Fraser,N.W., Zabolotny,J.M. and Krummenacher,C.F.
TITLE Method and compositions for stabilizing unstable gene transcripts
JOURNAL Patent: US 6159710-A 33 12-DEC-2000;
FEATURES
    source
        Location/Qualifiers
            1..12
                /organism="unknown"
                /db_xref="taxon:32630"
                /note="chemisch vorbehandelte Genom-DNA"
BASE COUNT 4 a 3 c 2 g 3 t
ORIGIN

Query Match      100.0%; Score 7; DB 6; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 6 TACTAAC 12

RESULT 5
AR037996/c
LOCUS AR037996 13 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2 from patent US 5804407.
ACCESSION AR037996
VERSION AR037996.1 GI:5956713
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 13)
AUTHORS Tamaoki,T. and Nakabayashi,H.
TITLE Method of expressing genes in mammalian cells
JOURNAL Patent: US 5804407-A 2 08-SEP-1998;
FEATURES
    source
        Location/Qualifiers
            1..13
                /organism="unknown"
                /db_xref="taxon:32630"
                /note="chemisch vorbehandelte Genom-DNA"
BASE COUNT 4 a 1 c 2 g 6 t
ORIGIN

Query Match      100.0%; Score 7; DB 6; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 7 TACTAAC 1

RESULT 6
AR039094/c
LOCUS AR039094 13 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2 from patent US 5807738.
ACCESSION AR039094
VERSION AR039094.1 GI:5958457
FEATURES
    source
        Location/Qualifiers
            1..13
                /organism="unknown"
                /db_xref="taxon:32630"
                /note="chemisch vorbehandelte Genom-DNA"
BASE COUNT 4 a 1 c 2 g 6 t
ORIGIN

```

```
KEYWORDS
SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 13)
AUTHORS      Tamaoki,T. and Nakabayashi,H.
TITLE        Method of expressing genes in mammalian cells
JOURNAL      Patent: US 5807738-A 2 15-SEP-1998;
FEATURES     Location/Qualifiers
              1..13
              /organism="unknown"
BASE COUNT   4 a 1 c 2 g 6 t
ORIGIN

Query Match      100.0%; Score 7; DB 6; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 7 TACTAAC 1

RESULT 9
I76088
LOCUS      I76088
DEFINITION Sequence 4 from patent US 5691137.
ACCESSION  I76088
VERSION     I76088.1 GI:3012242
KEYWORDS   .
SOURCE     .
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 14)
AUTHORS    Rosbash,M. and Stutz,F.
TITLE      Methods of screening candidate agents for biological activity using
            yeast cells
JOURNAL    Patent: US 5691137-A 4 25-NOV-1997;
FEATURES   Location/Qualifiers
            1..14
            /organism="unknown"
BASE COUNT 5 a 5 c 0 g 4 t
ORIGIN

Query Match      100.0%; Score 7; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.5e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 1 TACTAAC 7

RESULT 10
AR039499
LOCUS      AR039499
DEFINITION Sequence 347 from patent US 5807743.
ACCESSION  AR039499
VERSION     AR039499.1 GI:5958862
KEYWORDS   .
SOURCE     .
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Stinchcomb,D.T. and McSwiggen,J.A.
TITLE      Interleukin-2 receptor gamma-chain ribozymes
JOURNAL    Patent: US 5807743-A 347 15-SEP-1998;
FEATURES   Location/Qualifiers
            1..17
            /organism="unknown"
BASE COUNT 5 a 2 c 3 g 7 t
ORIGIN

Query Match      100.0%; Score 7; DB 6; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 8 TACTAAC 14

RESULT 11
```

```
KEYWORDS
SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 13)
AUTHORS      Tamaoki,T. and Nakabayashi,H.
TITLE        Method of expressing genes in mammalian cells
JOURNAL      Patent: US 5807738-A 2 15-SEP-1998;
FEATURES     Location/Qualifiers
              1..13
              /organism="unknown"
BASE COUNT   4 a 1 c 2 g 6 t
ORIGIN

Query Match      100.0%; Score 7; DB 6; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 7 TACTAAC 1

RESULT 7
AR050339/c
LOCUS      AR050339
DEFINITION Sequence 2 from patent US 5827686.
ACCESSION  AR050339
VERSION     AR050339.1 GI:5973064
KEYWORDS   .
SOURCE     .
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 13)
AUTHORS    Tamaoki,T. and Nakabayashi,H.
TITLE      Method of expressing genes in mammalian cells
JOURNAL    Patent: US 5827686-A 2 27-OCT-1998;
FEATURES   Location/Qualifiers
            1..13
            /organism="unknown"
BASE COUNT 4 a 1 c 2 g 6 t
ORIGIN

Query Match      100.0%; Score 7; DB 6; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 7 TACTAAC 1

RESULT 8
AR062898/c
LOCUS      AR062898
DEFINITION Sequence 2 from patent US 5843776.
ACCESSION  AR062898
VERSION     AR062898.1 GI:5990589
KEYWORDS   .
SOURCE     .
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 13)
AUTHORS    Tamaoki,T. and Nakabayashi,H.
TITLE      Method of expressing genes in mammalian cells
JOURNAL    Patent: US 5843776-A 2 01-DEC-1998;
FEATURES   Location/Qualifiers
            1..13
            /organism="unknown"
BASE COUNT 4 a 1 c 2 g 6 t
ORIGIN
```

AR039501
LOCUS AR039501 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 349 from patent US 5807743.
ACCESSION AR039501
VERSION AR039501.1 GI:5958864
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.
TITLE Interleukin-2 receptor gamma-chain ribozymes
JOURNAL Patent: US 5807743-A 349 15-SEP-1998;
FEATURES
source
1. .17
/organism="unknown"
BASE COUNT 3 a 4 c 3 g 7 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
Db 5 TACTAAC 11

RESULT 12
AR039503
LOCUS AR039503 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 351 from patent US 5807743.
ACCESSION AR039503
VERSION AR039503.1 GI:5958866
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.
TITLE Interleukin-2 receptor gamma-chain ribozymes
JOURNAL Patent: US 5807743-A 351 15-SEP-1998;
FEATURES
source
1. .17
/organism="unknown"
BASE COUNT 4 a 5 c 0 g 8 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
Db 1 TACTAAC 7

RESULT 13
AR040467
LOCUS AR040467 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1315 from patent US 5807743.
ACCESSION AR040467
VERSION AR040467.1 GI:5959830
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.
TITLE Interleukin-2 receptor gamma-chain ribozymes
JOURNAL Patent: US 5807743-A 1315 15-SEP-1998;

Query Match 100.0%; Score 7; DB 6; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
Db 1 TACTAAC 7

RESULT 14
AR040469
LOCUS AR040469 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1317 from patent US 5807743.
ACCESSION AR040469
VERSION AR040469.1 GI:5959832
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.
TITLE Interleukin-2 receptor gamma-chain ribozymes
JOURNAL Patent: US 5807743-A 1317 15-SEP-1998;
FEATURES
source
1. .17
/organism="unknown"
BASE COUNT 5 a 3 c 1 g 8 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
Db 11 TACTAAC 17

RESULT 15
AR040471
LOCUS AR040471 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1319 from patent US 5807743.
ACCESSION AR040471
VERSION AR040471.1 GI:5959834
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.
TITLE Interleukin-2 receptor gamma-chain ribozymes
JOURNAL Patent: US 5807743-A 1319 15-SEP-1998;
FEATURES
source
1. .17
/organism="unknown"
BASE COUNT 4 a 6 c 1 g 6 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
Db 8 TACTAAC 14

Db 5 TACTAAC 11

Search completed: July 21, 2002, 09:45:15
Job time: 12306 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run On: July 21, 2002, 09:55:18 ; Search time 467.25 Seconds
(without alignments)
25.722 Million cell updates/sec

Title: US-09-754-014-10_COPY_16_22

Perfect score: 7
Sequence: 1 TACTAAC 7

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_032802.*

- 1: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT.*
- 2: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT.*
- 3: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT.*
- 4: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT.*
- 5: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT.*
- 6: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT.*
- 7: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT.*
- 8: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT.*
- 9: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT.*
- 10: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT.*
- 11: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT.*
- 12: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT.*
- 13: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT.*
- 14: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT.*
- 15: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT.*
- 16: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT.*
- 17: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT.*
- 18: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT.*
- 19: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT.*
- 20: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT.*
- 21: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT.*
- 22: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT.*
- 23: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT.*
- 24: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query	Score	Match	Length	ID	Description
1	7	100.0	7	19	AAV64932	Yeast intron conse
2	7	100.0	7	19	AAV43552	Insertion sequence
3	7	100.0	7	19	AAV43560	Insertion sequence
C 4	7	100.0	10	21	AAZ78514	Human dendritic ce
C 5	7	100.0	10	21	AAZ81140	Metastatic breast
C 6	7	100.0	10	22	AAF41210	Yeast NORF gene SA
C 7	7	100.0	10	22	AAF41530	Yeast NORF gene SA
C 8	7	100.0	10	22	AAF42338	Yeast NORF gene SA
C 9	7	100.0	10	22	AAF42417	Yeast NORF gene SA

c	11	7	100.0	10	22	AAF43472	Yeast NORF gene SA
c	12	7	100.0	11	22	AAH55245	Genomic DNA methyl
c	13	7	100.0	11	22	AAH55246	Genomic DNA methyl
c	14	7	100.0	11	22	AAH55253	Genomic DNA methyl
c	15	7	100.0	11	22	AAH55254	Genomic DNA methyl
c	16	7	100.0	12	18	AAZ28509	Target sequence fo
c	17	7	100.0	12	21	AAZ99828	Nucleotide sequenc
c	18	7	100.0	12	21	AAZ99829	Nucleotide sequenc
c	19	7	100.0	12	23	ABH67674	Oligonucleotide pr
c	20	7	100.0	12	23	ABH68017	Oligonucleotide pr
c	21	7	100.0	12	23	ABH68161	Oligonucleotide pr
c	22	7	100.0	12	23	ABH69292	Oligonucleotide pr
c	23	7	100.0	12	23	ABH69440	Oligonucleotide pr
c	24	7	100.0	12	23	ABH69448	Oligonucleotide pr
c	25	7	100.0	12	23	ABH69976	Oligonucleotide pr
c	26	7	100.0	12	23	ABH70202	Oligonucleotide pr
c	27	7	100.0	12	23	ABH71367	Oligonucleotide pr
c	28	7	100.0	12	23	ABH71653	Oligonucleotide pr
c	29	7	100.0	12	23	ABH72304	Oligonucleotide pr
c	30	7	100.0	12	23	ABH72862	Oligonucleotide pr
c	31	7	100.0	12	23	ABH73012	Oligonucleotide pr
c	32	7	100.0	12	23	ABH74291	Oligonucleotide pr
c	33	7	100.0	12	23	ABH74947	Oligonucleotide pr
c	34	7	100.0	12	23	ABH75567	Oligonucleotide pr
c	35	7	100.0	12	23	ABH76565	Oligonucleotide pr
c	36	7	100.0	12	23	ABH76876	Oligonucleotide pr
c	37	7	100.0	12	23	ABH77257	Oligonucleotide pr
c	38	7	100.0	12	23	ABH77374	Oligonucleotide pr
c	39	7	100.0	12	23	ABH77375	Oligonucleotide pr
c	40	7	100.0	12	23	ABH77914	Oligonucleotide pr
c	41	7	100.0	12	23	ABH78354	Oligonucleotide pr
c	42	7	100.0	12	23	ABH78666	Oligonucleotide pr
c	43	7	100.0	12	23	ABH78667	Oligonucleotide pr
c	44	7	100.0	12	23	ABH78976	Oligonucleotide pr
c	45	7	100.0	12	23	ABH79343	Oligonucleotide pr
c	46	7	100.0	12	23	ABH79427	Oligonucleotide pr

ALIGNMENTS

RESULT 1	
AAV64932	
ID	AAV64932 standard; RNA; 7 BP.
XX	
AC	AAV64932;
XX	
DT	15-MAR-1999 (first entry)
XX	
DE	Yeast intron consensus branch site.
XX	
KW	Herpes simplex virus type-1; HSV-1; latency associated transcript;
KW	LAT; LATin; gene transcript stabilisation; gene expression;
KW	gene therapy; yeast; ss.
XX	
OS	Saccharomyces cerevisiae.
XX	
FH	Key Location/Qualifiers
FT	misc_feature 6
FT	/*tag= a
FT	/note= "branchsite"
XX	
PN	WO9848004-A1.
XX	
PD	29-OCT-1998.
XX	
PF	17-APR-1998; 98WO-US07691.
XX	
PR	18-APR-1997; 97US-0044664.
XX	
PA	(WIST-) WISTAR INST ANATOMY & BIOLOGY.
XX	
PI	Fraser NW, Krummenacher CF, Zabolotny JM;

XX WPI; 1998-609982/51.
 XX
 PT Increasing expression of genes having unstable RNA transcripts,
 PT particularly for gene therapy - using a construct including gene
 PT flanked by intron fragments that include a hairpin next to the
 PT intron branchpoint
 XX
 PS Example 7; Page 35; 106pp; English.
 XX
 CC This is the nucleotide sequence of the yeast intron consensus
 CC branch site. It was used as a control for determining which
 CC nucleotide within the branchpoint region of herpes simplex virus
 CC type 1 (HSV-1), latency associated transcript (LAT) is the nucleotide
 CC that forms a 2'-5' phosphodiester bond with the 5' splice donor
 CC site (see AAV64934). The invention relates to methods of stabilising
 CC unstable gene transcripts. A claimed polynucleotide comprises: (a)
 CC a polynucleotide encoding a gene product; (b) a 5'-sequence of an
 CC intron, including the splice donor and splice acceptor sites (see
 CC AAV64885-86); and (c) a 3'-sequence of the same intron, including a
 CC hairpin structure (see AAV64887) next to the intron's branchpoint. A
 CC preferred intron is the 2.0 kb LAT of a herpes virus. Methods and
 CC compositions using the polynucleotide can be used in gene therapy
 CC and more generally as research reagents, markers of gene production,
 CC in therapeutic or diagnostic compositions, in drug screening and to
 CC identify transcripts produced only at selected stages of the cell
 CC cycle.
 XX
 SQ Sequence 7 BP; 3 A; 2 C; 0 G; 2 U; 0 other;
 Query Match 100.0%; Score 7; DB 19; Length 7;
 Best Local Similarity 71.4%; Pred. No. 2.4e+08;
 Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 TACTAAC 7
 Db :||:|
 1 uacuaac 7
 RESULT 2
 ID AAV43552
 XX AAV43552 standard; DNA; 7 BP.
 AC AAV43552;
 XX
 DT 16-SEP-1998 (first entry)
 XX
 DE Insertion sequence 5 used for creating a tagged gene.
 XX
 KW Tagged gene; tagged transcript; hybrid intron; protein tag;
 KW protein isolation; recombination; hybrid intron; protein tag;
 KW transcriptional regulation; viral infection; ss.
 OS Synthetic.
 OS Unidentified.
 OS
 PN WO9820031-A1.
 XX
 PD 14-MAY-1998.
 XX
 PF 07-NOV-1997; 97WO-US20150.
 XX
 PR 08-NOV-1996; 96US-0705404.
 XX
 PA (JARV/) JARVIK J W.
 XX
 PI Jarvik JW;
 XX
 DR WPI; 1998-286861/25.
 XX
 PT Tagging genes, transcripts and proteins - using tag-creating DNA
 PT Inserted into intron of gene to create 2 hybrid introns separated by

PT new exon encoding protein tag
 XX
 PS Claim 1; Page 33; 66pp; English.
 XX
 CC This sequence is used in the method of invention for tagging genes,
 CC transcripts and proteins in cells in a single recombinational event. The
 CC method comprises producing a tagged gene by inserting a DNA sequence
 CC into an intron of a gene by selecting a DNA sequence having a 5' portion
 CC free of any nucleotide sequence selected from AAV43548 to AAV43551, a
 CC nucleotide sequence selected from AAV43552 to AAV43560 and nucleotide
 CC sequences identical to a known splice branch site in a known gene,
 CC sequences identical in length to a known spacer region between splice
 CC branch and acceptor sites in a known gene, sequences identical to a known
 CC splice acceptor site in a known gene, sequence identical to a known
 CC splice donor site in a known gene, an open reading frame (ORF) 3N-1
 CC nucleotides in length, the ORF encoding a known peptide tag recognisable
 CC by a known reaction characteristic of the known peptide tag and sequences
 CC selected from CAGG and TAGG. The DNA sequence is inserted into the intron
 CC within the gene to create a tagged gene, and the tagged gene is incubated
 CC within a cell so as to maintain intact or to introduce the tagged gene
 CC within the genome of the cell. The method is used for isolating proteins,
 CC RNA and genes, for analysis of subcellular structures, cellular responses,
 CC and transcriptional regulation, for the study of viral infection and for
 CC diagnosis of disease.
 XX
 SQ Sequence 7 BP; 3 A; 2 C; 0 G; 2 T; 0 other;
 Query Match 100.0%; Score 7; DB 19; Length 7;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 TACTAAC 7
 Db :|||
 1 tactaac 7
 RESULT 3
 ID AAV43560
 XX AAV43560 standard; DNA; 7 BP.
 AC AAV43560;
 XX
 DT 16-SEP-1998 (first entry)
 XX
 DE Insertion sequence 13 used for creating a tagged gene.
 XX
 KW Tagged gene; tagged transcript; hybrid intron; protein tag;
 KW protein isolation; recombination; hybrid intron; protein tag;
 KW transcriptional regulation; viral infection; ss.
 OS Synthetic.
 OS Unidentified.
 OS
 PN WO9820031-A1.
 XX
 PD 14-MAY-1998.
 XX
 PF 07-NOV-1997; 97WO-US20150.
 XX
 PR 08-NOV-1996; 96US-0705404.
 XX
 PA (JARV/) JARVIK J W.
 XX
 PI Jarvik JW;
 XX
 DR WPI; 1998-286861/25.
 XX
 PT Tagging genes, transcripts and proteins - using tag-creating DNA
 PT Inserted into intron of gene to create 2 hybrid introns separated by
 PT new exon encoding protein tag
 XX
 PS Claim 1; Page 33; 66pp; English.

XX This sequence is used in the method of invention for tagging genes,
 CC transcripts and proteins in cells in a single recombinational event. The
 CC method comprises producing a tagged gene by inserting a DNA sequence
 CC into an intron of a gene by selecting a DNA sequence having a 3' portion
 CC free of any nucleotide sequence selected from AAV43548 to AAV43551, a
 CC nucleotide sequence selected from AAV43552 to AAV43560 and nucleotide
 CC sequences identical to a known splice branch site in a known gene,
 CC sequences identical in length to a known spacer region between splice
 CC branch and acceptor sites in a known gene, sequences identical to a known
 CC splice acceptor site in a known gene, sequence identical to a known
 CC splice donor site in a known gene, an open reading frame (ORF) 3N-1
 CC nucleotides in length, the ORF encoding a known peptide tag recognisable
 CC by a known reaction characteristic of the known peptide tag and sequences
 CC selected from CAGG and TAGG. The DNA sequence is inserted into the intron
 CC within the gene to create a tagged gene, and the tagged gene is incubated
 CC within a cell so as to maintain intact or to introduce the tagged gene
 CC within the genome of the cell. The method is used for isolating proteins,
 CC RNA and genes, for analysis of subcellular structures, cellular responses
 CC and transcriptional regulation, for the study of viral infection and for
 CC diagnosis of disease.

SQ Sequence 7 BP; 3 A; 2 C; 0 G; 2 T; 0 other;

Query Match 100.0%; Score 7; DB 19; Length 7;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
 Db 1 tactaac 7

RESULT 4

AAZ78514/C
 ID AAZ78514 standard; DNA; 10 BP.

AC AAZ78514;

XX 10-APR-2000 (first entry)

XX Human dendritic cell SAGE tag, SEQ ID NO:942.

DE SAGE tag; serial analysis of gene expression; antigen-presenting cell;
 KW APC; monocyte-derived dendritic cell; differential gene expression;
 KW immunostimulatory cofactor; costimulatory factor; CTL;
 KW cytotoxic T-lymphocyte; tumour antigen; immunotherapy; anticancer; ss.

OS Homo sapiens.

XX W09965924-A2.

XX 23-DEC-1999.

PD 18-JUN-1999; 99WO-US13800.

XX 19-JUN-1998; 98US-0089833.

XX 19-JUN-1998; 98US-0089844.

XX 19-JUN-1998; 98US-0089853.

XX 19-JUN-1998; 98US-0089878.

XX 19-JUN-1998; 98US-0089991.

XX 19-JUN-1998; 98US-0089992.

XX 19-JUN-1998; 98US-0089993.

XX 19-JUN-1998; 98US-0089994.

XX 19-JUN-1998; 98US-0089997.

XX 19-JUN-1998; 98US-0089999.

XX 19-JUN-1998; 98US-0090000.

XX 19-JUN-1998; 98US-0090035.

XX 19-JUN-1998; 98US-0090036.

XX 19-JUN-1998; 98US-0090039.

XX 19-JUN-1998; 98US-0090040.

XX 19-JUN-1998; 98US-0090041.

PR 19-JUN-1998; 98US-0090042.
 PR 19-JUN-1998; 98US-0090043.
 PR 19-JUN-1998; 98US-0090044.
 PR 19-JUN-1998; 98US-0090045.
 PR 19-JUN-1998; 98US-0090047.
 PR 19-JUN-1998; 98US-0090048.
 PR 19-JUN-1998; 98US-0090072.
 PR 19-JUN-1998; 98US-0090076.
 PR 19-JUN-1998; 98US-0090077.
 PR 19-JUN-1998; 98US-0090078.
 PR 19-JUN-1998; 98US-0090079.
 PR 19-JUN-1998; 98US-0090080.
 PR 08-DEC-1998; 98US-0111715.

XX (GENZ) GENZYME CORP.

PA (ROBE/) ROBERTS B L.

PA (SHAN/) SHANKARA S.

XX Roberts BL, Shankara S;

PI WPI; 2000-106077/09.

XX Isolated polynucleotides differentially expressed in antigen-presenting cells, useful in gene vaccines against cancer .

PS Claim 1; Page 92; 130pp; English.

XX Sequences AAZ77573-779709 represent SAGE (serial analysis of gene expression) tags used to identify mRNA transcripts encoding immunostimulatory cofactor proteins which are preferentially or differentially expressed in monocyte-derived dendritic cells compared with monocytes. Some of the transcripts correspond to known genes or ESTs (expressed sequence tags) which were previously unknown to be preferentially or differentially expressed in dendritic cells, while other transcripts correspond to novel genes. Antigen-presenting cell (APC)-associated costimulatory factors play an important role in the activation of the cytotoxic immune response, particularly against tumour cells. Tumour antigen presentation via the MHC (major histocompatibility complex) and subsequent recognition by T-cell receptors is alone insufficient to activate a robust cytotoxic immune response that can lyse the tumour cells, immunostimulatory cofactors also being required for efficient activation of cytotoxic T-lymphocytes (CTLs). Nucleic acid sequences identified using the SAGE tags have several potential uses. They may be used in vaccines to induce an immune response, particularly against a tumour antigen; to modulate the genotype of an APC; to screen for agents that modulate expression of differentially expressed genes in an APC; and as hybridisation probes/amplification primers for the diagnosis, prognosis and monitoring of diseases related to abnormal expression of these genes. Detection of the dendritic cell to identify cells as belonging to the monocyte lineage. Cells containing these genes can be used in active immunotherapy (or to stimulate production of a population of antigen-specific effector cells) and vectors containing them are used in gene therapy. Co-administration of tumour antigens and APC-associated costimulatory factors ensures adequate antigen presentation to endogenous APCs and upregulates the APCs for the presentation of co-stimulatory signals, migration to T cell-rich sites, secretion of T cell growth factors and secretion of chemokines for recruitment of immune effector cells.

SQ Sequence 10 BP; 4 A; 1 C; 2 G; 3 T; 0 other;

Query Match 100.0%; Score 7; DB 21; Length 10;

Best Local Similarity 100.0%; Pred. No. 6.4e+04;

Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7

Db 9 TACTAAC 3

RESULT 5

AAZ81140/c
 ID AAZ81140 standard; DNA; 10 BP.
 XX AAZ81140;
 AC AAZ81140;
 DT 07-APR-2000 (first entry)
 XX Metastatic breast tumour cell upregulated transcript tag #374.
 DE Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 XX non-metastatic breast tumour tissue; gene therapy; anticancer;
 KW antimetastatic; vaccine; diagnosis; ss.
 KW Homo sapiens.
 XX WO9965928-A2.
 PN 23-DEC-1999.
 XX 18-JUN-1999; 99WO-US13647.
 XX 19-JUN-1998; 98US-0089853.
 PR 19-JUN-1998; 98US-0089997.
 PR 19-JUN-1998; 98US-0090039.
 PR 19-JUN-1998; 98US-0090040.
 PR 19-JUN-1998; 98US-0090041.
 XX (GENZ) GENZYME CORP.
 PA (ROBE/) ROBERTS B L.
 PA (SHAN/) SHANKARA S.
 XX Roberts BL, Shankara S;
 PI WPI; 2000-106079/09.
 DR Isolated polynucleotides differentially expressed between metastatic
 XX and non-metastatic breast cancer cells, useful for diagnosis,
 PT prevention and treatment of cancer -
 PT Claim 1; Page 68; 219pp; English.
 PS AAZ80767 to AAZ83941 represent tags corresponding to distinct
 XX transcripts that are preferentially transcribed in the metastatic breast
 CC tumour tissue (i.e. are upregulated in metastatic breast tumour cells).
 CC AAZ83942 to AAZ86677 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the primary or non-metastatic
 CC breast tumour tissue (i.e. are downregulated in metastatic breast tumour
 CC cells). These transcripts can be used for diagnosis, prognosis,
 CC monitoring and treatment of breast cancer, particularly where metastatic.
 CC Diagnosis is by standard immunoassays or hybridisation/amplification
 CC reactions. Compounds that modulate expression of the transcripts are
 CC potentially useful for treatment of (metastatic) breast cancer, while
 CC promoters from the transcripts are used to direct expression, in selected
 CC cell types, of e.g. therapeutic genes (also ribozymes or antisense
 CC sequences), particularly an antigen-encoding sequence for use in gene or
 CC cell-based vaccines. Polypeptides encoded by the transcripts are also
 CC useful in vaccines; for diagnosing breast cancer and for raising
 CC specific antibodies (Ab). Ab are used to detect the polypeptides or as
 CC therapeutic agents. Host cells that produce the polypeptides can be used
 CC to expand and isolate populations of educated, antigen-specific immune
 CC effector cells, e.g. cytotoxic T lymphocytes, and these used for
 CC adoptive immunotherapy.
 XX Sequence 10 BP; 3 A; 0 C; 3 G; 4 T; 0 other;
 SQ

Query Match 100.0%; Score 7; DB 21; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6.4e+04;

Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7

Db 10 TACTAAC 4

RESULT

AAAF1210/c

XX AAF41210 standard; DNA; 10 BP.

AC AAF41210;

DT 23-MAR-2001 (first entry)

XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:7949.

DE Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 XX nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX Saccharomyces cerevisiae.

OS WO200077214-A2.

PN 21-DEC-2000.

XX 14-JUN-2000; 2000WO-US16223.

PR 16-JUN-1999; 99US-0335032.

XX (UYJO) UNIV JOHNS HOPKINS.

PA Velculescu V, Vogelstein B, Kinzler K;

XX WPI; 2001-061874/07.

DR Yeast gene coding sequences comprising NORF genes with serial analysis

XX of gene expression (SAGE) tags, useful for studying, monitoring and

PT affecting phases of the cell cycle -

XX Example; Page 283; 419pp; English.

PS The present invention describes an isolated DNA molecule comprising a

XX coding sequence of a yeast gene selected from a group of 745 NORF (not

CC previously assigned open reading frame; or nonannotated ORF) genes

CC comprising a SAGE (serial analysis of gene expression) tag. Also

CC described are: (1) a method (M1) of using NORF genes to affect the cell

CC cycle comprising administering a NORF gene whose expression varies by at

CC least 10% between any two phases of the cell cycle selected from log

CC phase, S phase and G2/M; (2) a method (M2) for screening candidate

CC antifungal drugs comprising: (a) contacting a test substance with a

CC yeast cell; and (b) monitoring expression of a NORF gene whose

CC expression varies as in M1, where a test substance which modifies the

CC expression of the yeast gene is a candidate antifungal drug; (3) a method

CC (M3) for identifying human genes which are involved in cell cycle

CC progression comprising contacting human DNA with a probe which comprises

CC at least 10 contiguous nucleotides of a NORF gene whose expression varies

CC as in M1; and (4) a method (M4) for identifying a candidate drug as a

CC member of a class of drugs having a characteristic effect on gene

CC expression in a yeast cell comprising contacting a yeast cell with a

CC candidate drug and monitoring expression in the yeast cell of at least 1

CC NORF gene whose expression is affected by the class of drugs. The NORF

CC genes may be used to study, monitor and affect phases of the cell cycle,

CC the differentially expressed genes may be used as markers of phases of

CC the cell cycle. The methods may be used to identify candidate drugs which

CC affect the cell cycle and for identification of antifungal drugs.

CC AAF33268 to AAF4064 represent SAGE tags used in the exemplification of

CC the present invention. AAF33262 to AAF33267 represent linkers and PCR

CC primers used in the SAGE method, in the exemplification of the present

CC invention.

XX Sequence 10 BP; 2 A; 1 C; 3 G; 4 T; 0 other;

SQ

Query Match 100.0%; Score 7; DB 22; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6.4e+04;

Matches 7: Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
 |||||
Db 9 TACTAAC 3

RESULT 7
AAF41530/c
ID AAF41530 standard; DNA; 10 BP.
XX
AC AAF41530;
XX
DT 23-MAR-2001 (first entry)
XX
DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:8269.
XX
KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX
OS Saccharomyces cerevisiae.
XX
PN WO200077214-A2.
XX
PD 21-DEC-2000.
XX
PF 14-JUN-2000; 2000WO-US16223.
XX
PR 16-JUN-1999; 99US-0335032.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PI Velulescu V, Vogelstein B, Kinzler K;
XX
DR WPI; 2001-061874/07.
XX
PT Yeast gene coding sequences comprising NORF genes with serial analysis
PT of gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle -
XX
PS Example; Page 295; 419pp; English.

CC The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a
CC yeast cell; and (b) monitoring expression of a NORF gene whose
CC expression varies as in M1, where a test substance which modifies the
CC expression of the yeast gene is a candidate antifungal drug; (3) a method
CC (M3) for identifying human genes which are involved in cell cycle
CC progression comprising contacting human DNA with a probe which comprises
CC at least 10 contiguous nucleotides of a NORF gene whose expression varies
CC as in M1; and (4) a method (M4) for identifying a candidate drug as a
CC member of a class of drugs having a characteristic effect on gene
CC expression in a yeast cell comprising contacting a yeast cell with a
CC candidate drug and monitoring expression in the yeast cell of at least 1
CC NORF gene whose expression is affected by the class of drugs. The NORF
CC genes may be used to study, monitor and affect phases of the cell cycle,
CC the differentially expressed genes may be used as markers of phases of
CC the cell cycle. The methods may be used to identify candidate drugs which
CC affect the cell cycle and for identification of antifungal drugs.
CC AAF33268 to AAF44064 represent SAGE tags used in the exemplification of
CC the present invention. AAF33262 to AAF33767 represent linkers and PCR
CC primers used in the SAGE method, in the exemplification of the present
CC invention.
XX

QY 1 TACTAAC 7
 |||||
Db 9 TACTAAC 3

Query Match 100.0%; Score 7; DB 22; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.4e-04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
 |||||
Db 9 TACTAAC 3

RESULT 8
AAF42338
ID AAF42338 standard; DNA; 10 BP.
XX
AC AAF42338;
XX
DT 23-MAR-2001 (first entry)
XX
DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:9077.
XX
KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX
OS Saccharomyces cerevisiae.
XX
PN WO200077214-A2.
XX
PD 21-DEC-2000.
XX
PF 14-JUN-2000; 2000WO-US16223.
XX
PR 16-JUN-1999; 99US-0335032.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PI Velulescu V, Vogelstein B, Kinzler K;
XX
DR WPI; 2001-061874/07.
XX
PT Yeast gene coding sequences comprising NORF genes with serial analysis
PT of gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle -
XX
PS Example; Page 324; 419pp; English.

CC The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a
CC yeast cell; and (b) monitoring expression of a NORF gene whose
CC expression varies as in M1, where a test substance which modifies the
CC expression of the yeast gene is a candidate antifungal drug; (3) a method
CC (M3) for identifying human genes which are involved in cell cycle
CC progression comprising contacting human DNA with a probe which comprises
CC at least 10 contiguous nucleotides of a NORF gene whose expression varies
CC as in M1; and (4) a method (M4) for identifying a candidate drug as a
CC member of a class of drugs having a characteristic effect on gene
CC expression in a yeast cell comprising contacting a yeast cell with a
CC candidate drug and monitoring expression in the yeast cell of at least 1
CC NORF gene whose expression is affected by the class of drugs. The NORF
CC genes may be used to study, monitor and affect phases of the cell cycle,
CC the differentially expressed genes may be used as markers of phases of
CC the cell cycle. The methods may be used to identify candidate drugs which
CC affect the cell cycle and for identification of antifungal drugs.
CC AAF33268 to AAF44064 represent SAGE tags used in the exemplification of
CC the present invention. AAF33262 to AAF33767 represent linkers and PCR
CC primers used in the SAGE method, in the exemplification of the present
CC invention.
XX

CC AAF33268 to AAF44064 represent SAGE tags used in the exemplification of
CC the present invention. AAF33262 to AAF33267 represent linkers and PCR
CC primers used in the SAGE method, in the exemplification of the present
CC invention.
XX
SQ Sequence 10 BP; 4 A; 3 C; 1 G; 2 T; 0 other;

Query Match 100.0%; Score 7; DB 22; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.4e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 4 tactaac 10

RESULT 9
AAF42417/G
ID AAF42417 standard; DNA; 10 BP.
XX
AC AAF42417;
XX
DT 23-MAR-2001 (first entry)
XX
DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:9156.
XX
KW Yeast; Saccharomyces cerevisiae;
KW nor previously assigned open reading frame; characterisation; cell cycle; NORF;
KW serial analysis of gene expression; nonannotated ORF; SAGE;
KW linker; PCR primer; ds.
XX
OS Saccharomyces cerevisiae.
XX
PN WO200077214-A2.
XX
PD 21-DEC-2000.
XX
PF 14-JUN-2000; 2000WO-US16223.
XX
PR 16-JUN-1999; 99US-0335032.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PI Velulescu V, Vogelstein B, Kinzler K;
XX
DR WPI; 2001-061874/07.
XX
PT Yeast gene coding sequences comprising NORF genes with serial analysis
PT of gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle -
XX
PS Example; Page 327; 419pp; English.
XX
CC The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a
CC yeast cell; and (b) monitoring expression of a NORF gene whose
CC expression varies as in M1, where a test substance which modifies the
CC expression of the yeast gene is a candidate antifungal drug; (3) a method
CC (M3) for identifying human genes which are involved in cell cycle
CC progression comprising contacting human DNA with a probe which comprises
CC at least 10 contiguous nucleotides of a NORF gene whose expression varies
CC as in M1; and (4) a method (M4) for identifying a candidate drug as a
CC member of a class of drugs having a characteristic effect on gene
CC expression in a yeast cell comprising contacting a yeast cell with a
CC candidate drug and monitoring expression in the yeast cell of at least 1

CC NORF gene whose expression is affected by the class of drugs. The NORF
CC genes may be used to study, monitor and affect phases of the cell cycle,
CC the differentially expressed genes may be used as markers of phases of
CC the cell cycle. The methods may be used to identify candidate drugs which
CC affect the cell cycle and for identification of antifungal drugs.
CC AAF33268 to AAF44064 represent SAGE tags used in the exemplification of
CC the present invention. AAF33262 to AAF33267 represent linkers and PCR
CC primers used in the SAGE method, in the exemplification of the present
CC invention.
XX
SQ Sequence 10 BP; 2 A; 2 C; 3 G; 3 T; 0 other;

Query Match 100.0%; Score 7; DB 22; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.4e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 10 TACTAAC 4

RESULT 10
AAF43472
ID AAF43472 standard; DNA; 10 BP.
XX
AC AAF43472;
XX
DT 23-MAR-2001 (first entry)
XX
DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:11611.
XX
KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX
OS Saccharomyces cerevisiae.
XX
PN WO200077214-A2.
XX
PD 21-DEC-2000.
XX
PF 14-JUN-2000; 2000WO-US16223.
XX
PR 16-JUN-1999; 99US-0335032.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PI Velulescu V, Vogelstein B, Kinzler K;
XX
DR WPI; 2001-061874/07.
XX
PT Yeast gene coding sequences comprising NORF genes with serial analysis
PT of gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle -
XX
PS Example; Page 364; 419pp; English.
XX
CC The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a
CC yeast cell; and (b) monitoring expression of a NORF gene whose
CC expression varies as in M1, where a test substance which modifies the
CC expression of the yeast gene is a candidate antifungal drug; (3) a method
CC (M3) for identifying human genes which are involved in cell cycle
CC progression comprising contacting human DNA with a probe which comprises

CC at least 10 contiguous nucleotides of a NORF gene whose expression varies
CC as in M1; and (4) a method (M4) for identifying a candidate drug as a
CC member of a class of drugs having a characteristic effect on gene
CC expression in a yeast cell comprising contacting a yeast cell with a
CC candidate drug and monitoring expression in the yeast cell of at least 1
CC NORF gene whose expression is affected by the class of drugs. The NORF
CC genes may be used to study, monitor and affect phases of the cell cycle,
CC the differentially expressed genes may be used as markers of phases of
CC the cell cycle. The methods may be used to identify candidate drugs which
CC affect the cell cycle and for identification of antifungal drugs.
CC AAF33268 to AAF44064 represent SAGE tags used in the exemplification of
CC the present invention. AAF33262 to AAF33267 represent linkers and PCR
CC primers used in the SAGE method, in the exemplification of the present
CC invention.

XX Sequence 10 BP; 4 A; 2 C; 0 G; 4 T; 0 other;
SQ

Query Match 100.0%; Score 7; DB 22; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.4e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
DB 2 tactaac 8

RESULT 11
AAH55245/C
ID AAH55245 standard; DNA; 11 BP.
XX AC AAH55245;
XX DT 03-SEP-2001 (first entry)
XX DE Genomic DNA methylation parallel detection associated DNA fragment #147.
XX KW DNA methylation; parallel detection; 5-unmethylated cytosine; CpG;
XX KW CpNG; amplification; transcription regulation; genetic imprinting;
XX KW tumorigenesis; primer; ss.
XX OS Unidentified.
XX PN WO200142493-A2.
XX PD 14-JUN-2001.
XX PF 06-DEC-2000; 2000WO-DE04381.
XX PR 06-DEC-1999; 99DE-1059691.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C;
XX WPI; 2001-381705/40.

XX This invention describes a novel method for the parallel detection of the
XX methylation status of genomic DNA (I) which involves a (I) sample being
XX treated chemically to convert 5-unmethylated cytosine to uracil,
XX thymidine or some other base having hybridization behavior different from
XX that of C, then amplifying simultaneously at least 10 different fragments
XX (of fewer than 2 kb) using synthetic oligonucleotide (ON) primers. These
XX primers are based on regulatory, transcribed and/or translated segments
XX present in the sample after chemical treatment. The sequence context of
XX all, or some, of the CpG and CpNG motifs in the amplified products is
XX then determined. The method is used to detect aberrant methylation

CC patterns in the genome, these are implicated in regulation of
CC transcription, genetic imprinting and tumorigenesis. Many target regions
CC in the genome can be analyzed simultaneously and it is not essential to
CC know the sequence context of all targeted regions. Primers may be
CC designed for preferential amplification of particular segments of
CC interest (e.g. promoters and exons).

XX Sequence 11 BP; 3 A; 0 C; 4 G; 4 T; 0 other;
SQ

Query Match 100.0%; Score 7; DB 22; Length 11;
Best Local Similarity 100.0%; Pred. No. 6.3e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
DB 11 TACTAAC 5

RESULT 12
AAH55246
ID AAH55246 standard; DNA; 11 BP.
XX AC AAH55246;
XX DT 03-SEP-2001 (first entry)
XX DE Genomic DNA methylation parallel detection associated DNA fragment #148.
XX KW DNA methylation; parallel detection; 5-unmethylated cytosine; CpG;
XX KW CpNG; amplification; transcription regulation; genetic imprinting;
XX KW tumorigenesis; primer; ss.
XX OS Unidentified.
XX PN WO200142493-A2.
XX PD 14-JUN-2001.
XX PF 06-DEC-2000; 2000WO-DE04381.
XX PR 06-DEC-1999; 99DE-1059691.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C;
XX WPI; 2001-381705/40.

XX This invention describes a novel method for the parallel detection of the
XX methylation status of genomic DNA (I) which involves a (I) sample being
XX treated chemically to convert 5-unmethylated cytosine to uracil,
XX thymidine or some other base having hybridization behavior different from
XX that of C, then amplifying simultaneously at least 10 different fragments
XX (of fewer than 2 kb) using synthetic oligonucleotide (ON) primers. These
XX primers are based on regulatory, transcribed and/or translated segments
XX present in the sample after chemical treatment. The sequence context of
XX all, or some, of the CpG and CpNG motifs in the amplified products is
XX then determined. The method is used to detect aberrant methylation

XX patterns in the genome, these are implicated in regulation of
XX transcription, genetic imprinting and tumorigenesis. Many target regions
XX in the genome can be analyzed simultaneously and it is not essential to
XX know the sequence context of all targeted regions. Primers may be
XX designed for preferential amplification of particular segments of
XX interest (e.g. promoters and exons).

XX Sequence 11 BP; 4 A; 4 C; 0 G; 3 T; 0 other;
SQ

Query Match 100.0%; Score 7; DB 22; Length 11;
Best Local Similarity 100.0%; Pred. No. 6.3e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
|||||
Db 1 tactaac 7

RESULT 13
AAH55253/c
ID AAH55253 standard; DNA; 11 BP.
XX AC
XX AAH55253;
XX
DT 03-SEP-2001 (first entry)
XX
DE Genomic DNA methylation parallel detection associated DNA fragment #155.

XX DNA methylation; parallel detection; 5-unmethylated cytosine; CpG;
XX CpnPg; amplification; transcription regulation; genetic imprinting;
XX tumorigenesis; primer; ss.

XX Unidentified.
XX WO200142493-A2.
XX PN
XX 14-JUN-2001.

XX 06-DEC-2000; 2000WO-DE04381.

XX 06-DEC-1999; 99DE-1059691.

XX (EPiG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C;

XX WPI; 2001-381705/40.

XX Parallel detection of the methylation pattern of many genomic DNA
XX regions, useful for detecting aberrant methylation, includes multiple
XX amplification of chemically modified DNA -

XX Claim 18; Page 21; 63pp; German.

XX This invention describes a novel method for the parallel detection of the
XX methylation status of genomic DNA (I) which involves a (I) sample being
XX treated chemically to convert 5-unmethylated cytosine to uracil,
XX thymidine or some other base having hybridization behavior different from
XX that of C, then amplifying simultaneously at least 10 different fragments
XX (of fewer than 2 kb) using synthetic oligonucleotide (ON) primers. These
XX primers are based on regulatory, transcribed and/or translated segments
XX present in the sample after chemical treatment. The sequence context of
XX all, or some, of the CpG and CpnPg motifs in the amplified products is
XX then determined. The method is used to detect aberrant methylation
XX patterns in the genome, these are implicated in regulation of
XX transcription, genetic imprinting and tumorigenesis. Many target regions
XX in the genome can be analyzed simultaneously and it is not essential to
XX know the sequence context of all targeted regions. Primers may be
XX designed for preferential amplification of particular segments of
XX interest (e.g. promoters and exons).

XX Sequence 11 BP; 3 A; 0 C; 4 G; 4 T; 0 other;

Query Match 100.0%; Score 7; DB 22; Length 11;
Best Local Similarity 100.0%; Pred. No. 6.3e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
|||||

Db 11 TACTAAC 5
RESULT 14
AAH55254
ID AAH55254 standard; DNA; 11 BP.
XX AC
XX AAH55254;

XX 03-SEP-2001 (first entry)

XX Genomic DNA methylation parallel detection associated DNA fragment #156.
XX DNA methylation; parallel detection; 5-unmethylated cytosine; CpG;
XX CpnPg; amplification; transcription regulation; genetic imprinting;
XX tumorigenesis; primer; ss.

XX Unidentified.

XX WO200142493-A2.

XX 14-JUN-2001.

XX 06-DEC-2000; 2000WO-DE04381.

XX 06-DEC-1999; 99DE-1059691.

XX (EPiG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C;

XX WPI; 2001-381705/40.

XX Parallel detection of the methylation pattern of many genomic DNA
XX regions, useful for detecting aberrant methylation, includes multiple
XX amplification of chemically modified DNA -

XX Claim 18; Page 21; 63pp; German.

XX This invention describes a novel method for the parallel detection of the
XX methylation status of genomic DNA (I) which involves a (I) sample being
XX treated chemically to convert 5-unmethylated cytosine to uracil,
XX thymidine or some other base having hybridization behavior different from
XX that of C, then amplifying simultaneously at least 10 different fragments
XX (of fewer than 2 kb) using synthetic oligonucleotide (ON) primers. These
XX primers are based on regulatory, transcribed and/or translated segments
XX present in the sample after chemical treatment. The sequence context of
XX all, or some, of the CpG and CpnPg motifs in the amplified products is
XX then determined. The method is used to detect aberrant methylation
XX patterns in the genome, these are implicated in regulation of
XX transcription, genetic imprinting and tumorigenesis. Many target regions
XX in the genome can be analyzed simultaneously and it is not essential to
XX know the sequence context of all targeted regions. Primers may be
XX designed for preferential amplification of particular segments of
XX interest (e.g. promoters and exons).

XX Sequence 11 BP; 4 A; 4 C; 0 G; 3 T; 0 other;

Query Match 100.0%; Score 7; DB 22; Length 11;
Best Local Similarity 100.0%; Pred. No. 6.3e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
|||||
Db 1 tactaac 7

RESULT 15
AAH28509/c
ID AAX28509 standard; DNA; 12 BP.
XX AC

XX AAX28509;

XX 08-JUN-1999 (first entry)
XX Target sequence for minor groove binding polyamide.
XX
XX
XX Netropsin; Distamycin A analogue; polypyrrole; polyimidazole;
KW carboxamide; polyamide; minor groove binding; oligonucleotide;
KW conjugate; ds.
XX
XX Synthetic.
XX
XX WO9730975-A2.
XX
XX 28-AUG-1997.
XX
XX 20-FEB-1997; 97WO-US03332.
XX
XX 26-FEB-1996; 96US-0607078.
XX
XX (CALY) CALIFORNIA INST OF TECHNOLOGY.
XX
XX Baird EE, Dervan PB;
XX
XX WPI; 1997-435067/40.
XX
XX Preparation of poly-pyrrole and poly-imidazole carboxamides - and
PT production of polyamide-protein and polyamide-oligo:nucleotide
PT conjugates on solid supports
XX
XX Disclosure; Page 14; 167pp; English.
XX
XX The patent describes methods for the preparation of polyamides
CC containing imidazole and pyrrole carboxamides, and also their
CC conjugates with oligonucleotides and proteins. The processes
CC may be used e.g. for solid phase synthesis of analogues of the
CC di- and tri-N-methylpyrrole carboxamide antiviral antibiotics
CC Netropsin and Distamycin A. Materials may be produced which
CC recognise double stranded DNA by interaction with the minor
CC groove of the DNA. These materials may be used as antiviral,
CC antibacterial and antitumour agents. They may be used in design
CC of therapeutic agents. They may be used to bind/cleave double
CC stranded DNA at specific sites using iron and EDTA. The methods
CC give the polyamides and conjugates with high stepwise coupling
CC yields and give highly pure products.
XX
XX Sequence 12 BP; 2 A; 2 C; 3 G; 5 T; 0 other;
SQ

Query Match 100.0%; Score 7; DB 18; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.3e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
 |||||
Db 9 TACTAAC 3

Search completed: July 21, 2002, 09:55:19
Job time: 6380 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 21, 2002, 09:47:18 ; Search time 112.48 Seconds
(without alignments)
15.287 Million cell updates/sec

Title: US-09-754-014-10_COPY_16_22

Perfect score: 7
Sequence: 1 TACTAAC 7

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 383533 seqs, 122816752 residues
Total number of hits satisfying chosen parameters: 767066

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_NA.*
1: /cgn2_6/ptodata/2/ina/5A_COMB.seq.*
2: /cgn2_6/ptodata/2/ina/5B_COMB.seq.*
3: /cgn2_6/ptodata/2/ina/6A_COMB.seq.*
4: /cgn2_6/ptodata/2/ina/6B_COMB.seq.*
5: /cgn2_6/ptodata/2/ina/PCITUS_COMB.seq.*
6: /cgn2_6/ptodata/2/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	7	100.0	7	3 US-09-403-267-1	Sequence 1, Appli
2	7	100.0	9	3 US-08-646-789A-63	Sequence 63, Appli
c 3	7	100.0	12	3 US-08-607-078-5	Sequence 5, Appli
4	7	100.0	12	3 US-09-403-267-33	Sequence 33, Appli
c 5	7	100.0	13	1 US-08-148-058A-2	Sequence 2, Appli
c 6	7	100.0	13	1 US-08-478-042-2	Sequence 2, Appli
c 7	7	100.0	13	1 US-08-645-215-2	Sequence 2, Appli
c 8	7	100.0	13	2 US-08-466-604-2	Sequence 2, Appli
9	7	100.0	14	1 US-08-297-808A-4	Sequence 4, Appli
10	7	100.0	15	4 US-09-242-690A-16	Sequence 16, Appli
11	7	100.0	17	1 US-07-990-965-3	Sequence 3, Appli
12	7	100.0	17	1 US-08-758-306-347	Sequence 347, App
13	7	100.0	17	1 US-08-758-306-349	Sequence 349, App
14	7	100.0	17	1 US-08-758-306-351	Sequence 351, App
15	7	100.0	17	1 US-08-758-306-1315	Sequence 1315, Ap
16	7	100.0	17	1 US-08-758-306-1317	Sequence 1317, Ap
17	7	100.0	17	1 US-08-758-306-1319	Sequence 1319, Ap
18	7	100.0	17	1 US-08-758-306-1321	Sequence 1321, Ap
c 19	7	100.0	18	2 US-08-683-743-19	Sequence 19, Appli
20	7	100.0	18	2 US-08-810-599-65	Sequence 65, Appli
c 21	7	100.0	18	3 US-08-784-582-63	Sequence 63, Appli
22	7	100.0	18	4 US-08-413-740A-152	Sequence 152, App
23	7	100.0	18	5 PCR-US95-04063-152	Sequence 152, App
24	7	100.0	19	1 US-08-219-842-24	Sequence 24, Appli
25	7	100.0	19	1 US-08-066-325-20	Sequence 20, Appli
26	7	100.0	19	1 US-08-451-096-24	Sequence 24, Appli
c 27	7	100.0	19	2 US-08-483-695-15	Sequence 15, Appli

c 28	7	100.0	19	2 US-07-965-285-15	Sequence 15, Appli
c 29	7	100.0	19	4 US-08-487-231-15	Sequence 15, Appli
c 30	7	100.0	19	4 US-09-201-912-15	Sequence 15, Appli
c 31	7	100.0	19	4 US-09-338-907-477	Sequence 477, App
c 32	7	100.0	19	4 US-09-218-207-477	Sequence 477, App
c 33	7	100.0	20	1 US-08-229-145-15	Sequence 15, Appli
c 34	7	100.0	20	1 US-08-229-145-16	Sequence 16, Appli
c 35	7	100.0	20	1 US-08-466-285-7	Sequence 7, Appli
36	7	100.0	20	1 US-08-647-584-123	Sequence 123, App
37	7	100.0	20	1 US-08-639-501-28	Sequence 28, Appli
38	7	100.0	20	3 US-09-044-946-28	Sequence 28, Appli
39	7	100.0	20	3 US-09-166-186-184	Sequence 184, App
40	7	100.0	20	3 US-09-166-186-185	Sequence 185, App
41	7	100.0	20	3 US-09-044-908-28	Sequence 28, Appli
c 42	7	100.0	20	3 US-09-288-461-76	Sequence 76, Appli
43	7	100.0	20	4 US-09-313-932-184	Sequence 184, App
44	7	100.0	20	4 US-09-313-932-185	Sequence 185, App
45	7	100.0	20	4 US-08-397-220B-34	Sequence 34, Appli

ALIGNMENTS

RESULT 1
US-09-403-267-1
; Sequence 1, Application US/09403267
; Patent No. 6159710
; GENERAL INFORMATION:
; APPLICANT: Wistar Institute of Anatomy, and Biology
; APPLICANT: Fraser, Nigel W.
; APPLICANT: Zabolotny, Janice M.
; APPLICANT: Krummenacher, Claude F.
; TITLE OF INVENTION: Method and Compositions for Stabilizing
; UNSTABLE GENE TRANSCRIPTS
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESS: Howson and Howson
; STREET: Spring House Corporate Cntr., P.O. Box 457
; CITY: Spring House
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19477
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/403,267
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/044,664
; FILING DATE: 18-APR-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Bak, Mary E.
; REGISTRATION NUMBER: 31,215
; REFERENCE/DOCKET NUMBER: WST78APCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-540-9200
; TELEFAX: 215-540-5818
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: unknown
; MOLECULE TYPE: RNA (genomic)
US-09-403-267-1

Query Match 100.0%; Score 7; DB 3; Length 7;
Best Local Similarity 71.4%; Pred. No. 3.3e+07;

Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
:|||||
Db 1 UACUAC 7

RESULT 2

US-08-646-789A-63
; Sequence 63, Application US/08646789A
; Patent No. 6022863
; GENERAL INFORMATION:
; APPLICANT: Peyman, John A.
; TITLE OF INVENTION: REGULATION OF GENE EXPRESSION
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PENNIE & EDMONDS
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/646.789A
; FILING DATE: May 21, 1996
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Mirock, S. Leslie
; REGISTRATION NUMBER: 18,872
; REFERENCE/DOCKET NUMBER: 6523-006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 790-9090
; TELEFAX: (212) 869-9741/8864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 63:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-646-789A-63

Query Match 100.0%; Score 7; DB 3; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.5e+07;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
:|||||
Db 2 TACTAAC 8

RESULT 3

US-08-607-078-5/c
; Sequence 5, Application US/08607078
; Patent No. 6090947
; GENERAL INFORMATION:
; APPLICANT: California Institute of Technology
; TITLE OF INVENTION: Method for the synthesis of Pyrrole
; TITLE OF INVENTION: and Imidazole Carboxamides on a
; TITLE OF INVENTION: Solid Support
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Swanson & Bratschun, L.L.C.
; STREET: 8400 E. Prentice Avenue, Suite 200
; CITY: Englewood
; STATE: Colorado

; COUNTRY: USA
; ZIP: 80111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MG
; COMPUTER: IBM pc compatible
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/607.078
; FILING DATE: February 26, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Rosemary P. Kellogg
; REGISTRATION NUMBER: 39,726
; REFERENCE/DOCKET NUMBER: CIT 2347
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (303) 793-3333
; TELEFAX: (303) 793-3433
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-607-078-5

Query Match 100.0%; Score 7; DB 3; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.7e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
:|||||
Db 9 TACTAAC 3

RESULT 4

US-09-403-267-33
; Sequence 33, Application US/09403267
; Patent No. 6159710
; GENERAL INFORMATION:
; APPLICANT: Wistar Institute of Anatomy, and Biology
; APPLICANT: Fraser, Nigel W.
; APPLICANT: Zabolotny, Janice M.
; APPLICANT: Krummenacher, Claude F.
; TITLE OF INVENTION: Method and Compositions for Stabilizing
; TITLE OF INVENTION: Unstable Gene Transcripts
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Howson and Howson
; STREET: Spring House Corporate Cntr., P.O. Box 457
; CITY: Spring House
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19477
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/403.267
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/044,664
; FILING DATE: 18-APR-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Bak, Mary E.
; REGISTRATION NUMBER: 31,215

REFERENCE/DOCKET NUMBER: WST78APCT
TELEPHONE: 215-540-9200
TELEFAX: 215-540-5818
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-09-403-267-33

Query Match 100.0%; Score 7; DB 3; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.7e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0;

Qy 1 TACTAAC 7
Db 6 TACTAAC 12

RESULT 5
US-08-148-058A-2/c
Sequence 2, Application US/08148058A
Patent No. 5804407
GENERAL INFORMATION:
APPLICANT: TAMAOKI, TAIKI
APPLICANT: NAKABAYASHI, HIDEKAZU
TITLE OF INVENTION: IMPROVED METHOD OF EXPRESSING GENES IN
TITLE OF INVENTION: MAMMALIAN CELLS
NUMBER OF SEQUENCES: 46
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
STREET: 699 PRINCE STREET
CITY: ALEXANDRIA
STATE: VA
COUNTRY: USA
ZIP: 22313-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/148,058A
FILING DATE: 04-NOV-1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: MOOI, LESLIE A.
REGISTRATION NUMBER: 37,047
REFERENCE/DOCKET NUMBER: 028722-074
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-854-7400
TELEFAX: 415-854-8275
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
US-08-148-058A-2

Query Match 100.0%; Score 7; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 6.6e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0;

Qy 1 TACTAAC 7
Db 7 TACTAAC 1

RESULT 6
US-08-478-042-2/c
Sequence 2, Application US/08478042
Patent No. 5807738
GENERAL INFORMATION:
APPLICANT: TAMAOKI, TAIKI
APPLICANT: NAKABAYASHI, HIDEKAZU
TITLE OF INVENTION: IMPROVED METHOD OF EXPRESSING GENES IN
TITLE OF INVENTION: MAMMALIAN CELLS
NUMBER OF SEQUENCES: 46
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
STREET: 699 PRINCE STREET
CITY: ALEXANDRIA
STATE: VA
COUNTRY: USA
ZIP: 22313-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/478,042
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: MOOI, LESLIE A.
REGISTRATION NUMBER: 37,047
REFERENCE/DOCKET NUMBER: 028722-126
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-854-7400
TELEFAX: 415-854-8275
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
US-08-478-042-2

Query Match 100.0%; Score 7; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 6.6e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0;

Qy 1 TACTAAC 7
Db 7 TACTAAC 1

RESULT 7
US-08-645-215-2/c
Sequence 2, Application US/08645215
Patent No. 5827686
GENERAL INFORMATION:
APPLICANT: TAMAOKI, TAIKI
APPLICANT: NAKABAYASHI, HIDEKAZU
TITLE OF INVENTION: IMPROVED METHOD OF EXPRESSING GENES IN
TITLE OF INVENTION: MAMMALIAN CELLS
NUMBER OF SEQUENCES: 46
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS, L.L.P.
STREET: 699 PRINCE STREET
CITY: ALEXANDRIA
STATE: VA
COUNTRY: USA
ZIP: 22313-1404
COMPUTER READABLE FORM:

;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/645,215
;; FILING DATE: 13-MAY-1996
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/148,058
;; FILING DATE: 04-NOV-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: MOOI, LESLIE A.
;; REGISTRATION NUMBER: 37,047
;; REFERENCE/DOCKET NUMBER: 028722-135
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 415-854-7400
;; TELEFAX: 415-854-8275
;; INFORMATION FOR SEQ ID NO: 2:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 13 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: double
;; TOPOLOGY: linear
US-08-645-215-2

Query Match 100.0%; Score 7; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 6.6e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 7 TACTAAC 1

RESULT 8
US-08-466-604-2/c
; Sequence 2, Application US/08466604
; Patent No. 5843776
; GENERAL INFORMATION:
; APPLICANT: TAMAOKI, TAIKI
; APPLICANT: NAKABAYASHI, HIDEKAZU
; TITLE OF INVENTION: IMPROVED METHOD OF EXPRESSING GENES IN
; TITLE OF INVENTION: MAMMALIAN CELLS
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: 699 PRINCE STREET
; CITY: ALEXANDRIA
; STATE: VA
; COUNTRY: USA
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,604
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/148,058
; FILING DATE: 04-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: MOOI, LESLIE A.
; REGISTRATION NUMBER: 37,047
; REFERENCE/DOCKET NUMBER: 028722-125
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-854-7400
; TELEFAX: 415-854-8275
; INFORMATION FOR SEQ ID NO: 2:

;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 13 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: double
;; TOPOLOGY: linear
US-08-466-604-2

Query Match 100.0%; Score 7; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 6.6e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 7 TACTAAC 1

RESULT 9
US-08-297-808A-4
; Sequence 4, Application US/08297808A
; Patent No. 5691137
; GENERAL INFORMATION:
; APPLICANT: Rosbash, Michael
; APPLICANT: Stutz, Francoise
; TITLE OF INVENTION: Methods of Screening Candidate Agents
; TITLE OF INVENTION: for Biological Activity Using Yeast Cells
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: US
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/297,808A
; FILING DATE: 30-AUG-1994
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Brook, David E.
; REGISTRATION NUMBER: 22,592
; REFERENCE/DOCKET NUMBER: BRU94-01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-861-6240
; TELEFAX: 617-861-9540
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-297-808A-4

Query Match 100.0%; Score 7; DB 1; Length 14;
Best Local Similarity 71.4%; Pred. No. 6.6e+03;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 1 UACUAC 7

RESULT 10
US-09-242-690A-16
; Sequence 16, Application US/09242690A
; Patent No. 6284534
; GENERAL INFORMATION:

; APPLICANT: KONDO, KEIJI
; APPLICANT: MIURA, YUTAKA
; TITLE OF INVENTION: YEAST VECTOR AND METHOD OF PRODUCING PROTEINS USING THE
; TITLE OF INVENTION: SAME
; FILE REFERENCE: 049441/0118
; CURRENT APPLICATION NUMBER: US/09/242,690A
; CURRENT FILING DATE: 1999-02-23
; PRIOR APPLICATION NUMBER: PCT/JP97/02924
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: JP 8/241062
; PRIOR FILING DATE: 1996-08-23
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Sequence which
; Patent No. 6284534
; OTHER INFORMATION: is common to intron
US-09-242-690A-16

Query Match 100.0%; Score 7; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.5e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 7 tactaac 13

RESULT 11
US-07-990-965-3
; Sequence 3, Application US/07990965
; Patent No. 556954
; GENERAL INFORMATION:
; APPLICANT: Burn, Timothy C.
; APPLICANT: Satterthwaite, Anne B.
; APPLICANT: Tenen, Daniel G.
; TITLE OF INVENTION: Hematopoietic Stem Cell Specific
; TITLE OF INVENTION: Gene
; TITLE OF INVENTION: Expression
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: MA
; COUNTRY: USA
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/990,965
; FILING DATE: 19921215
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Brook, David E.
; REGISTRATION NUMBER: 22,592
; REFERENCE/DOCKET NUMBER: BIH91-03A
; TELEPHONE: 617 861 6240
; TELEFAX: 617 861 9540
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double

; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-07-990-965-3

Query Match 100.0%; Score 7; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.5e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 3 TACTAAC 9

RESULT 12
US-08-758-306-347
; Sequence 347, Application US/08758306
; Patent No. 5807743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Fastseq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 347:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-758-306-347

Query Match 100.0%; Score 7; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 6.5e+03;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 8 UACUAC 14

RESULT 13
US-08-758-306-349
; Sequence 349, Application US/08758306
; Patent No. 5807743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Fastseq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 349:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-758-306-349

Query Match 100.0%; Score 7; DB 1; Length 17;
Best Local Similarity 71.4%; pred. No. 6.5e+03;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 5 UACUAC 11

RESULT 14
US-08-758-306-351
; Sequence 351, Application US/08758306
; Patent No. 5807743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION

; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Fastseq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 351:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-758-306-351

Query Match 100.0%; Score 7; DB 1; Length 17;
Best Local Similarity 71.4%; pred. No. 6.5e+03;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 1 UACUAC 7

RESULT 15
US-08-758-306-1315
; Sequence 1315, Application US/08758306
; Patent No. 5807743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible

```

; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1315:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-758-306-1315

Query Match      100.0%; Score 7; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 6.5e+03;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 TACTAAC 7
    :||:|
Db 11 UACUAAAC 17

```

Search completed: July 21, 2002, 09:47:18
Job time: 11949 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 21, 2002, 09:11:03 ; Search time 3274.61 Seconds
(without alignments)
28.852 Million cell updates/sec

Title: US-09-754-014-10_COPY_16_22
Perfect score: 7
Sequence: 1 TACTAAC 7

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 13736207 seqs, 6748477542 residues

Total number of hits satisfying chosen parameters: 27472414

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST:
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_htc:*
9: gb_est1:*
10: gb_est2:*
11: gb_htc:*
12: gb_gss:*
13: em_gss_hum:*
14: em_gss_inv:*
15: em_gss_pln:*
16: em_gss_vrt:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
C 1	7	100.0	19	12	AZ623493	AZ623493 1M0461M13
2	7	100.0	19	12	AZ778302	AZ778302 2M0013C02
C 3	7	100.0	19	12	AZ806669	AZ806669 2M0068G19
4	7	100.0	21	12	AZ812861	AZ812861 2M0079C19
5	7	100.0	22	12	AZ851620	AZ851620 2M0153M24
6	7	100.0	23	12	AZ345908	AZ345908 1M0080F22
7	7	100.0	23	12	AZ476882	AZ476882 1M0296L02
8	7	100.0	23	12	TA164G12Q	AL473175 T. brucei
9	7	100.0	24	12	AZ304717	AZ304717 1M0004I20
10	7	100.0	26	12	AZ364052	AZ364052 1M0110O02
11	7	100.0	27	12	AZ351430	AZ351430 1M0089C05
C 12	7	100.0	28	12	AZ609297	AZ609297 1M0434B06
13	7	100.0	30	12	AZ480938	AZ480938 1M0302M09
14	7	100.0	30	12	AZ591759	AZ591759 1M0402J02
15	7	100.0	30	12	AZ857764	AZ857764 2M0162M08
C 16	7	100.0	31	12	AZ318049	AZ318049 1M0036F13
17	7	100.0	31	12	AZ831899	AZ831899 2M0111I22

18	7	100.0	32	12	AZ387853	AZ387853 1M0147K23
19	7	100.0	32	12	AZ391582	AZ391582 1M0153I18
C 20	7	100.0	32	12	AZ605009	AZ605009 1M0426E09
21	7	100.0	32	12	TA253H10P	AL483650 T. brucei
C 22	7	100.0	33	12	AZ769247	AL769247 1M0569P10
23	7	100.0	33	12	TA227B09Q	AL479999 T. brucei
24	7	100.0	33	12	TA364B10P	AL494156 T. brucei
C 25	7	100.0	34	10	BJ040894	BJ040894 BJ040894
C 26	7	100.0	34	12	AZ474616	AZ474616 1M0292B14
27	7	100.0	34	12	AZ828219	AZ828219 2M0105P01
28	7	100.0	34	12	TA373F08P	AL496435 T. brucei
29	7	100.0	35	12	AZ345949	AZ345949 1M0080N23
30	7	100.0	35	12	TA369E01Q	AL496036 T. brucei
C 31	7	100.0	37	9	AV853613	AV853613 AV853613
32	7	100.0	37	12	AZ447236	AZ447236 1M0244L18
33	7	100.0	37	12	AZ465835	AZ465835 1M0276H02
C 34	7	100.0	37	12	AZ490406	AZ490406 1M0323A22
C 35	7	100.0	39	9	AU008671	AU008671 AU008671
36	7	100.0	39	12	AZ455333	AZ455333 1M0257J08
C 37	7	100.0	40	10	BF381362	BF381362 ASIR0002
38	7	100.0	40	12	AZ591989	AZ591989 1M0402E06
C 39	7	100.0	41	10	T54451	T54451 Yb06h05_r2
40	7	100.0	41	12	AZ329290	AZ329290 1M0053P22
41	7	100.0	41	12	AZ504919	AZ504919 1M0345A24
42	7	100.0	41	12	AZ790809	AZ790809 2M0039B04
43	7	100.0	42	10	C21089	C21089 HUMGS000260
C 44	7	100.0	42	10	D21033	D21033 HUMGS02016
C 45	7	100.0	42	12	AZ770413	AZ770413 1M0572B01

ALIGNMENTS

AZ623493 19 bp DNA linear GSS 13-DEC-2000
1M0461M13F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0461M13 F, DNA sequence.

ACCESSION AZ623493
VERSION
KEYWORDS
SOURCE
ORGANISM

REFERENCE 1 (bases 1 to 19)
AUTHORS

Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0461 row: M column: 13
Seq primer: CGTTGTAACGACGCCACT
Class: plasmid ends
High quality sequence stop: 19.

JOURNAL
COMMENT

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0461 row: M column: 13
Seq primer: CGTTGTAACGACGCCACT
Class: plasmid ends
High quality sequence stop: 19.

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0461 row: M column: 13
Seq primer: CGTTGTAACGACGCCACT
Class: plasmid ends
High quality sequence stop: 19.

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0461 row: M column: 13
Seq primer: CGTTGTAACGACGCCACT
Class: plasmid ends
High quality sequence stop: 19.

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0461 row: M column: 13
Seq primer: CGTTGTAACGACGCCACT
Class: plasmid ends
High quality sequence stop: 19.

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0461 row: M column: 13
Seq primer: CGTTGTAACGACGCCACT
Class: plasmid ends
High quality sequence stop: 19.

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0461 row: M column: 13
Seq primer: CGTTGTAACGACGCCACT
Class: plasmid ends
High quality sequence stop: 19.

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0461 row: M column: 13
Seq primer: CGTTGTAACGACGCCACT
Class: plasmid ends
High quality sequence stop: 19.

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0461 row: M column: 13
Seq primer: CGTTGTAACGACGCCACT
Class: plasmid ends
High quality sequence stop: 19.

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0461 row: M column: 13
Seq primer: CGTTGTAACGACGCCACT
Class: plasmid ends
High quality sequence stop: 19.

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0461 row: M column: 13
Seq primer: CGTTGTAACGACGCCACT
Class: plasmid ends
High quality sequence stop: 19.

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0461 row: M column: 13
Seq primer: CGTTGTAACGACGCCACT
Class: plasmid ends
High quality sequence stop: 19.

```

/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/notes="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PWD42 (gil4732114[gb]AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
4 a 3 c 5 g 7 t

```

```

Query Match 100.0%; Score 7; DB 12; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 TACTAAC 7
    ||| ||| |||
Db 14 TACTAAC 8

```

```

RESULT 2
LOCUS AZ778302 19 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M0013C02F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0013C02 F, DNA sequence.
AZ778302
ACCESSION AZ778302
VERSION AZ778302.1 GI:12907800
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 19)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0013 row: C column: 02
Seq primer: CGTTGTAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 19.
Location/Qualifiers
1. .19
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0013C02"

```

```

FEATURES
source

```

```

/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/notes="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PWD42 (gil4732114[gb]AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
5 a 9 c 0 g 5 t

```

```

Query Match 100.0%; Score 7; DB 12; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 TACTAAC 7
    ||| ||| |||
Db 8 TACTAAC 14

```

```

RESULT 3
LOCUS AZ806669/c 19 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0068G19R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0068G19 R, DNA sequence.
AZ806669
ACCESSION AZ806669
VERSION AZ806669.1 GI:12970249
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 19)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0068 row: G column: 19
Seq primer: CACACAGAACACGTATGACC
Class: plasmid ends
High quality sequence stop: 19.
Location/Qualifiers
1. .19
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"

```

```

FEATURES
source

```

```

/clone="UUGC2M0068G19"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
3 a 2 c 7 g 7 t
BASE COUNT
ORIGIN
Query Match 100.0%; Score 7; DB 12; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TACTAAC 7
Db 18 TACTAAC 12
RESULT 4
A2812861
LOCUS 2M0079C19R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION 2M0079C19R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
ACCESSION A2812861
VERSION A2812861.1 GI:12982526
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 21)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: dunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0079 row: C column: 19
Seq primer: CACACGAGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 21.
FEATURES
Location/Qualifiers
1..21
/organism="Mus musculus"
/strain="C57BL/6J"

```

```

/db_xref="taxon:10090"
/clone="UUGC2M0079C19"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
4 a 9 c 3 g 5 t
BASE COUNT
ORIGIN
Query Match 100.0%; Score 7; DB 12; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.8e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TACTAAC 7
Db 5 TACTAAC 11
RESULT 5
A2851620
LOCUS 2M0153M24R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION 2M0153M24R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
ACCESSION A2851620
VERSION A2851620.1 GI:13037799
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 22)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: dunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0153 row: M column: 24
Seq primer: CACACGAGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 22.
FEATURES
Location/Qualifiers
1..22
/organism="Mus musculus"

```

```

/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M015M24"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gii14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
BASE COUNT      9 a      7 c      0 g      6 t
ORIGIN

```

```

Query Match      100.0%; Score 7; DB 12; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.9e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
    |
Db 6 TACTAAC 12

```

```

RESULT 6
LOCUS      AZ345908                23 bp      DNA      linear      GSS 29-SEP-2000
DEFINITION 1M0080F22R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0080F22 R, DNA sequence.
ACCESSION  AZ345908
VERSION     AZ345908.1 GI:10425145
KEYWORDS    GSS.
SOURCE      house mouse.
ORGANISM    Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
            Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
            ,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
            and Wright,D., Weiss,R.
            Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
            Unpublished (2000)
            Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000 Std Error: 0.00
            Plate: 0080 row: F column: 22
            Seq primer: CACACAGGAACACGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 23.
FEATURES             source 1..23
            Location/Qualifiers

```

```

/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0080F22"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gii14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
BASE COUNT      10 a      2 c      1 g      10 t
ORIGIN

```

```

Query Match      100.0%; Score 7; DB 12; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.9e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
    |
Db 13 TACTAAC 19

```

```

RESULT 7
LOCUS      AZ476882                23 bp      DNA      linear      GSS 04-OCT-2000
DEFINITION 1M0296L02F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0296L02 F, DNA sequence.
ACCESSION  AZ476882
VERSION     AZ476882.1 GI:10635007
KEYWORDS    GSS.
SOURCE      house mouse.
ORGANISM    Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
            Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
            ,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
            and Wright,D., Weiss,R.
            Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
            Unpublished (2000)
            Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000 Std Error: 0.00
            Plate: 0296 row: L column: 02
            Seq primer: CGTTGTAACACGACGCCACT
            Class: plasmid ends
            High quality sequence stop: 23.
FEATURES             Location/Qualifiers

```



```

source
1. .23
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0236L02"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PWD42 (gi14732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid RL. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
7 a 5 c 2 g 9 t
BASE COUNT
ORIGIN

FEATURES
Location/Qualifiers
1. .23
/organism="Trypanosoma brucei"
/strain="TREU927"
/db_xref="taxon:5691"
/clone="164g12"
11 a 5 c 1 g 6 t
BASE COUNT
ORIGIN

Query Match 100.0%; Score 7; DB 12; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.9e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 2 TACTAAC 8

RESULT 9
AZ304717
LOCUS AZ304717 24 bp DNA linear GSS 29-SEP-2000
DEFINITION 1M0004120R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0004120 R, DNA sequence.
ACCESSION AZ304717
VERSION AZ304717.1 GI:10341011
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 24)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0004 row: I column: 20
Seq primer: CACACAGGAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 24.
Location/Qualifiers
1. .24
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0004120"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PWD42 (gi14732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid RL. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
7 a 5 c 2 g 9 t
BASE COUNT
ORIGIN

FEATURES
Location/Qualifiers
1. .23
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0236L02"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PWD42 (gi14732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid RL. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
7 a 5 c 2 g 9 t
BASE COUNT
ORIGIN

Query Match 100.0%; Score 7; DB 12; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.9e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
Db 4 TACTAAC 10

RESULT 8
TA164G12Q
LOCUS TA164G12Q 23 bp DNA linear GSS 13-DEC-2000
DEFINITION T. brucei sheared genomic DNA clone 164g12, reverse sequence,
genomic survey sequence.
ACCESSION AL473175
VERSION AL473175.1 GI:11838448
KEYWORDS GSS.
SOURCE Trypanosoma brucei.
ORGANISM Trypanosoma brucei
Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae;
Trypanosoma.
1 (bases 1 to 23)
REFERENCE Hall,N., Bowman,S., Lennard,N.J., Doggett,J., Atkin,R.,
Chillingworth,C., Ormond,D., Harris,B., El-Sayed,N., Hou,L.,
Melville,S.E., Rajandream,M.A. and Barrell,B.G.
Direct Submission
Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing
project, Sanger Centre. The Wellcome Trust Genome Campus, Hinxton,
Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and
nh@sanger.ac.uk
Constructed at the Institute for Genomic Research (TIGR),
Rockville, MD. Genomic DNA isolated from a cloned population of
Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared
to give a tight size distribution (
4 kb). The v + i method used for the library construction is
described in detail in Smith, H. and Venter, J.C. (Making small
insert libraries for whole genome shotgun sequencing projects. In
Genome Sequencing: A Practical Approach, eds. M. Vaudin and B.
Barrell, Oxford University Press, 1999).
Email: nelsayed@tigr.org
Details of T. brucei sequencing at the Sanger Centre are available
at http://www.sanger.ac.uk/projects/T_brucei/.

```

of pWD42 (gi14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid RL. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 7 a 8 c 3 g 6 t
ORIGIN

Query Match 100.0%; Score 7; DB 12; Length 24;
Best Local Similarity 100.0%; Pred. No. 2.9e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TACTAAC 7
| | | | | | |
Db 2 TACTAAC 8

RESULT 10
AZ364052
LOCUS 26 bp DNA linear GSS 02-OCT-2000
DEFINITION IM0110002F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0110002 F, DNA sequence.
ACCESSION AZ364052
VERSION AZ364052.1 GI:10477752
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 26)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0110 row: 0 column: 02
Seq primer: CGTTGTAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 26.

FEATURES
source
1..26
Location/Qualifiers
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0110002"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid RL. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 10 a 10 c 0 g 6 t
ORIGIN

Query Match 100.0%; Score 7; DB 12; Length 26;
Best Local Similarity 100.0%; Pred. No. 2.9e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TACTAAC 7
| | | | | | |
Db 16 TACTAAC 22

RESULT 11
AZ351430
LOCUS 27 bp DNA linear GSS 29-SEP-2000
DEFINITION IM0089C05R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0089C05 R, DNA sequence.
ACCESSION AZ351430
VERSION AZ351430.1 GI:10430667
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 27)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0089 row: C column: 05
Seq primer: CACACAGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 27.

FEATURES
source
1..27
Location/Qualifiers
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0089C05"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to

10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN

10 a 7 c 2 g 8 t

Query Match 100.0%; Score 7; DB 12; Length 27;
Best Local Similarity 100.0%; Pred. No. 2.9e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
Db 10 TACTAAC 16

RESULT 12
A2609297/c
LOCUS A2609297 28 bp DNA linear GSS 13-DEC-2000
DEFINITION 1M0434B06F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0434B06 F, DNA sequence.

ACCESSION A2609297
VERSION A2609297.1 GI:11731487
KEYWORDS GSS.

SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 28)

AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177

Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0434 row: B column: 06
Seq primer: CGTTCTAAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 28.

Location/Qualifiers
1. 28
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0434B06"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"

/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: pWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 9 a 1 c 9 g 9 t

ORIGIN

Query Match 100.0%; Score 7; DB 12; Length 28;
Best Local Similarity 100.0%; Pred. No. 2.9e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
Db 22 TACTAAC 16

RESULT 13
A2480938
LOCUS A2480938 30 bp DNA linear GSS 04-OCT-2000
DEFINITION 1M0302M09R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0302M09 R, DNA sequence.

ACCESSION A2480938
VERSION A2480938.1 GI:10641919
KEYWORDS GSS.

SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 30)

AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177

Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0302 row: M column: 09
Seq primer: CACACAGGAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 30.

Location/Qualifiers
1. 30
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0302M09"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"

/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: pWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were

ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (gi14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid RL. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN

9 a 9 c 3 g 9 t

Query Match 100.0%; Score 7; DB 12; Length 30;
Best Local Similarity 100.0%; Pred. No. 2.9e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
|||||||
Db 18 TACTAAC 24

RESULT 14

AZ591759 30 bp DNA linear GSS 13-DEC-2000
LOCUS
DEFINITION MW402J02F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0402J02 F, DNA sequence.

ACCESSION AZ591759
VERSION AZ591759.1 GI:11713949
KEYWORDS GSS.
SOURCE house mouse.

ORGANISM

Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 30)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
and Wright,D., Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

University of Utah

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0402 row: J column: 02

Seq primer: CGTGTAAACAGCGCCACT

Class: plasmid ends

High quality sequence stop: 30.

Location/Qualifiers

1. .30

/organism="Mus musculus"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGC1M0402J02"

/clone_lib="Mouse 10kb plasmid UUGC1M library"

/sex="Male"

/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"

/note="Vector: PWD42nv; Purified genomic DNA from M.

musculus C57BL/6J (male) was obtained from the Jackson

Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA

was hydrodynamically sheared by repeated passage through a

0.005 inch orifice at constant velocity. The sheared DNA

was blunt end-repaired with T4 DNA polymerase and T4

polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (gi14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid RL. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN

8 a 6 c 8 g 8 t

Query Match 100.0%; Score 7; DB 12; Length 30;
Best Local Similarity 100.0%; Pred. No. 2.9e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TACTAAC 7
|||||||
Db 13 TACTAAC 19

RESULT 15

AZ857764 30 bp DNA linear GSS 21-FEB-2001
LOCUS
DEFINITION ZM0162M08R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0162M08 R, DNA sequence.

ACCESSION AZ857764
VERSION AZ857764.1 GI:13050236
KEYWORDS GSS.
SOURCE house mouse.

ORGANISM

Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 30)

AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
and Wright,D., Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

University of Utah

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0162 row: M column: 08

Seq primer: CACACAGAAACACGATGACC

Class: plasmid ends

High quality sequence stop: 30.

Location/Qualifiers

1. .30

/organism="Mus musculus"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGC2M0162M08"

/clone_lib="Mouse 10kb plasmid UUGC1M library"

/sex="Male"

/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"

/note="Vector: PWD42nv; Purified genomic DNA from M.

musculus C57BL/6J (male) was obtained from the Jackson

Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA

was hydrodynamically sheared by repeated passage through a

0.005 inch orifice at constant velocity. The sheared DNA

was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 6 a 4 c 8 g 12 t
ORIGIN

Query Match 100.0%; Score 7; DB 12; Length 30;
Best Local Similarity 100.0%; Pred. No. 2.9e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TACTAAC 7
 |||||
DB 6 TACTAAC 12

Search completed: July 21, 2002, 09:11:05
Job time: 10381 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 21, 2002, 09:45:15 ; Search time 2038.31 Seconds

(without alignments)
215.599 Million cell updates/sec

Title: US-09-754-014-10_COPY_25_45

Perfect score: 21

Sequence: 1 TTCTTTTTCCTTCACAGG 21

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 1797656 seqs, 10463268293 residues

Total number of hits satisfying chosen parameters: 3595312

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : GenEmbl.*

1: gb_ba.*

2: gb_htg.*

3: gb_in.*

4: gb_em.*

5: gb_ov.*

6: gb_pat.*

7: gb_ph.*

8: gb_pl.*

9: gb_pr.*

10: gb_ro.*

11: gb_sts.*

12: gb_sy.*

13: gb_un.*

14: gb_vi.*

15: em_ba.*

16: em_fun.*

17: em_hum.*

18: em_in.*

19: em_mu.*

20: em_om.*

21: em_or.*

22: em_ov.*

23: em_pat.*

24: em_ph.*

25: em_pl.*

26: em_ro.*

27: em_sts.*

28: em_un.*

29: em_vi.*

30: em_htg_hum.*

31: em_htg_inv.*

32: em_htg_other.*

33: em_htgo_inv.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
------------	-------	-------------	--------	----	-------------

RESULT 1

BD007073

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

BD007073

IL-12 gene expression and delivery systems and uses.

BD007073

BD007073.1 GI:18635444

JP 2001503257-A/4.

unidentified.

unclassified.

1 (bases 1 to 45)

Nodosutoromu,J., Freemark,B. and Dishupande,D.

IL-12 gene expression and delivery systems and uses

Patent: JP 2001503257-A 4 13-MAR-2001;

BARENISU INC,SYNTEX INC

OS Unidentified

PN JP 2001503257-A/4

PD 13-MAR-2001

PF 10-OCT-1997 JP 1998519514

PR 18-OCT-1996 US 60/028676

PI JEFF NODOSUTOROMU,BLOUCE FREEMARK,DIPA DISHUPANDE PC

C12N15/09,A61K31/711,A61K38/00,A61K47/18,A61K48/00, PC

A61P11/06.

ALIGNMENTS

45 bp DNA linear PAT 31-JAN-2002

```
PC C12N15/00,A61K37/02
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1..45
FT /organism='Unidentified'.
FEATURES
    source
        Location/Qualifiers
            1..45
            /organism='unidentified'
            /db_xref='taxon:32644'
BASE COUNT 8 a 10 c 8 g 19 t
ORIGIN
    1 TTCTTTTCTCTTCACAGG 21
      |||
      25 TTCTTTTCTCTTCACAGG 45

RESULT 2
BD007083
LOCUS BD007083 45 bp DNA linear PAT 31-JAN-2002
DEFINITION Gene expression and delivery systems and uses.
ACCESSION BD007083
VERSION BD007083.1 GI:18635454
KEYWORDS JP 2001503258-A/8.
SOURCE unclassified.
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 45)
AUTHORS Nodosutorom,J., Freemark,B. and Dishupande,D.
TITLE Gene expression and delivery systems and uses
JOURNAL Patent: JP 2001503258-A 8 13-MAR-2001;
BARENTISO INC
OS Unidentified
PN JP 2001503258-A/8
PD 13-MAR-2001
PF 10-OCT-1997 JP 1998519520
PR 18-OCT-1996 US 60/028687
PI JEFF NODOSUTOROMU,BLUCE FREEMARK,DIPA DISHUPANDE PC
C12N15/00,A61K48/00,A61P11/06,A61P35/00,A61P43/00//C07K14/54, PC
C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1..45
FT /organism='Unidentified'.
FEATURES
    source
        Location/Qualifiers
            1..45
            /organism='unidentified'
            /db_xref='taxon:32644'
BASE COUNT 8 a 10 c 8 g 19 t
ORIGIN
    1 TTCTTTTCTCTTCACAGG 21
      |||
      25 TTCTTTTCTCTTCACAGG 45

Query Match 100.0%; Score 21; DB 6; Length 45;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCTTTTCTCTTCACAGG 21
  |||
  25 TTCTTTTCTCTTCACAGG 45

Db 25 TTCTTTTCTCTTCACAGG 45

RESULT 3
AX249943
LOCUS AX249943 3589 bp DNA linear PAT 28-SEP-2001
DEFINITION Sequence 1 from Patent WO0166149.
ACCESSION AX249943
```

```
PC C12N15/00,A61K37/02
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1..45
FT /organism='Unidentified'.
FEATURES
    source
        Location/Qualifiers
            1..45
            /organism='unidentified'
            /db_xref='taxon:32644'
BASE COUNT 8 a 10 c 8 g 19 t
ORIGIN
    1 TTCTTTTCTCTTCACAGG 21
      |||
      25 TTCTTTTCTCTTCACAGG 45

RESULT 2
BD007083
LOCUS BD007083 45 bp DNA linear PAT 31-JAN-2002
DEFINITION Gene expression and delivery systems and uses.
ACCESSION BD007083
VERSION BD007083.1 GI:18635454
KEYWORDS JP 2001503258-A/8.
SOURCE unclassified.
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 45)
AUTHORS Nodosutorom,J., Freemark,B. and Dishupande,D.
TITLE Gene expression and delivery systems and uses
JOURNAL Patent: JP 2001503258-A 8 13-MAR-2001;
BARENTISO INC
OS Unidentified
PN JP 2001503258-A/8
PD 13-MAR-2001
PF 10-OCT-1997 JP 1998519520
PR 18-OCT-1996 US 60/028687
PI JEFF NODOSUTOROMU,BLUCE FREEMARK,DIPA DISHUPANDE PC
C12N15/00,A61K48/00,A61P11/06,A61P35/00,A61P43/00//C07K14/54, PC
C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1..45
FT /organism='Unidentified'.
FEATURES
    source
        Location/Qualifiers
            1..45
            /organism='unidentified'
            /db_xref='taxon:32644'
BASE COUNT 8 a 10 c 8 g 19 t
ORIGIN
    1 TTCTTTTCTCTTCACAGG 21
      |||
      25 TTCTTTTCTCTTCACAGG 45

Query Match 100.0%; Score 21; DB 6; Length 45;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCTTTTCTCTTCACAGG 21
  |||
  25 TTCTTTTCTCTTCACAGG 45

Db 25 TTCTTTTCTCTTCACAGG 45

RESULT 3
AX249943
LOCUS AX249943 3589 bp DNA linear PAT 28-SEP-2001
DEFINITION Sequence 1 from Patent WO0166149.
ACCESSION AX249943
```

```
VERSION AX249943.1 GI:15864429
KEYWORDS synthetic construct.
ORGANISM synthetic construct
          artificial sequence.
REFERENCE 1 (bases 1 to 3589)
AUTHORS Fewell,J.G., MacLaughlin,F., Smith,L.C., Nicol,F. and Rolland,A.
TITLE Nucleic acid formulations for gene delivery and methods of use
JOURNAL Patent: WO 0166149-A 1 13-SEP-2001;
          Valentis, Inc. (US)
FEATURES
    source
        Location/Qualifiers
            1..3589
            /organism='synthetic construct'
            /db_xref='taxon:32630'
            /note='Expression plasmid pIF0921 encoding for human
            interferon alpha (7 68) ---. (1334).'"
            768..1334
            /note='unnamed protein product'
            /codon_start=1
            /transl_table=11
            /protein_id='CAC88666.1'
            /db_xref='GI:15864430'
            /translation='MALTFALLVALLVLSCSKSCSVGCDLPQTHSLGSRRTMLLAQM
            RRISLFSCLKNRHDFGPOEEFGNFOKAETIPVLHEMIQQIIPNLFSTKDSSAAWDET
            LLDKFYTELYQQNDLEACVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSP
            CAWEVVRABIMRSFSLTNLQESLSRKE"
BASE COUNT 833 a 983 c 932 g 841 t
ORIGIN
    1 TTCTTTTCTCTTCACAGG 21
      |||
      742 TTCTTTTCTCTTCACAGG 762

Query Match 100.0%; Score 21; DB 6; Length 3589;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCTTTTCTCTTCACAGG 21
  |||
  742 TTCTTTTCTCTTCACAGG 762

Db 742 TTCTTTTCTCTTCACAGG 762

RESULT 4
AX249944
LOCUS AX249944 3609 bp DNA linear PAT 28-SEP-2001
DEFINITION Sequence 2 from Patent WO0166149.
ACCESSION AX249944
VERSION AX249944.1 GI:15864431
KEYWORDS synthetic construct.
SOURCE synthetic construct.
ORGANISM synthetic construct.
          artificial sequence.
REFERENCE 1 (bases 1 to 3609)
AUTHORS Fewell,J.G., MacLaughlin,F., Smith,L.C., Nicol,F. and Rolland,A.
TITLE Nucleic acid formulations for gene delivery and methods of use
JOURNAL Patent: WO 0166149-A 2 13-SEP-2001;
          Valentis, Inc. (US)
FEATURES
    source
        Location/Qualifiers
            1..3609
            /organism='synthetic construct'
            /db_xref='taxon:32630'
            /note='Expression plasmid pep1403 encoding for mouse
            erythropoietin (801) ---. (1379)"
            801..1379
            /note='unnamed protein product'
            /codon_start=1
            /transl_table=11
            /protein_id='CAC88667.1'
            /db_xref='GI:15864432'
            /translation='MGVPERPTLLLSLLLSLLPLGLPVLCAAPRLICDSRVLELYILE
            AKEAENVTMGCAEGRPLSENITVPDITKVNFYAKRMVEEQAIYVWQGLSLSEAILQ
            AQALLANSQPPETLQLHIDKATISGLRSLTSLRLVLAQKELMSPDTPPPAPLRLTLT
            VDTFCKLFRVYANFLRGLKLYTGFVCRGDR"
BASE COUNT 811 a 1031 c 953 g 814 t
ORIGIN
    1 TTCTTTTCTCTTCACAGG 21
      |||
      811 TTCTTTTCTCTTCACAGG 814
```


Query Match 100.0%; Score 21; DB 6; Length 3609;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCCTTTTCTCTTCACAGG 21
|||||
DB 767 TTCCTTTTCTCTTCACAGG 787

RESULT 5
AX249946
LOCUS AX249946 4276 bp DNA linear PAT 28-SEP-2001
DEFINITION Sequence 4 from Patent WO0166149.
ACCESSION AX249946
VERSION AX249946.1 GI:15864435
KEYWORDS
SOURCE synthetic construct.
ORGANISM artificial sequence.
REFERENCE 1 (bases 1 to 4276)
AUTHORS Fewell,J.G., MacLaughlin,F., Smith,L.C., Nicol,F. and Rolland,A.
TITLE Nucleic acid formulations for gene delivery and methods of use
JOURNAL Patent: WO 0166149-A 4 13-SEP-2001;
Valentis, Inc. (US)
FEATURES
source
1..4276
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Expression plasmid pFN1645 having codon optimized
sequence encoding ng for human coagulation factor IX (786)
(2171)."
786..2171
/note="unnamed protein product"
/codon_start=1
/transl_table=11
/protein_id="CAC88669.1"
/db_xref="GI:15864436"
/translation="MORVNMIMAESPLITICLLGYLSAECTVFLDHNANKILNRP
KRYNSGLEEFVQGNLERECMEKCSFEAREVFENTERTTEFWKYVDGDCESNPC
LNGSKDDINSYECWCPGEGKNCELDVTICNKGRCCEQCKNSADNKVVCSTEG
YRLAENQSCPEAPFPFCGRVSVQTSKLTAEAVFPDVIYNSTEAEITLNIITQST
QSFNDFTRVGGEDAKPGQFPQWVVLNGKVDACFGSIVNEKWIYTAACHVETGKIT
VVAEGHNIETEHTQKRNIRIIPHHYNAAINKYNHDIALLDEPLVLSYVPTI
CTADKEYTNIFLFGSGYVSGWGRVPHKRSALVQLYLRVPLVDRATCLRSKFTIYN
NMFCAGFHEGGRDSCQDGGPHVTEGTSFLTGLISGEECAMKGKGIYTKVSR
VNWIKETKLT"
BASE COUNT 1059 a 1092 c 1120 g 1005 t
ORIGIN

Query Match 100.0%; Score 21; DB 6; Length 4276;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCCTTTTCTCTTCACAGG 21
|||||
DB 749 TTCCTTTTCTCTTCACAGG 769

RESULT 6
AX249945
LOCUS AX249945 4496 bp DNA linear PAT 28-SEP-2001
DEFINITION Sequence 3 from Patent WO0166149.
ACCESSION AX249945
VERSION AX249945.1 GI:15864433
KEYWORDS
SOURCE synthetic construct.
ORGANISM artificial sequence.
REFERENCE 1 (bases 1 to 4496)
AUTHORS Fewell,J.G., MacLaughlin,F., Smith,L.C., Nicol,F. and Rolland,A.
TITLE Nucleic acid formulations for gene delivery and methods of use

JOURNAL Patent: WO 0166149-A 3 13-SEP-2001;
Valentis, Inc. (US)
FEATURES
Location/Qualifiers
source
1..4496
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Expression plasmid pFN0945 having natural sequence
encoding human coagulation factor IX"
782..2167
/note="unnamed protein product"
/codon_start=1
/transl_table=11
/protein_id="CAC88668.1"
/db_xref="GI:15864434"
/translation="MORVNMIMAESPLITICLLGYLSAECTVFLDHNANKILNRP
KRYNSGLEEFVQGNLERECMEKCSFEAREVFENTERTTEFWKYVDGDCESNPC
LNGSKDDINSYECWCPGEGKNCELDVTICNKGRCCEQCKNSADNKVVCSTEG
YRLAENQSCPEAPFPFCGRVSVQTSKLTAEAVFPDVIYNSTEAEITLNIITQST
QSFNDFTRVGGEDAKPGQFPQWVVLNGKVDACFGSIVNEKWIYTAACHVETGKIT
VVAEGHNIETEHTQKRNIRIIPHHYNAAINKYNHDIALLDEPLVLSYVPTI
CTADKEYTNIFLFGSGYVSGWGRVPHKRSALVQLYLRVPLVDRATCLRSKFTIYN
NMFCAGFHEGGRDSCQDGGPHVTEGTSFLTGLISGEECAMKGKGIYTKVSR
VNWIKETKLT"
BASE COUNT 1127 a 1119 c 1147 g 1103 t
ORIGIN

Query Match 100.0%; Score 21; DB 6; Length 4496;
Best Local Similarity 100.0%; Pred. No. 56;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCCTTTTCTCTTCACAGG 21
|||||
DB 748 TTCCTTTTCTCTTCACAGG 768

RESULT 7
AF302194/c
LOCUS AF302194 362 bp DNA linear BCT 02-OCT-2001
DEFINITION Streptococcus suis clone iri7 iron-restricted induced promoter
region.
ACCESSION AF302194
VERSION AF302194.1 GI:15824351
KEYWORDS
SOURCE Streptococcus suis.
ORGANISM Streptococcus suis.
REFERENCE 1 (bases 1 to 362)
AUTHORS Smith,H.E., Buijs,H., de Vries R.R., Wisselink,H.J.,
Stockhofe-Zurwieden,N. and Smits,M.A.
TITLE Environmentally regulated genes of Streptococcus suis:
identification by the use of iron-restricted conditions in vitro
and by experimental infection of piglets
JOURNAL Microbiology 147 (Pt 2), 271-280 (2001)
MEDLINE 21097266
PUBMED 11158344
REFERENCE 2 (bases 1 to 362)
AUTHORS Smith,H.E., Buijs,H., de Vries R.R., Wisselink,H.J.,
Stockhofe-Zurwieden,N. and Smits,M.A.
TITLE Direct Submission
JOURNAL Submitted (01-SEP-2000) Department of Bacteriology, Institute for
Animal Science and Health, P.O. Box 65, Lelystad 8200 AB, The
Netherlands
FEATURES
Location/Qualifiers
source
1..362
/organism="Streptococcus suis"
/db_xref="taxon:1307"
/clone="iri7"
misc_feature 1..362
/note="includes iron-restricted induced promoter"
BASE COUNT 124 a 56 c 74 g 100 t 8 others
ORIGIN

```

Query Match      95.2%; Score 20; DB 1; Length 362;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCTTTTTCCTCTCAGG 20
    |||||
Db 129 TTCTTTTTCCTCTCAGG 110

RESULT 8
AC098692/c
LOCUS AC098692 154761 bp DNA linear HTG 30-OCT-2001
DEFINITION Homo sapiens chromosome 1 clone RP11-60K15, WORKING DRAFT SEQUENCE,
7 unordered pieces.
ACCESSION AC098692
VERSION AC098692.1 GI:16519529
KEYWORDS HTG; HTGS_PHASE1; HTGS_DRAFT; HTGS_FULLTOP; HTGS_ACTIVEFIN.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 154761)
Kaul, R.K., Olson, M.V., Raymond, C. and Haugen, E.D.
Direct Submission
Unpublished
2 (bases 1 to 154761)
Kaul, R.K., Olson, M.V., Raymond, C. and Haugen, E.D.
Direct Submission
Submitted (30-OCT-2001) Genome Center, University of Washington,
Box 352145, Seattle, WA 98195, USA
-----
Center: University of Washington Genome Center
Center Code: UWGC
Web site: http://www.genome.washington.edu
Contact: uwchgsg@u.washington.edu
-----
Project Information
Center project name: chr-1
Center clone name: RP11-60K15 (sc0443)
-----
Summary Statistics
Sequencing vector: plasmid; L08752; 100% of reads
Chemistry: Dye-terminator ET; 84% of reads
Chemistry: Dye-terminator Big Dye; 16% of reads
Assembly program: Phrap; version 0.990319
Consensus quality: 150156 bases at least Q40
Consensus quality: 152633 bases at least Q30
Consensus quality: 153757 bases at least Q20
Insert size: 134161; sum-of-contigs
Quality coverage: 11.9x in Q20 bases; sum-of-contigs
-----
* NOTE: This is a 'working draft' sequence. It currently
* consists of 7 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.
*
1 2732: contig of 2732 bp in length
* 2733: gap of unknown length
* 2833: contig of 3320 bp in length
* 6152: gap of unknown length
* 6252: gap of unknown length
* 14109: contig of 7857 bp in length
* 14110: gap of unknown length
* 14209: contig of 9169 bp in length
* 23378: gap of unknown length
* 23379: contig of 16084 bp in length
* 23479: gap of unknown length
* 39562: gap of unknown length
* 39663: contig of 36316 bp in length
* 75978: gap of unknown length
* 75979: contig of 78683 bp in length.
* 76079 154761: Location/Qualifiers

FEATURES
Source
1..154761
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="1"
/clone="RP11-60K15"
/clone_lib="RPCI human BAC library 11"
1..2732
/feature="assembly_name:Contig15"
2833..6152
/feature="assembly_name:Contig16"
6253..14109
/feature="assembly_name:Contig17"
14210..23378
/feature="assembly_name:Contig18"
23479..39562
/feature="assembly_name:Contig19"
39663..75978
/feature="assembly_name:Contig20"
76079..154761
/feature="assembly_name:Contig21"
603 others
BASE COUNT 50562 a 26801 c 25413 g 51382 t
ORIGIN

Query Match      92.4%; Score 19.4; DB 2; Length 154761;
Best Local Similarity 95.2%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TTCTTTTTCCTCTCAGG 21
    |||||
Db 102134 TTTTTCCTCTCTCAGG 102114

RESULT 9
AL359205/c
LOCUS AL359205 169434 bp DNA linear PRI 13-DEC-2000
DEFINITION Human DNA sequence from clone RP11-345N16 on chromosome 1, complete
sequence.
ACCESSION AL359205
VERSION AL359205.15 GI:11863412
KEYWORDS HTG.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 169434)
Williams, S.
Direct Submission
Submitted (13-DEC-2000) Sanger Centre, Hinxton, Cambridgeshire,
CB10 1SA, UK. E-mail enquiries: humquery@sanger.ac.uk
requests: clonerequest@sanger.ac.uk
On Dec 15, 2000 this sequence version replaced gi:11691506.
During sequence assembly data is compared from overlapping clones.
Where differences are found these are annotated as variations
together with a note of the overlapping clone name. Note that the
variation annotation may not be found in the sequence submission
corresponding to the overlapping clone, as we submit sequences with
only a small overlap as described above.
This sequence has been finished according to sequence map criteria
as follows. An attempt is made to resolve all sequencing problems,
such as compressions and repeats, but not necessarily within known
annotated repeat sequence elements. Where the sequence is
ambiguous, there is an annotation using the 'unsure' feature key.
The following abbreviations are used to associate primary accession
numbers given in the feature table with their source databases:
Em., EMBL; Sw., SWISSPROT; Tr., TREMBL; Wp., WORMPEP; Information
on the WORMPEP database can be found at
http://www.sanger.ac.uk/Projects/C.elegans/wormpep
This sequence
was generated from part of bacterial clone contigs of human
chromosome 1, constructed by the Sanger Centre Chromosome 1 Mapping
Group. Further information can be found at
http://www.sanger.ac.uk/HGP/Chr1
RP11-345N16 is from the library RPCI-11.2 constructed by the group
```



```

/note="L1MA5 repeat: matches 3964. .4566 of consensus"
57512. .57861
/note="THE1C repeat: matches 15. .371 of consensus"
57862. .59586
/note="L1MA5 repeat: matches 4561. .6300 of consensus"
59595. .55783
/note="L1M4 repeat: matches 5396. .5568 of consensus"
59780. .60717
/note="L1M4 repeat: matches 4309. .5287 of consensus"
60724. .60892
/note="L1M4 repeat: matches 3243. .3420 of consensus"
60894. .60989
/note="48 copies 2 mer tt 66% conserved"
61123. .61328
/note="L1M4 repeat: matches 2870. .3091 of consensus"
61330. .61426

Query Match          92.4%; Score 19.4; DB 9; Length 169434;
Best local Similarity 95.2%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TTTCTTTTCTCTCTCAGG 21
|| ||||| ||||| |||||
Db 111932 TTTTCTTTCTCTCTCAGG 111912

RESULT 10
AC023198 171588 bp DNA linear HTG 28-MAR-2000
LOCUS Homo sapiens chromosome 1 clone RP11-345N16 map 1, WORKING DRAFT
DEFINITION AC023198
ACCESSION AC023198
VERSION AC023198.2 GI:7331456
KEYWORDS HTG; HTGS_PHASE1; HTGS_DRAFT.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 171588)
Birren,B., Linton,L., Nusbaum,C., Lander,E., Abraham,H., Allen,N.,
Anderson,S., Baldwin,J., Barna,N., Beckerly,R., Beda,F.,
Boguslavskiy,L., Boukhgalter,B., Brown,A., Burkett,G., Castle,A.,
Choepel,Y., Collangelo,M., Collins,S., Collymore,A., Cooke,P.,
Dearellano,K., Dewar,K., Domino,M., Doyle,M., Fenestor,J.,
Ferrelira,P., Fitzhugh,W., Forrest,C., Gage,D., Galagan,J.,
Gardyna,S., Grant,G., Hagos,B., Heaford,A., Horton,L.,
Howland,J.C., Johnson,R., Jones,C., Kann,L., Karatas,A., Klein,J.,
Landers,T., Lehoczy,J., Levine,R., Lieu,C., Liu,G., Locke,K.,
Macdonald,P., Marquis,N., McEwan,P., McGurk,A., McKernan,K.,
McPheeters,R., Meldrim,J., Maneus,L., Morrow,J., Naylor,J.,
Norman,C.H., O'Connor,T., O'Donnell,P., Oliver,T.M., Peterson,K.,
Pierre,N., Pisani,C., Pollara,V., Raymond,C., Riley,R., Rothman,D.,
Roy,A., Santos,R., Severy,P., Spencer,B., Stange-Thomann,N.,
Stojanovic,N., Subramanian,A., Talamas,J., Tesfaye,S., Theodore,J.,
Tirrell,A., Vassiliev,H., Viel,R., Vo,A., Wu,X., Wyman,D., Ye,W.J.,
Zimmer,A. and Zody,M.
Direct Submission
Submitted (09-FEB-2000) Whitehead Institute/MIT Center for Genome
Research, 320 Charles Street, Cambridge, MA 02141, USA
On Mar 28, 2000 this sequence version replaced gi:6957780.
All repeats were identified using RepeatMasker:
Smit, A.F.A. & Green, P. (1996-1997)
http://ftp.genome.washington.edu/RM/RepeatMasker.html
----- Genome Center
Center: Whitehead Institute/ MIT Center for Genome Research
Center code: WTBH
Web site: http://www-seq.wi.mit.edu
Contact: sequence_submissions@genome.wi.mit.edu
----- Project Information

```

```

Center project name: L5962
Center clone name: 345_N_16
----- Summary Statistics
Sequencing vector: M13; M7815; 100% of reads
Chemistry: Dye-terminator Big Dye; version 0.960731
Assembly program: Phrap; version 0.960731
Consensus quality: 161125 bases at least Q40
Consensus quality: 165418 bases at least Q30
Consensus quality: 167739 bases at least Q20
Insert size: 176000; agarose-fp
Insert size: 169888; sum-of-contigs
Quality coverage: 5.0 in Q20 bases; agarose-fp
Quality coverage: 5.2 in Q20 bases; sum-of-contigs
-----
* NOTE: This is a 'working draft' sequence. It currently
* consists of 18 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.
* 1 2304: contig of 2304 bp in length
* 2305 2404: gap of 100 bp
* 2405 4339: contig of 1935 bp in length
* 4340 4439: gap of 100 bp
* 4440 7773: contig of 3334 bp in length
* 7774 7873: gap of 100 bp
* 7874 11812: contig of 3939 bp in length
* 11813 11912: gap of 100 bp
* 11913 15783: contig of 3871 bp in length
* 15784 15883: gap of 100 bp
* 15884 20493: contig of 4610 bp in length
* 20494 20593: gap of 100 bp
* 20594 24877: contig of 4284 bp in length
* 24878 24977: gap of 100 bp
* 24978 29978: contig of 5001 bp in length
* 29979 30078: gap of 100 bp
* 30079 36535: contig of 6457 bp in length
* 36536 36635: gap of 100 bp
* 36636 44045: contig of 7410 bp in length
* 44046 44145: gap of 100 bp
* 44146 52402: contig of 8257 bp in length
* 52403 52502: gap of 100 bp
* 52503 62821: contig of 10319 bp in length
* 62822 62921: gap of 100 bp
* 62922 72744: contig of 9823 bp in length
* 72745 72844: gap of 100 bp
* 72845 88300: contig of 15456 bp in length
* 88301 88400: gap of 100 bp
* 88401 104799: contig of 16399 bp in length
* 104800 104899: gap of 100 bp
* 104900 123814: contig of 18915 bp in length
* 123815 123914: gap of 100 bp
* 123915 146837: contig of 22923 bp in length
* 146838 146937: gap of 100 bp
* 146938 171588: contig of 24651 bp in length.
FEATURES
source
1..171588
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="1"
/map="1"
/clone="RP11-345N16"
/clone_lib="RPC1-11 Human Male BAC"
1..2304
/note="assembly_fragment"
2405..4339
/note="assembly_fragment"
4440..7773
/note="assembly_fragment"
7874..11812
/note="assembly_fragment"
misc_feature
misc_feature
misc_feature
misc_feature

```

```

misc_feature 11913..15783
/note="assembly_fragment"
misc_feature 15884..20493
/note="assembly_fragment"
misc_feature 20594..24877
/note="assembly_fragment"
misc_feature 24978..29978
/note="assembly_fragment"
misc_feature 30079..36535
/note="assembly_fragment"
misc_feature 36636..44045
/note="assembly_fragment"
misc_feature 44146..52402
/note="assembly_fragment"
misc_feature 52503..62821
/note="assembly_fragment"
misc_feature 62922..72744
/note="assembly_fragment"
clone_end:SP6
vector_side:right"
72845..88300
/note="assembly_fragment"
misc_feature 88401..104799
/note="assembly_fragment"
misc_feature 104900..123814
/note="assembly_fragment"
misc_feature 123915..146837
/note="assembly_fragment"
clone_end:T7
vector_side:right"
146938..171588
/note="assembly_fragment"
BASE COUNT 54344 a 29344 c 29364 g 56833 t 1703 others
ORIGIN

```

Query Match 92.4%; Score 19.4; DB 2; Length 171588;
 Matches Local Similarity 95.2%; Pred. No. 1.9e+02;
 Match 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 1 TTCTTTTCTCTTCACAGG 21
|| |||||
Db 149939 TTTTTCCTTCACAGG 149959

```

```

RESULT 11
AC084411 AC084411 203668 bp DNA linear HTG 01-NOV-2000
LOCUS Mus musculus clone RP23-125M20, WORKING DRAFT SEQUENCE, 32
DEFINITION unordered pieces.
ACCESSION AC084411
VERSION AC084411.1 GI:11067260
KEYWORDS HTG; HTGS_PHASE1; HTGS_DRAFT.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 203668)
AUTHORS McCombie,W.R., Baker,J.P., Bahret,A., Bal,H., Ballja,V.,
Dedhia,N.N., de la Bastide,M., Huang,E.N., King,L., Kirchoff,K.A.,
Miller,B., Nascimento,L.U., O'Shaughnessy,A.L., Preston,R.R.,
Rodriguez,S., Santos,L., Shah,R.S., Spiegel,L.A., Toth,K., Vill,M.D.
and Zutavern,T.
TITLE Mouse Genomic Sequence
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 203668)
AUTHORS McCombie,W.R.
TITLE Direct Submission
JOURNAL Submitted (01-NOV-2000) Lita Annenberg Hazen Genome Sequencing
Center, Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring
Harbor, NY 11724, USA
COMMENT ----- Genome Center
Center: Lita Annenberg Hazen Genome Center, Cold Spring Harbor

```

```

Laboratory
Center code: CSHL
Web site: http://www.cshl.org/geneseq
Contact: mcombie@cshl.org
----- Project Information
Center project name: RP23-125M20
Center clone name: RP23-125M20
-----
* NOTE: This is a 'working draft' sequence. It currently
* consists of 32 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.
*
* 1 21298: contig of 21298 bp in length
* 21299 21390: gap of unknown length
* 21391 37719: contig of 16329 bp in length
* 37720 37811: gap of unknown length
* 37812 52285: contig of 14474 bp in length
* 52286 52377: gap of unknown length
* 52378 66315: contig of 13938 bp in length
* 66316 66407: gap of unknown length
* 66408 79620: contig of 13213 bp in length
* 79621 79712: gap of unknown length
* 79713 92050: contig of 12338 bp in length
* 92051 92142: gap of unknown length
* 92143 102157: contig of 10015 bp in length
* 102158 102249: gap of unknown length
* 102250 110283: contig of 8034 bp in length
* 110284 110375: gap of unknown length
* 110376 117524: contig of 7149 bp in length
* 117525 117616: gap of unknown length
* 117617 124464: contig of 6847 bp in length
* 124465 124555: gap of unknown length
* 124556 130800: contig of 6245 bp in length
* 130801 130892: gap of unknown length
* 130893 136994: contig of 6102 bp in length
* 136995 137086: gap of unknown length
* 137087 143118: contig of 6032 bp in length
* 143119 143211: gap of unknown length
* 143212 148264: contig of 5054 bp in length
* 148265 148355: gap of unknown length
* 148356 153298: contig of 4943 bp in length
* 153299 153389: gap of unknown length
* 153390 158314: contig of 4925 bp in length
* 158315 158405: gap of unknown length
* 158406 162746: contig of 4341 bp in length
* 162747 162837: gap of unknown length
* 162838 167078: contig of 4241 bp in length
* 167079 167169: gap of unknown length
* 167170 170577: contig of 3408 bp in length
* 170578 170669: gap of unknown length
* 170670 173666: contig of 2998 bp in length
* 173667 173757: gap of unknown length
* 173758 176695: contig of 2938 bp in length
* 176696 176786: gap of unknown length
* 176787 179696: contig of 2910 bp in length
* 179697 179787: gap of unknown length
* 179788 182656: contig of 2869 bp in length
* 182657 182747: gap of unknown length
* 182748 185462: contig of 2715 bp in length
* 185463 185553: gap of unknown length
* 185554 188209: contig of 2656 bp in length
* 188210 188301: gap of unknown length
* 188302 190826: contig of 2526 bp in length
* 190827 190917: gap of unknown length
* 190918 193443: contig of 2526 bp in length
* 193444 193534: gap of unknown length
* 193535 195903: contig of 2369 bp in length
* 195904 195994: gap of unknown length
* 195995 198332: contig of 2338 bp in length

```

```

* 198333 198423: gap of unknown length
* 198424 200537: contig of 2114 bp in length
* 200538 200628: gap of unknown length
* 202629 202638: contig of 2010 bp in length
* 202639 202728: gap of unknown length
* 202730 203668: contig of 939 bp in length.
FEATURES
    Location/Qualifiers
        1..203668
            /organism="Mus musculus"
            /db_xref="taxon:10090"
            /clone="RP23-125M20"
            /clone_lib="RPCI-23"
BASE COUNT 53265 a 46398 c 45935 g 54709 t 3361 others
ORIGIN

Query Match          92.4%  Score 19.4:  DB 2:  Length 203668;
Best Local Similarity 95.2%  Pred. No. 1.8e+02;
Matches 20:  Conservative 0;  Mismatches 1;  Indels 0;  Gaps 0;

Qy 1 TTTCTTTTCTCTCTCCAGG 21
    TTTCTTTTCTCTCTCTCCAGG 179629
Db 179609 TTTCTTTTCTCTCTCCAGG 179629

RESULT 12
AC019313
LOCUS      208618 bp  DNA  linear  HTG 17-MAR-2000
DEFINITION Homo sapiens chromosome 18 clone RP11-119p12 map 18, WORKING DRAFT
SEQUENCE, 49 unordered pieces.
ACCESSION AC019313
VERSION    GI:7259732
KEYWORDS   HTG; HTGS_PHASE1; HTGS_DRAFT.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE  1 (bases 1 to 208618)
            Birren,B., Linton,L., Nusbaum,C., Lander,E., Abraham,H., Allen,N.,
            Anderson,S., Baldwin,J., Barna,N., Beckerly,R., Bida,F.,
            Boguslavskiy,L., Boukhgalter,B., Brown,A., Burkett,G., Castle,A.,
            Choepel,Y., Collangelo,M., Collins,S., Collymore,A., Cooke,P.,
            DeArellano,K., Dewar,K., Domino,M., Doyle,M., Fenestor,J.,
            Ferreira,P., FitzHugh,W., Forrest,C., Gage,D., Galagan,J.,
            Gardyna,S., Grant,G., Hagos,B., Heaford,A., Horton,L.,
            Howland,J.C., Johnson,R., Jones,C., Kann,L., Karatas,A., Klein,J.,
            Landers,T., Lehoczy,J., Levine,R., Lieu,C., Liu,G., Locke,K.,
            Macdonald,P., Marguis,N., McEwan,P., McGurk,A., McKernan,K.,
            McPheeters,R., Meldrim,J., Meneus,L., Morrow,J., Naylor,J.,
            Norman,C.H., O'Connor,T., O'Donnell,P., Oliver,T.M., Peterson,K.,
            Pierre,N., Pisani,C., Pollara,V., Raymond,C., Riley,R., Rothman,D.,
            Roy,A., Santos,R., Severy,P., Spencer,B., Stange-Thomann,N.,
            Stojanovic,N., Subramanian,A., Talamas,J., Tesfaye,S., Theodore,J.,
            Tirrell,A., Vassiliev,H., Viel,R., Vo,A., Wu,X., Wyman,D., Ye,W.J.,
            Zimmer,A. and Zody,M.
            Direct Submission
            Submitted (31-DEC-1999) Whitehead Institute/MIT Center for Genome
            Research, 320 Charles Street, Cambridge, MA 02141, USA
            On Mar 17, 2000 this sequence version replaced gi:6984442.
            All repeats were identified using RepeatMasker:
            Smit, A.F.A. & Green, P. (1996-1997)
            http://ftp.genome.washington.edu/RM/RepeatMasker.html
            ----- Genome Center
            Center: Whitehead Institute/ MIT Center for Genome Research
            Center code: WIBR
            Web site: http://www-seq.wi.mit.edu
            Contact: sequence_submissions@genome.wi.mit.edu
            ----- Project Information
            ----- Project name: L5386

```

Center clone name: 119_P_12

----- Summary Statistics

Sequencing vector: M13; M77815: 100% of reads

Chemistry: Dye-terminator Big Dye; 100% of reads

Assembly program: Phrap; version 0.960731

Consensus quality: 161318 bases at least Q40

Consensus quality: 181693 bases at least Q30

Consensus quality: 194050 bases at least Q20

Insert size: 203818; sum-of-contigs

Quality coverage: 3.2 in Q20 bases; sum-of-contigs

* NOTE: This is a 'working draft' sequence. It currently consists of 49 contigs. The true order of the pieces is not known and their order in this sequence record is arbitrary. Gaps between the contigs are represented as runs of N, but the exact sizes of the gaps are unknown. This record will be updated with the finished sequence as soon as it is available and the accession number will be preserved.

* 1 1052: contig of 1052 bp in length

* 1053 1152: gap of 100 bp

* 1153 2486: contig of 1334 bp in length

* 2487 2586: gap of 100 bp

* 2587 3719: contig of 1133 bp in length

* 3720 3819: gap of 100 bp

* 3820 3915: contig of 96 bp in length

* 3916 4015: gap of 100 bp

* 4016 5118: contig of 1103 bp in length

* 5119 5218: gap of 100 bp

* 5219 6275: contig of 1057 bp in length

* 6276 6375: gap of 100 bp

* 6376 7721: contig of 1346 bp in length

* 7722 7821: gap of 100 bp

* 7822 8956: contig of 1135 bp in length

* 8957 9056: gap of 100 bp

* 9057 10726: contig of 1670 bp in length

* 10727 10826: gap of 100 bp

* 10827 12216: contig of 1390 bp in length

* 12217 12316: gap of 100 bp

* 12317 13744: contig of 1428 bp in length

* 13745 13844: gap of 100 bp

* 13845 15089: contig of 1245 bp in length

* 15090 15189: gap of 100 bp

* 15190 16739: contig of 1550 bp in length

* 16740 16839: gap of 100 bp

* 16840 17920: contig of 1081 bp in length

* 17921 18020: gap of 100 bp

* 18021 19143: contig of 1123 bp in length

* 19144 19243: gap of 100 bp

* 19244 20489: contig of 1246 bp in length

* 20490 20589: gap of 100 bp

* 20590 21851: contig of 1262 bp in length

* 21852 21951: gap of 100 bp

* 21952 23358: contig of 1407 bp in length

* 23359 23458: gap of 100 bp

* 23459 25234: contig of 1776 bp in length

* 25235 25334: gap of 100 bp

* 25335 27169: contig of 1835 bp in length

* 27170 27269: gap of 100 bp

* 27270 29801: contig of 2532 bp in length

* 29802 29901: gap of 100 bp

* 29902 32268: contig of 2367 bp in length

* 32269 32368: gap of 100 bp

* 32369 34415: contig of 2047 bp in length

* 34416 34515: gap of 100 bp

* 34516 36552: contig of 2037 bp in length

* 36553 36652: gap of 100 bp

* 36653 39620: contig of 2968 bp in length

* 39621 39720: gap of 100 bp

* 39721 42451: contig of 2731 bp in length

* 42452 42551: gap of 100 bp

* 42552 46217: contig of 3666 bp in length

* 46218 46317: gap of 100 bp

```
* 46318 48687: contig of 2370 bp in length
* 48688 48787: gap of 100 bp
* 48788 52204: contig of 3417 bp in length
* 52205 52304: gap of 100 bp
* 52305 55124: contig of 2820 bp in length
* 55125 55224: gap of 100 bp
* 55225 59236: contig of 4012 bp in length
* 59237 59336: gap of 100 bp
* 59337 63427: contig of 4091 bp in length
* 63428 63527: gap of 100 bp
* 63528 68235: contig of 4708 bp in length
* 68236 68335: gap of 100 bp
* 68336 74336: contig of 6001 bp in length
* 74337 74436: gap of 100 bp
* 74437 79648: contig of 5212 bp in length
* 79649 79748: gap of 100 bp
* 79749 86527: contig of 6779 bp in length
* 86528 86627: gap of 100 bp
* 86628 93092: contig of 6465 bp in length
* 93093 93192: gap of 100 bp
* 93193 97736: contig of 4544 bp in length
* 97737 97836: gap of 100 bp
* 97837 103589: contig of 5753 bp in length
* 103590 103689: gap of 100 bp
* 103690 111389: contig of 7700 bp in length
* 111390 111489: gap of 100 bp
* 111490 117615: contig of 6126 bp in length
* 117616 117715: gap of 100 bp
* 117716 126146: contig of 8431 bp in length
* 126147 126246: gap of 100 bp
* 126247 133762: contig of 7516 bp in length
* 133763 133862: gap of 100 bp
* 133863 143183: contig of 9321 bp in length
* 143184 143283: gap of 100 bp
* 143284 154009: contig of 10726 bp in length
* 154010 154109: gap of 100 bp
* 154110 164224: contig of 10115 bp in length
* 164225 164324: gap of 100 bp
* 164325 176540: contig of 12216 bp in length
* 176541 176640: gap of 100 bp
* 176641 192181: contig of 15541 bp in length
* 192182 192281: gap of 100 bp
* 192282 208618: contig of 16337 bp in length.
FEATURES
    Location/Qualifiers
        1..208618
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            /map="18"
            /chromosome="18"
            /clone_lib="RPC1-11 Human Male BAC"
            /clone="RP11-119P12"
            1..1052
                /note="assembly_fragment"
                1153..2486
                    /note="assembly_fragment"
                    2587..3719
                        /note="assembly_fragment"
                        3820..3915
                            /note="assembly_fragment"
                            clone_end:17
                                vector_side:right
                                4016..5118
                                    /note="assembly_fragment"
                                    5219..6275
                                        /note="assembly_fragment"
                                        6376..7721
                                            /note="assembly_fragment"
                                            7822..8956
                                                /note="assembly_fragment"
                                                9057..10726
                                                    /note="assembly_fragment"
                                                    10827..12216
                                                        /note="assembly_fragment"
```

```
misc_feature 12317..13744
              /note="assembly_fragment"
misc_feature 13845..15089
              /note="assembly_fragment"
misc_feature 15190..16739
              /note="assembly_fragment"
misc_feature 16840..17920
              /note="assembly_fragment"
```

Query Match 92.4%; Score 19.4; DB 2; Length 208618;
Best Local Similarity 95.2%; Pred.No.1.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TTCTTTTTCCTCTTCACAGG 21
|||||

Db 61291 TTCTTTTTCCTTCACAGG 61311
|||||

RESULT 13

AC092824

LOCUS Homo sapiens chromosome 12p clone RP11-158N24, WORKING DRAFT
AC092824
SEQUENCE, 2 unordered pieces.

ACCESSION AC092824.10 GI:17223142

VERSION HTG; HTGS_PHASE1; HTGS_DRAFT; HTGS_FULLTOP; HTGS_ACTIVEFIN.

KEYWORDS human.

SOURCE

ORGANISM

Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 162522)

AUTHORS

Muzny, D.M., Adams, C., Adio-Oduola, B., Ali-osman, F.R., Allen, C.,
Beaton, J., Bimage, K., Blankenburg, K., Bonnin, D., Bouck, J.,
Bowie, S., Brieva, M., Brown, E., Brown, M., Bryant, N.P., Buhay, C.,
Burch, P., Burkett, C., Burrell, K.L., Byrd, N.C., Carron, T.F.,
Carter, M., Cavazos, S.R., Chacko, J., Chavez, D., Chen, G., Chen, R.,
Chen, Z., Chowdhry, I., Christopoulos, C., Cleveland, C.D., Cox, C.,
Coyle, M.D., Dathorne, S.R., David, R., Davila, M.L., Davis, C.,
Davy-Carroll, L., Dederich, D.A., Delaney, K.R., Delgado, O.,
Denn, A.L., Ding, Y., Dinh, H.H., Douthwaite, K.J., Draper, H.,
Dugan-Rocha, S., Durbain, K.J., Earnhart, C., Edgar, D., Edwards, C.C.,
Elhaj, C., Escotto, M., Falls, T., Ferraguto, D., Flagg, N., Ford, J.,
Foster, P., Frantz, P., Gabisi, A., Gao, J., Garcia, A., Garner, T.,
Garza, N., Gill, R., Gorrell, J.H., Guevara, W., Gunaratne, P., Hale, S.,
Hamilton, K., Harris, C., Harris, K., Hart, M., Havlak, P., Hawes, A.,
Hernandez, J., Hernandez, O., Hodgson, A., Hognes, M., Holloway, C.,
Hollins, B., Honsi, F., Howard, S., Huber, J., Hulyk, S., Hume, J.,
Jackson, L.E., Jacobson, B., Jia, Y., Johnson, R., Jolivet, S.,
Joudah, S., Karlsson, E., Kelly, S., Khan, U., King, L., Korvah, J.,
Kovar, C., Kratovic, J., Kureshi, A., Landry, N., Leal, B., Lewis, L.C.,
Lewis, L., Li, J., Li, Z., Lichtarge, O., Lieu, C., Liu, J., Liu, W.,
Loulsegh, H., Lozano, R.J., Lu, X., Lucier, A., Lucier, R., Luna, R.,
Ma, J., Maheshwari, M., Mapua, P., Martin, R., Martindale, A.,
Martinez, E., Massey, E., Mawhney, E., McLeod, M.P., Meador, M.,
Mei, G., Metzker, M., Miner, G., Miner, Z., Mitchell, T., Mohabbat, K.,
Morgan, A., Morris, S., Moser, M., Neal, D., Newton, J., Newton, N.,
Nguyen, A., Nguyen, N., Nguyen, N., Nickerson, E., Nwokenwo, S.,
Oguh, M., Okwuonu, G., Oragunye, N., Oviedo, R., Pace, A., Payton, B.,
Peery, J., Perez, L., Peters, L., Pickens, R., Primus, E., Pu, L.L.,
Quiles, M., Ren, Y., Rives, M., Rojas, A., Rojibokan, I., Rolfe, M.,
Ruiz, S., Savery, G., Scherer, S., Scott, G., Shen, H., Shooshtari, N.,
Sisson, I., Sodergren, E., Sonaike, T., Sparks, A., Stanley, H.,
Stone, H., Sutton, A., Svatek, A., Tabor, P., Tamerisa, A., Tamerisa, K.,
Tang, H., Tansey, J., Taylor, C., Taylor, T., Telford, B., Thomas, N.,
Thomas, S., Usmani, K., Vasquez, L., Vera, V., Villalon, D., Vinson, R.,
Wall, R., Wang, S., Ward-Moore, S., Warren, R., Washington, C.,
Watlington, S., Williams, G., Williamson, A., Wleczyk, R., Wooden, S.,
Worley, K., Wu, C., Wu, Y., Wu, Y.F., Zhou, J., Zorrilla, S., Nelson, D.,
Weinstock, G. and Gibbs, R.

Direct Submission

TITLE

JOURNAL

REFERENCE 2 (bases 1 to 162522)

AUTHORS
TITLE
JOURNAL

Worley, K.C.
Direct Submission
Submitted (30-JUL-2001) Human Genome Sequencing Center, Department
of Molecular and Human Genetics, Baylor College of Medicine, One
Baylor Plaza, Houston, TX 77030, USA
On Dec 1, 2001 this sequence version replaced gi:17136092.

COMMENT

----- Genome Center of Medicine
Center: Baylor College of Medicine
Center code: BCM
Web site: <http://www.hgsc.bcm.tmc.edu/>
Contact: hgsc-help@bcm.tmc.edu
----- Project Information
Center project name: HDKG
Center clone name: RP11-158N24
----- Summary Statistics
Sequencing vector: Plasmid; M77789
Chemistry: Dye-terminator Big Dye; 100% of reads
Assembly program: Phrap; version 0.990329
Consensus quality: 162690 bases at least Q40
Consensus quality: 162922 bases at least Q30
Estimated insert size: 162375; sum-of-contigs estimation
Quality coverage: 0x in Q20 bases; agarose-fp estimation
Quality coverage: 10.2x in Q20 bases; sum-of-contigs estimation

* NOTE: Estimated insert size may differ from sequence length
(see http://www.hgsc.bcm.tmc.edu/docs/Genbank_draft_data.html).
* NOTE: This is a 'working draft' sequence. It currently
* consists of 2 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.

* 1 108667: contig of 108667 bp in length
* 108668 108767: gap of unknown length
* 108768 162522: contig of 53755 bp in length.

FEATURES
source

Location/Qualifiers
1. .162522
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="12p"
/clone="RP11-158N24"

BASE COUNT 46500 a 35361 c 32754 g 47807 t 100 others

ORIGIN

Query Match 90.5%; Score 19; DB 2; Length 162522;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTCTACAC 19

|||||

Db 86548 TTCTTTTCTCTCTACAC 86566

RESULT 14
AF033189/c

LOCUS AF033189 2283 bp mRNA linear VRT 13-DEC-1997
DEFINITION Gallus gallus sulfotransferase mRNA, complete cds.
ACCESSION AF033189
VERSION AF033189.1 GI:2687359

SOURCE

Keywords: chicken.

ORGANISM

Gallus gallus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus

REFERENCE

1 (bases 1 to 2283)
Cao, H., Agarwal, S. and Burnside, J.
Direct Submission
Submitted (06-NOV-1997) Animal and Food Science, University of

FEATURES

source

Delaware, 40 Townsend Hall, Newark, DE 19350, USA

Location/Qualifiers

1. .2283
/organism="Gallus gallus"
/strain="domesticus"
/db_xref="taxon:9031"
/tissue_type="liver"
71. .1009

CDS

/codon_start=1
/product="sulfotransferase"
/protein_id="AAB88818.1"
/db_xref="GI:2687360"
/translation="MEKSRKFFDIVDKAIVIGNMORDELLFSYKGLYVPAVCSP
VFRAMESFEARSDDVILAGYPKSGTNVVGQILSDVATFEKERLEESVNDLEEF
YLEIGDTEKVERMKLPSRVILTHSPKLSIFKNKAKILLIRNKDIAISFFH
FSNRWSALPSYETWDDFFIAFMTEKMPGYSFNYLSEMNKYAADENVMTLYEEL
OTLGKNIASFFGISTLGEELRSVIERSFSQSKENSLKTHGALGSMLEFRKGGV
NLFNEQNERKMDKVFERRIARTKLTGLKYEYCKA"

BASE COUNT 749 a 401 c 447 g 686 t

ORIGIN

Query Match 87.6%; Score 18.4; DB 5; Length 2283;
Best Local Similarity 95.0%; Pred. No. 7.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTCTACAC 20

|||||

Db 2281 TTCTTTTCTCTCTACAC 2262

RESULT 15

AX082205/c

LOCUS AX082205 3382 bp DNA linear PAT 27-FEB-2001

DEFINITION Sequence 7 from Patent WO0100826.

ACCESSION AX082205

VERSION AX082205.1 GI:13170989

SOURCE human.

ORGANISM

Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Bertin, J.
1 (bases 1 to 3382)

REFERENCE

AUTHORS

TITLE

JOURNAL

Novel molecules of the card-related protein family and uses thereof

Patent: WO 0100826-A 7 04-JAN-2001.

Millennium Pharmaceuticals, Inc. (US)

FEATURES

source

Location/Qualifiers

1. .3382

/organism="Homo sapiens"

/db_xref="taxon:9606"

245. .3106

/note="unnamed protein product"

CDS

/codon_start=1

/protein_id="CAC33156.1"

/db_xref="GI:13170990"

/translation="MEEQGHSEMIIPSESHPIQLKSNRELLVTHIRNTOCLVDNL
LKNDFSAEDAEIVCACPTQDKVRKILDLVQSKGEVSEFFLYLQQLADAYVDLPR
WLEIGFSPSLTQSKVWVNDPVSRYTQOLRHLGRDSKFVLCYAKQKELLLEIYM
DTIMELVGSNESLGSINSLACLDHTTGILNQGETIFILGDAGVKSKMLQLQSL
WATGRDAGVKFFHFRCRMFSCFKESDRILQDLDFKHYCYPERDPEVFALLRFP
GIEVPRQFLRKVLLRGFSPLRVARARMPERAPLQDRLLSOLEANPNCSLCISVPL
FCWIIFRCQHPRAAFEGSPOLPDCVTMTLDVFLVTEVHLNRMOPSSLVQRTSRPV
ETLHAGEDTCLSLGQVAHRGMEKSLFVFTQEEVQASGLQERDMLQFLRALPELGGG
DQSYEFHTLQAFATFLVDDRVTQELRFFQEWMPAGAAATTCYPPPLFPQ
CLOGSGPAREDLFNKDHQFTNLFLGSLSKAKQLLRHLVPAALRRKRKALMAHL
FSLRGLYKSLPRVQSFNQVAMPTFIWMLRCIYETQSKVQQAARIGICANYLKL
TYCNACSDCSALSVLHHFPRKLRALDNLNNDLVGRELQVCFRLTVRLSNQI
TDGKVKVLSLELTKYKIVYLGLYNNQITDVGARYVTILDECKGTLTKLGNKITS
EGKYLALAVKNSKSISEVGMGNQVDSGAKAFALRNHPSLTLSLNSGISLEG
GKSLARLQNTSLEILWLTQNELNDEVAESAEMLKVNQTLKHLMLQNTITAKGTA
QLADLQSNQITEICLGNLNPKEAKVIEDEKRIICF"

Mon Jul 22 09:26:26 2002

BASE COUNT 775 a 975 c 933 g 693 t 6 others
ORIGIN

Query Match 87.6%; Score 18.4; DB 6; Length 3382;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TTCTTTTTCCTTCACAG 20
|||
Db 3371 TTTTTCCTTCACAG 3352

Search completed: July 21, 2002, 09:45:33
Job time: 12324 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 21, 2002, 09:55:19 ; Search time 467.25 Seconds
(without alignments)
77.165 Million cell updates/sec

Title: US-09-754-014-10_COPY_25_45
Perfect score: 21
Sequence: 1 TTCTTTTCTCTTCACAGG 21

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_032802.*
1: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*
2: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*
3: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*
4: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*
5: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*
6: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*
7: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*
8: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*
9: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*
10: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*
11: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*
12: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*
13: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*
14: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*
15: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*
16: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*
17: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*
18: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*
19: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*
20: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*
21: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*
22: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.*
23: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
24: /SIDSL/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	21	100.0	30	AAZ40413	3' splice site seq
2	21	100.0	45	AAV07276	Plasmid pIN0773 In
3	21	100.0	45	AAZ50395	Synthetic intron,
4	21	100.0	3589	AAZ40418	Plasmid pIF0921 co
5	21	100.0	3589	AAI70084	Plasmid pIF0921 en
6	21	100.0	3609	AAI70085	Plasmid pEP1403 en
7	21	100.0	4276	AAI70087	Codon optimised pl
8	21	100.0	4496	AAI70086	Plasmid pFN0945 en
9	21	100.0	5686	AAZ40415	Plasmid pIN1143 co

10	21	100.0	5966	20	AAZ40417	Plasmid pIN0961 co
c 11	18.4	87.6	1462	20	AAZ09247	Human CARD-4L part
c 12	18.4	87.6	3382	22	AAF30002	Human CARD-4L (lon
c 13	17.8	84.8	366	22	AAI87537	Human polynucleoti
c 14	17.8	84.8	3810	22	AAK87602	Human immune/haema
15	17.8	84.8	4098	16	AAT43682	Medium chain-speci
16	17.8	84.8	39746	23	ABL13398	Drosophila melanog
17	17.8	84.8	161425	22	AAH02340	Human AKAP10 gene
18	17.8	84.8	162025	22	AAH02339	Human AKAP10 gene
19	17.4	82.9	495	21	AAK75463	Human ORFX ORF1018
20	17.4	82.9	754	22	AAI97059	Human neuroblastom
c 21	17.4	82.9	1930	20	AAK02108	Mouse FEN-1 cDNA.
c 22	17.4	82.9	2033	20	AAK02111	Human FEN-1 genomi
c 23	17.4	82.9	6749	22	AAK46526	Tumour suppressor
c 24	17.4	82.9	19480	22	AAK80384	Human immune/haema
c 25	17.4	82.9	19481	22	AAK80383	Human immune/haema
c 26	17.4	82.9	19332	17	AAK46159	CagI locus. Helic
c 27	17.4	82.9	30013	22	AAK36932	Human musculoskele
c 28	17.4	82.9	30013	22	AAK41960	Genomic sequence #
29	17.4	82.9	96583	21	AAF22297	BAC containing rep
c 30	17	81.0	1225	15	AAQ73396	CviJI ORF1 coding
c 31	17	81.0	5496	15	AAQ73395	CviJI coding seque
c 32	16.8	80.0	304	14	AAQ60333	Human brain Expres
c 33	16.8	80.0	386	16	AAK26283	Human gene signatu
c 34	16.8	80.0	414	22	AAK63511	Human immune/haema
c 35	16.8	80.0	414	22	AAK64652	Human immune/haema
c 36	16.8	80.0	420	22	AAK18660	Human breast cance
c 37	16.8	80.0	1215	22	AAI66509	Pig caspase coding
c 38	16.8	80.0	1216	21	AAK51370	Arabidopsis thalia
c 39	16.8	80.0	1254	21	AAK52518	Arabidopsis thalia
40	16.8	80.0	1374	22	AAK71327	Human immune/haema
41	16.8	80.0	1374	22	AAK71357	Human immune/haema
42	16.8	80.0	1419	22	AAK40333	DNA encoding human
43	16.8	80.0	1419	22	AAK03933	Human reproductive
44	16.8	80.0	1529	22	AAK40335	DNA encoding human
45	16.8	80.0	1529	22	AAK40341	DNA encoding human

ALIGNMENTS

RESULT 1
AAZ40413
ID AAZ40413 standard; DNA; 30 BP.
XX
AC AAZ40413;
XX
XX 15-FEB-2000 (first entry)
DT
DE 3' splice site sequence for interferon-alpha plasmid.

DE Wild type; human; interferon-alpha; plasmid; cytomegalovirus; CMV;
KW promoter; growth hormone; untranslated region; UTR; mammal; disease;
KW cancer; intron; ss.
XX

OS Synthetic.

PN WO9947678-A2.

XX 23-SEP-1999.

PF 12-MAR-1999; 99WO-US05394.

XX 19-MAR-1998; 98US-0078654.

XX (GENE-) GENEMEDICINE INC.

PI Nordstrom J, Pericle F, Rolland A, Ralston R;

XX WPI; 1999-562116/47.

XX New plasmids containing an interferon-alpha coding sequence, used for
PT the treatment of a mammalian condition or disease, particularly cancer

PT
XX
PS Disclosure; Page 31; 137pp; English.
XX
CC The invention relates to a novel plasmid comprising a cytomegalovirus
CC (CMV) promoter transcriptionally linked with an interferon alpha
CC (IFN-alpha) coding sequence, and a growth hormone 3'-untranslated
CC region (UTR). Sequences AAZ40412 and AAZ40413 represent synthetic 5' and
CC 3' splice donor and acceptor sites respectively for generating a
CC synthetic intron to be inserted into the plasmid of the invention. The
CC plasmids can be used for treating a mammalian condition or disease,
CC particularly cancer.
XX
SQ Sequence 30 BP; 5 A; 7 C; 4 G; 14 T; 0 other;

Query Match 100.0%; Score 21; DB 20; Length 30;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTTCACAGG 21
Db 10 ttctttttctcttcacagg 30

RESULT 2
AAV07276
ID AAV07276 standard; DNA; 45 BP.
XX
AC AAV07276;
XX
DT 25-SEP-1998 (first entry)
XX
DE Plasmid pIN0773 Intron.
XX
KW IL-12 subunit; expression construct; treatment; asthma; microbial
KW infection; viral infection; cancer; Human; Interleukin; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_feature 1..9
FT /*tag= a
FT /note= "5' splice site"
FT misc_feature 15..16
FT /*tag= b
FT /note= "Unspecified sequence of 77 bp not given"
FT misc_feature 16..22
FT /*tag= c
FT /note= "Branch point"
FT misc_feature 25..44
FT /*tag= d
FT /note= "3' splice site"
XX
PN WO9817689-A2.
XX
PD 30-APR-1998.
XX
PF 10-OCT-1997; 97WO-US18779.
XX
PR 18-OCT-1996; 96US-0028676.
XX
PA (GENE-) GENEMEDICINE INC.
XX
PI Deshpande D, Freimark B, Nordstrom J;
XX
DR WPI; 1998-261428/23.
XX
XX Constructs for expression of interleukin-12 sub-units - are used
PT for delivery of IL-12 sub-units for treating e.g. asthma, microbial
PT or viral infections and certain cancers
XX
PS Disclosure; Page 26; 80pp; English.

XX
CC The synthetic intron was designed for highly efficient and accurate RNA
CC splicing. The intron was used in the plasmid pIN0773 which can provide
CC for efficient expression of IL-12 subunits. The products can be used for
CC the treatment of asthma, microbial and viral infections and certain
CC cancers.
XX
SQ Sequence 45 BP; 8 A; 10 C; 8 G; 19 T; 0 other;

Query Match 100.0%; Score 21; DB 19; Length 45;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTTCACAGG 21
Db 25 ttctttttctcttcacagg 45

RESULT 3
AAZ50395
ID AAZ50395 standard; DNA; 45 BP.
XX
AC AAZ50395;
XX
DT 18-MAY-2000 (first entry)
XX
DE Synthetic intron, OPTIVS8.
XX
KW Synthetic intron; OPTIVS8; expression plasmid; anti-angiogenic agent;
KW cancer; translation; gene expression; RNA splicing; transfection;
KW tumour activity; solid tumour; lung metastatic tumour; cytostatic;
KW gene therapy; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_feature 3..4
FT /*tag= a
FT /label= 5' splice site
FT /note= "Corresponds to BbsI cleavage site"
FT misc_feature 15..16
FT /*tag= b
FT /note= "There are 77 residues between C15 and T16 that
FT are not shown in the specification"
FT misc_feature 44..44
FT /*tag= c
FT /label= 3' splice site
FT /note= "Corresponds to EarI cleavage site"
XX
PN WO200006759-A2.
XX
PD 10-FEB-2000.
XX
PF 20-JUL-1999; 99WO-US16388.
XX
PR 27-JUL-1998; 98US-0094375.
XX
PA (VALE-) VALENTIS INC.
XX
PI Min W, Szymanski P, Mehrens D, Ralston R, Sullivan S;
XX
DR WPI; 2000-183133/16.
XX
XX Plasmids comprising tissue specific transcription elements linked to an
PT anti-angiogenic gene is useful transfection of cells and treatment of,
PT e.g. cancer
XX
PS Disclosure; Page 34; 103pp; English.
XX
CC The present sequence is a synthetic intron, OPTIVS8 used in the
CC construction of the expression plasmid incorporating an anti-angiogenic
CC agent for the treatment of mammalian diseases, especially cancer. This

CC intron was designed for effective RNA splicing and increased gene
CC expression. The plasmids can be used for (in vivo) transfection of a
CC cell in situ in order to modulate tumour activity. Anti-angiogenic gene
CC inhibits growth of solid tumour and lung metastatic tumours by
CC intravenous or intramuscular delivery.

XX Sequence 45 BP; 8 A; 10 C; 8 G; 19 T; 0 other;

Query Match 100.0%; Score 21; DB 21; Length 45;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TTCTTTTCTCTTCACAGG 21
|||||
Db 25 ttctttttctcttcacagg 45

RESULT 4
AAZ40418
ID AAZ40418 standard; DNA; 3589 BP.

XX AC AAZ40418;

XX DT 15-FEB-2000 (first entry)

XX DE Plasmid pIF0921 containing human IFN- α sequence.

XX KW Wild type; human; interferon- α ; plasmid; cytomegalovirus; CMV;
KW promoter; growth hormone; untranslated region; UTR; mammal; disease;
XX cancer; intron; ss.

XX OS Synthetic.

XX PN WO9947678-A2.

XX PD 23-SEP-1999.

XX PF 12-MAR-1999; 99WO-US05394.

XX PR 19-MAR-1998; 98US-0078654.

XX FA (GENE-) GENEMEDICINE INC.

XX PI Nordstrom J, Pericle F, Rolland A, Ralston R;

XX DR WPI; 1999-562116/47.

XX PT New plasmids containing an interferon- α coding sequence, used for
PT the treatment of a mammalian condition or disease, particularly cancer

XX PS Disclosure; Fig 6; 137pp; English.

XX CC The invention relates to a novel plasmid comprising a cytomegalovirus
CC (CMV) promoter transcriptionally linked with an interferon α
CC (IFN- α) coding sequence, and a growth hormone 3'-untranslated
CC region (UTR). This sequence represents the plasmid pIF0921 which
CC contains the human interferon α (IFN- α) gene. The plasmids can be
CC used for treating a mammalian condition or disease, particularly cancer.

XX SQ Sequence 3589 BP; 832 A; 983 C; 933 G; 841 T; 0 other;

Query Match 100.0%; Score 21; DB 20; Length 3589;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TTCTTTTCTCTTCACAGG 21
|||||
Db 742 ttctttttctcttcacagg 762

RESULT 5

AAI70084

XX ID AAI70084 standard; DNA; 3589 BP.

XX AC AAI70084;

XX DT 21-DEC-2001 (first entry)

XX DE Plasmid pIF0921 encoding human interferon- α .

XX KW Plasmid pIF0921; interferon- α ; cytokine; human; gene delivery;
XX immune disorder; gene therapy; vaccine; ds.

XX OS Chimeric - Homo sapiens.

XX OS Chimeric - human cytomegalovirus.

XX FH Key Location/Qualifiers

XX FT CDS 768..1334

XX FT /*tag= a

XX FT /product= "human interferon- α "

XX PN WO200166149-A2.

XX PD 13-SEP-2001.

XX PF 02-MAR-2001; 2001WO-US06953.

XX PR 03-MAR-2000; 2000US-187236P.

XX PR 16-JAN-2001; 2001US-261751P.

XX FA (VALE-) VALENTIS INC.

XX PI Fewell JG, MacLaughlin F, Smith LC, Nicol F, Rolland A;

XX DR WPI; 2001-638995/73.

XX PT Nucleic acid formulation for gene delivery to a muscle or tumour tissue
PT to treat cancer, or infectious disease in a mammal, comprises a nucleic
PT acid and non-encapsulating anionic polymer such as poly-L-glutamate -

XX PS Example 5; Page 88-90; 98pp; English.

XX CC The present sequence is that of expression plasmid pIF0921, which
CC encodes human interferon- α (IFN- α). The IFN- α coding
CC sequence was inserted into the Valentis plasmid backbone containing
CC a 107 bp 5' untranslated region, a 117 bp synthetic intron, the
CC human growth hormone polyadenylation signal, a pUC12 origin of
CC replication and a kanamycin resistance gene, such that the
CC IFN- α gene was driven by the cytomegalovirus enhancer/promoter.
CC The resulting plasmid, pIF0921, was formulated with poly-L-glutamate
CC to produce a gene delivery vehicle, which was intramuscularly
CC injected into mice; both legs were electroporated with caliper
CC electrodes. A significant enhancement of human IFN- α expression
CC in CD-1 mice was observed. This is an example of a
CC method designed for non-viral plasmid-based gene therapy. In this
CC method, a nucleic acid is formulated with a non-encapsulating
CC anionic polymer, such as (biodegradable) poly-L-glutamate, which
CC enhances transfection of the nucleic acid into muscle or tumour
CC tissues, with or without electroporation, and which also stabilises
CC the nucleic acid during storage. The formulations allow for
CC vaccination and treatment of muscle disorders and serum protein
CC deficiencies, as well as cancer and infections. In the case of
CC IFN- α gene delivery, it may be used to treat a disease
CC characterised by dysregulation of the immune system.

XX SQ Sequence 3589 BP; 833 A; 983 C; 932 G; 841 T; 0 other;

Query Match 100.0%; Score 21; DB 22; Length 3589;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TTCTTTTCTCTTCACAGG 21

XX Sequence 4276 BP; 1059 A; 1092 C; 1120 G; 1005 T; 0 other;
SQ

Query Match 100.0%; Score 21; DB 22; Length 4276;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTCTCACAGG 21
|||||
Db 749 ttctttttctcttcacagg 769

RESULT 8

AAI70086
ID AAI70086 standard; DNA; 4496 BP.

XX AC AAI70086;

DT 21-DEC-2001 (first entry)

DE Plasmid pFN0945 encoding human coagulation Factor IX.

XX Plasmid pFN0945; Factor IX; coagulation; blood clotting; human;
KW gene delivery; haemophilia B; gene therapy; vaccine; ds.

XX Homo sapiens.

XX Key Location/Qualifiers
FH 782..2167
FT CDS /*tag= a
FT /*product= "human Factor IX"

XX WO200166149-A2.
XX 13-SEP-2001.

XX 02-MAR-2001; 2001WO-US06953.

XX 03-MAR-2000; 2000US-187236P.

PR 16-JAN-2001; 2001US-261751P.

XX (VALE-) VALENTIS INC.

XX Fewell JG, MacLaughlin F, Smith LC, Nicol F, Rolland A;

XX WPI; 2001-638995/73.

XX Nucleic acid formulation for gene delivery to a muscle or tumour tissue
PT to treat cancer, or infectious disease in a mammal, comprises a nucleic
PT acid and non-encapsulating anionic polymer such as poly-L-glutamate -

XX Claim 77; Page 92-93; 98pp; English.

XX The present sequence is that of expression plasmid pFN0945, which
CC encodes human Factor IX (FIX). The plasmid was formulated with
CC poly-L-glutamate to produce a gene delivery vehicle, which was
CC intramuscularly injected into C57BL/6 mice tibialis, augmented by
CC electroporation. The highest expression of human FIX achieved
CC using this method 280 ng/ml, compared with levels of 160 ng/ml
CC obtained with naked DNA treatment. Expression was dose
CC dependent, and the plasmid was stable and transcriptionally active
CC in muscle for a prolonged period of time. Applicability to large
CC animals (dog) was demonstrated. Some muscle damage was observed
CC 1 mth after treatment. This is an example of the method of the
CC invention for non-viral plasmid-based gene therapy. In this method,
CC a nucleic acid is formulated with a non-encapsulating anionic
CC polymer, such as (biodegradable) poly-L-glutamate, which not only
CC enhances transfection of the nucleic acid into muscle or tumour
CC tissues, with or without electroporation, but also stabilises the
CC nucleic acid during storage. The formulations allow for
CC vaccination and treatment of muscle disorders and serum protein
CC deficiencies, as well as cancer and infections. In the case of

CC FIX gene delivery, it may be used to treat haemophilia B.
XX
SQ Sequence 4496 BP; 1127 A; 1119 C; 1147 G; 1103 T; 0 other;

Query Match 100.0%; Score 21; DB 22; Length 4496;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTCTCACAGG 21
|||||
Db 748 ttctttttctcttcacagg 768

RESULT 9

AAZ40415
ID AAZ40415 standard; DNA; 5686 BP.

XX AC AAZ40415;

DT 15-FEB-2000 (first entry)

DE Plasmid pIN1143 containing human IL-12 sequence.

XX Wild type; human; interferon-alpha; plasmid; cytomegalovirus; CMV;
KW promoter; growth hormone; untranslated region; UTR; mammal; disease;
KW cancer; intron; ss.

XX Synthetic.

XX WO9947678-A2.

XX 23-SEP-1999.

XX 12-MAR-1999; 99WO-US05394.

XX 19-MAR-1998; 98US-0078654.

XX (GENE-) GENEMEDICINE INC.

XX Nordstrom J, Pericle F, Rolland A, Ralston R;

XX WPI; 1999-562116/47.

XX New plasmids containing an interferon-alpha coding sequence, used for
PT the treatment of a mammalian condition or disease, particularly cancer

XX Disclosure; Fig 2; 137pp; English.

XX The invention relates to a novel plasmid comprising a cytomegalovirus
CC (CMV) promoter transcriptionally linked with an interferon alpha
CC (IFN-alpha) coding sequence, and a growth hormone 3'-untranslated
CC region (UTR). This sequence represents the plasmid pIN1143 which
CC contains the human interleukin 12 (IL-12) gene. The plasmids can be
CC used for treating a mammalian condition or disease, particularly cancer.

XX Sequence 5686 BP; 1367 A; 1517 C; 1446 G; 1356 T; 0 other;

Query Match 100.0%; Score 21; DB 20; Length 5686;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTCTCACAGG 21
|||||
Db 1519 ttctttttctcttcacagg 1539

RESULT 10

AAZ40417
ID AAZ40417 standard; DNA; 5966 BP.

XX

```
AC AA240417;
XX
XX 15-FEB-2000 (first entry)
XX
XX Plasmid pIN0961 containing mouse IL-12 sequence.
XX
XX Wild type; human; interferon-alpha; plasmid; cytomegalovirus; CMV;
KW promoter; growth hormone; untranslated region; UTR; mammal; disease;
KW cancer; intron; ss.
XX
XX Synthetic.
XX
XX WO9947678-A2.
XX
XX 23-SEP-1999.
XX
XX 12-MAR-1999; 99WO-US05394.
XX
XX 19-MAR-1998; 98US-0078654.
XX
XX (GENE-) GENEMEDICINE INC.
XX
XX Nordstrom J, Pericle F, Rolland A, Ralston R;
XX
XX WPI; 1999-562116/47.
XX
XX New plasmids containing an interferon-alpha coding sequence, used for
XX the treatment of a mammalian condition or disease, particularly cancer
XX .
XX
XX Disclosure; Fig 5; 137pp; English.
XX
XX The invention relates to a novel plasmid comprising a cytomegalovirus
XX (CMV) promoter transcriptionally linked with an interferon alpha
XX (IFN-alpha) coding sequence, and a growth hormone 3'-untranslated
XX region (UTR). This sequence represents the plasmid pIN0961 which
XX contains the mouse interleukin 12 (IL-12) gene. The plasmids can be
XX used for treating a mammalian condition or disease, particularly cancer.
XX
XX Sequence 5966 BP; 1421 A; 1627 C; 1542 G; 1376 T; 0 other;
XX
XX
XX Query Match 100.0%; Score 21; DB 20; Length 5966;
XX Best Local Similarity 100.0%; Pred. No. 18;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 TTCTTTTCTCTTCACAGG 21
XX Db 2861 ttctttttctcttcacag 2881
XX
XX RESULT 11
XX AA209247/c
XX ID AA209247 standard; cDNA; 1462 BP.
XX
XX AC AA209247;
XX
XX 25-OCT-1999 (first entry)
XX
XX DE Human CARD-4L partial cDNA.
XX
XX CARD-3; caspase recruitment domain; CARD-4; regulation; detection;
KW caspase activation; detection; screening; therapy; diagnosis; disease;
KW apoptotic cell death; Fas/APO-1 receptor complex; TNF receptor complex;
KW cancer; follicular lymphoma; carcinoma; p53 mutation; viral infection;
KW hormone-dependent tumour; autoimmune disorder; Alzheimer's disease;
KW systemic lupus erythematosus; immune-mediated glomerulonephritis; stroke;
KW Parkinson's disease; amyotrophic lateral sclerosis; retinitis pigmentosa;
KW spinal muscular dystrophy; cerebellar degeneration; anaemia; drug;
KW myelodysplastic syndrome; myocardial infarction; cell proliferation;
KW cell differentiation; cell survival; CARD-4L; CARD-4S; CARD-4V;
KW CARD-4Z; human; ds.
XX
XX OS Homo sapiens.
XX
XX Key Location/Qualifiers
XX CDS 1..1186
XX FT /*tag= a
XX FT /codon_start= 2
XX FT /note= "Partial CARD-4L coding sequence"
XX
XX PN WO9940102-A1.
XX
XX PD 12-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US02544.
XX
XX 08-DEC-1998; 98US-0207359.
XX
XX 06-FEB-1998; 98US-0019942.
XX
XX 17-JUN-1998; 98US-0099041.
XX
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX Bertin J;
XX
XX WPI; 1999-494269/41.
XX
XX P-PSDB; AAY31141.
XX
XX Novel CARD-3 and CARD-4 genes and polypeptides used or treating
XX regulation of cellular proliferation and differentiation and cell
XX survival
XX
XX Example 2; Fig 3; 181pp; English.
XX
XX This invention describes the isolation of novel human caspase
XX recruitment domain, CARD-3 and CARD-4 polynucleotides and proteins and a
XX partial murine CARD-4L protein and genes. The genes and proteins of
XX the invention are involved in the regulation of caspase activation.
XX The caspase recruitment domain (CARD) polynucleotides, polypeptides,
XX homologues and antibodies can be used in screening assays, detection
XX assays, predictive medicine and therapeutic and prophylactic methods of
XX treatment. The methods may be used to diagnose and treat patients which
XX are suffering from a disorder associated with abnormal level or rate of
XX apoptotic cell death, abnormal activity of the Fas/APO-1 receptor
XX complex, abnormal activity of the TNF receptor complex, or abnormal
XX activity of a caspase. Diseases that may be treated include cancer
XX (particularly follicular lymphoma, carcinomas associated with mutations
XX in p53 and hormone-dependent tumours), autoimmune disorders (e.g.
XX systemic lupus erythematosus, immune-mediated glomerulonephritis), viral
XX infections, Alzheimer's disease, Parkinson's disease, amyotrophic lateral
XX sclerosis, retinitis pigmentosa, spinal muscular dystrophy, cerebellar
XX degeneration, anaemia, myelodysplastic syndrome, myocardial infarction,
XX and stroke. CARD-3 protein interacts with other cellular proteins, and so
XX can be used for regulation of cellular proliferation and differentiation
XX and cell survival. The CARD proteins may also be used to for screen drugs
XX or compounds which modulate their activity. The CARD-4 gene can express a
XX long transcript that encodes CARD-4L, a short transcript that encodes
XX CARD-4S or two CARD-4 splice variants, CARD-4Y and CARD-4Z. This sequence
XX encodes the human CARD-4L protein described in the method of the
XX invention. This sequence represents the 3'-end fragment of the CARD-4L
XX coding region, represented in Figure 3, however the specification
XX describes the full length CARD-4L cDNA sequence which encodes a 953
XX amino acid protein.
XX
XX Sequence 1462 BP; 389 A; 391 C; 389 G; 292 T; 1 other;
XX
XX Query Match 87.6%; Score 18.4; DB 20; Length 1462;
XX Best Local Similarity 95.0%; Pred. No. 1.7e+02;
XX Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1 TTCTTTTCTCTTCACAG 20
XX Db 1451 TTCTTTTCTCTTCACAG 1432
```



```
RESULT 12
AAAF30002/c
ID AAF30002 standard; cDNA; 3382 BP.
XX
AC AAF30002;
XX
DT 23-APR-2001 (first entry)
XX
DE Human CARD-4L (long form) cDNA.
XX
KW CARD-4L; caspase recruitment domain; human; cancer; infection;
KW autoimmune disease; neurological disease; haematological disease;
KW immune disease; inflammation; antitumour; antiseptic;
KW immunomodulator; antiinflammatory; apoptosis; diagnosis;
KW gene therapy; chromosome 7; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
CDS 245..3106
FT /*tag= a
FT /note= "the open reading frame is also specifically
FT claimed in Claim 1(a)"
XX
PN WO200100826-A2.
XX
PD 04-JAN-2001.
XX
PF 28-JUN-2000; 2000WO-US17691.
XX
PR 28-JUN-1999; 99US-0340620.
XX
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI Bertin J;
XX
DR WPI; 2001-061973/07.
DR P-PSDB; AAB20080.
XX
PT Isolated intracellular proteins predicted to be involved in regulating
PT caspase activation are used for diagnosis and treatment of e.g. cancer,
PT viral infections, autoimmune diseases, neurological diseases and
PT haematological disorders -
XX
PS Claim 1(a); Fig 3; 208pp; English.
XX
CC The present sequence is that of cDNA encoding human caspase
CC recruitment domain 4 long form (CARD-4L, see AAB20080). The cDNA
CC was isolated from a human umbilical vein endothelial library using
CC a partial CARD-4S clone as probe. Plasmid pC4L1 containing CARD-4L
CC cDNA is deposited as ATCC 203035. The human CARD-4 gene (see
CC AAF30011) maps to chromosome 7. CARD-4 exists in at least 4 forms,
CC i.e. the long form CARD-4L, the short form CARD-4S (see AAB20081),
CC and splice variants CARD-4Y (see AAB20082) and CARD-4Z (see
CC AAB20082). CARD-4 is an intracellular protein predicted to be
CC involved in regulating caspase activation. It activates the
CC NF-kappaB pathway and enhances caspase 9-mediated cell death.
CC Methods of diagnosing and treating patients suffering from a
CC disorder associated with an abnormal level or rate of apoptotic
CC cell death, abnormal activity of the Fas/APO-1 receptor complex,
CC abnormal activity of the tumour necrosis factor receptor complex
CC or abnormal activity of a caspase involve administering a compound
CC that modulates the expression or activity of CARD-3, CARD-4, CARD-5
CC or CARD-6 e.g. a small molecule, antisense nucleic acid, ribozyme
CC or polypeptide. Such disorders include cancer, viral infection,
CC autoimmune disorders, neurological diseases, haematological
CC disorders, inflammatory disorders and immune disorders. CARD
CC nucleic acids can be used to express CARD proteins in a host cell
CC e.g. for gene therapy applications, to detect a genetic lesion and
CC to modulate CARD activity.
XX
SQ Sequence 3382 BP; 775 A; 975 C; 933 G; 693 T; 6 other;

Query Match 87.6%; Score 18.4; DB 22; Length 3382;
Best Local Similarity 95.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TTCTTTTCTCTTCACAG 20
Db 3371 TTTTCTTTTCTCTTCACAG 3352

RESULT 13
AAI87537/c
ID AAI87537 standard; cDNA; 366 BP.
XX
AC AAI87537;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human polynucleotide SEQ ID NO 7597.
XX
KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorders; arthritis; inflammation; ss.
XX
OS Homo sapiens.
XX
PN WO200164835-A2.
XX
PD 07-SEP-2001.
XX
PF 26-FEB-2001; 2001WO-US04927.
XX
PR 28-FEB-2000; 2000US-0515126.
PR 18-MAY-2000; 2000US-0577409.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT;
XX
PWPI; 2001-514838/56.
DR P-PSDB; AAO07606.
XX
PT Isolated nucleic acids and polypeptides, useful for preventing
PT diagnosing and treating e.g. leukaemia, inflammation and immune
PT disorders -
XX
PS Claim 1; SEQ ID NO 7597; 1399pp + Sequence Listing; English.
XX
CC The invention relates to human polynucleotides (AAI79941-AAI93841) and
CC the encoded proteins (AAO00010-AAO13910) that exhibit activity relating to
CC cytokine, cell proliferation or cell differentiation or which may induce
CC production of other cytokines in other cell populations. The
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC peptide therapy. The polypeptides have various cytokine-like activities,
CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activin/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 366 BP; 210 A; 44 C; 45 G; 66 T; 1 other;

Query Match 84.8%; Score 17.8; DB 22; Length 366;
Best Local Similarity 90.5%; Pred. No. 2.7e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 TTCTTTTCTCTTCACAG 21
IIIIIIIIIIIIIIIIIIII
```

Db	299	TTCTTTTTTCTCTTGACGGG	279	
	RESULT 14			
	AAK87602/c			
ID	AAK87602 standard; DNA; 3610 BP.			
XX	AC			08-SEP-2000; 2000US-02320801
XX	AC			08-SEP-2000; 2000US-0232081
XX	AC			12-SEP-2000; 2000US-0231968
XX	AC			14-SEP-2000; 2000US-0232397
XX	AC			14-SEP-2000; 2000US-0232398
XX	AC			14-SEP-2000; 2000US-0232399
XX	AC			14-SEP-2000; 2000US-0232400
XX	AC			14-SEP-2000; 2000US-0232401
XX	AC			14-SEP-2000; 2000US-0233063
XX	AC			14-SEP-2000; 2000US-0233064
XX	AC			14-SEP-2000; 2000US-0233065
XX	AC			21-SEP-2000; 2000US-0234223
XX	AC			21-SEP-2000; 2000US-0234224
XX	AC			25-SEP-2000; 2000US-0234997
XX	AC			25-SEP-2000; 2000US-0234998
XX	AC			26-SEP-2000; 2000US-0235484
XX	AC			27-SEP-2000; 2000US-0235834
XX	AC			27-SEP-2000; 2000US-0235836
XX	AC			29-SEP-2000; 2000US-0236327
XX	AC			29-SEP-2000; 2000US-0236367
XX	AC			29-SEP-2000; 2000US-0236368
XX	AC			29-SEP-2000; 2000US-0236369
XX	AC			29-SEP-2000; 2000US-0236370
XX	AC			02-OCT-2000; 2000US-0236802
XX	AC			02-OCT-2000; 2000US-0237037
XX	AC			02-OCT-2000; 2000US-0237038
XX	AC			02-OCT-2000; 2000US-0237039
XX	AC			02-OCT-2000; 2000US-0237040
XX	AC			13-OCT-2000; 2000US-0239935
XX	AC			13-OCT-2000; 2000US-0239937
XX	AC			20-OCT-2000; 2000US-0240960
XX	AC			20-OCT-2000; 2000US-0241221
XX	AC			20-OCT-2000; 2000US-0241785
XX	AC			20-OCT-2000; 2000US-0241786
XX	AC			20-OCT-2000; 2000US-0241787
XX	AC			20-OCT-2000; 2000US-0241808
XX	AC			20-OCT-2000; 2000US-0241809
XX	AC			20-OCT-2000; 2000US-0241826
XX	AC			01-NOV-2000; 2000US-0244617
XX	AC			08-NOV-2000; 2000US-0246474
XX	AC			08-NOV-2000; 2000US-0246475
XX	AC			08-NOV-2000; 2000US-0246476
XX	AC			08-NOV-2000; 2000US-0246477
XX	AC			08-NOV-2000; 2000US-0246478
XX	AC			08-NOV-2000; 2000US-0246523
XX	AC			08-NOV-2000; 2000US-0246524
XX	AC			08-NOV-2000; 2000US-0246525
XX	AC			08-NOV-2000; 2000US-0246526
XX	AC			08-NOV-2000; 2000US-0246527
XX	AC			08-NOV-2000; 2000US-0246528
XX	AC			08-NOV-2000; 2000US-0246532
XX	AC			08-NOV-2000; 2000US-0246610
XX	AC			08-NOV-2000; 2000US-0246611
XX	AC			08-NOV-2000; 2000US-0246613
XX	AC			17-NOV-2000; 2000US-0249207
XX	AC			17-NOV-2000; 2000US-0249208
XX	AC			17-NOV-2000; 2000US-0249209
XX	AC			17-NOV-2000; 2000US-0249210
XX	AC			17-NOV-2000; 2000US-0249211
XX	AC			17-NOV-2000; 2000US-0249212
XX	AC			17-NOV-2000; 2000US-0249213
XX	AC			17-NOV-2000; 2000US-0249214
XX	AC			17-NOV-2000; 2000US-0249215
XX	AC			17-NOV-2000; 2000US-0249216
XX	AC			17-NOV-2000; 2000US-0249217
XX	AC			17-NOV-2000; 2000US-0249218
XX	AC			17-NOV-2000; 2000US-0249244
XX	AC			17-NOV-2000; 2000US-0249245
XX	AC			17-NOV-2000; 2000US-0249264
XX	AC			17-NOV-2000; 2000US-0249265
XX	AC			17-NOV-2000; 2000US-0249297
XX	AC			17-NOV-2000; 2000US-0249299
XX	AC			17-NOV-2000; 2000US-0249314
XX	AC			17-NOV-2000; 200

PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Barash SC, Ruben SM;
XX
XX WPI; 2001-483426/52.
DR
XX Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis -
XX
XX Disclosure; SEQ ID NO 42414; 3071pp + Sequence Listing; English.
PS
XX AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)
CC amino acid sequences given in AAK82170 to AAK91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/hematopoietic-related diseases, especially
CC cancers and cancer metastases of hematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/hematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAK82169
CC represent sequences used in the exemplification of the present invention.
XX
XX Sequence 3810 BP; 1081 A; 684 C; 703 G; 1321 T; 21 other;

Query Match 84.8%; Score 17.8; DB 22; Length 3810;
Best Local Similarity 90.5%; Pred. NO. 3.2e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 TCTCTTTTCTCTCTTCACAGG 21
Db 1951 TTTTCTTTCTCTCTTCACAGG 1931

RESULT 15
ID AAT43682
IT AAT43682 standard; DNA; 4098 BP.
XX
XX AC AAT43682;
XX
XX 03-FEB-1997 (first entry)
XX
DE Medium chain-specific acyl-(ACP)-thioesterase genomic clone ClTEgl.
XX
XX acyl-(ACP)-thioesterase; medium-chain length specificity;
KW oil seed; softener; pesticide; tenside; cosmetic; transgenic plant; ds.
XX
XX Cuphea lanceolata.
OS
XX Key Location/Qualifiers
FH

FT exon 1787..2294
FT /*tag= a
FT /number= 2
FT /codon_start= 1797..1799
FT intron 2295..2657
FT /*tag= b
FT /number= 2
FT 2658..2791
FT /*tag= c
FT /number= 3
FT 2792..2897
FT /*tag= d
FT /number= 3
FT 2898..3011
FT /*tag= e
FT /number= 4
FT 3012..3131
FT /*tag= f
FT /number= 4
FT 3132..3303
FT /*tag= g
FT /number= 5
FT 3304..3390
FT /*tag= h
FT /number= 5
FT 3391..3459
FT /*tag= i
FT /number= 6
FT 3460..3671
FT /*tag= j
FT /number= 6
FT 3672..3941
FT /*tag= k
FT /number= 7
FT /note= "stop codon is at 3942..3944"
XX
XX WO9506740-A.
PN
XX 09-MAR-1995.
PD
XX 02-SEP-1994; 94WO-EP02935.
XX
XX 03-SEP-1993; 93DE-4329828.
XX
XX (PLAC) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN.
PA
XX Martini N, Schell J, Toepfer R;
PI
XX
XX WPI; 1995-115455/15.
DR
XX P-PSDB; AAW06703.
XX
XX An acyl-(ACP)-thioesterase DNA of medium-chain specificity -
PT isolated from Cuphea lanceolata; for plant transformation to
PT produce C10:0 fatty acids, useful in the prodn of eg cosmetics.
XX
XX Claim 13; Page -: 40pp; German.
PS
XX
XX A primer based on amino acids 277-284 of the acyl-(ACP)-thioesterase
CC from Umbellularia californica was used with a modified oligo-dT
CC primer with restriction sites for BstBI, BamHI, HindIII and SalI,
CC in PCR amplification of a specific acyl-(ACP)-thioesterase
CC hybridisation probe ("PCR42") from a wild-type Umbellularia californica
CC cDNA library. Three cDNA clones, designated ClTE13, ClTE5 and ClTE12,
CC each coding for at least part of a thioesterase with medium-chain
CC specificity (C10:0-specific) were isolated by screening a Cuphea
CC lanceolata library with probe PCR42. Then, clone ClTE5 was itself
CC used as a probe to screen a C.lanceolata genomic DNA library and a
CC total of 23 clones were identified. Four of the genomic clones were
CC shown to correspond respectively to PCR42 and the three cDNA clones.
CC The present sequence is that of the genomic clone designated ClTEgl.
CC which corresponds to cDNA clone ClTE12. The binary vector pNM99-TEgl
CC (DSM 8477) comprising a fragment of ClTEgl is specifically claimed.
CC The DNA sequences will be useful for transforming oil-producing

CC plants (e.g. rapeseed, soya, oil palms) to produce C10:0 fatty acids
 CC which are starting materials for softeners, pesticides, tensides and
 CC cosmetics.
 CC N.B. The nucleotide sequences are referred to throughout the
 CC specification by their SEQ.ID. numbers but the sequence listing has
 CC not been printed in the original patent application.
 XX

SO Sequence 4098 BP; 1103 A; 808 C; 812 G; 1375 T; 0 other;

Query Match 84.8% Score 17.8; DB 16; Length 4098;
 Best Local Similarity 90.5%; Pred. No. 3.3e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 TTCTTTTCTCTTCACAGG 21
 || |||||
 Db 2638 tttttttctcttaacagg 2658

Search completed: July 21, 2002, 09:55:21
 Job time: 6382 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 21, 2002, 09:47:18 ; Search time 112.48 Seconds
(without alignments)
45.860 Million cell updates/sec

Title: US-09-754-014-10_COPY_25_45

Perfect score: 21

Sequence: 1 TTCTTTTCTCTTCACAGG 21

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 383533 seqs, 122816752 residues

Total number of hits satisfying chosen parameters: 767066

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued_Patents_NA.*

- 1: /cgn2_6/ptodata/2/ina/5A_COMB.seq.*
- 2: /cgn2_6/ptodata/2/ina/5B_COMB.seq.*
- 3: /cgn2_6/ptodata/2/ina/6A_COMB.seq.*
- 4: /cgn2_6/ptodata/2/ina/6B_COMB.seq.*
- 5: /cgn2_6/ptodata/2/ina/PCTUS_COMB.seq.*
- 6: /cgn2_6/ptodata/2/ina/backfiles.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	21	100.0	30	US-09-012-366-7	Sequence 7, Appli
2	18.4	87.6	3382	US-09-099-041A-7	Sequence 7, Appli
3	17.8	84.8	4098	US-08-605-106-4	Sequence 4, Appli
4	17.8	84.8	14753	US-09-821-736-3	Sequence 3, Appli
5	17.4	82.9	1930	US-08-455-968E-4	Sequence 4, Appli
6	17.4	82.9	2033	US-08-455-968E-9	Sequence 9, Appli
7	17.4	82.9	5599	US-08-477-451-9	Sequence 9, Appli
8	17.4	82.9	5599	US-08-477-451-13	Sequence 13, Appli
9	17.4	82.9	19932	US-08-477-451-25	Sequence 25, Appli
10	17	81.0	1225	US-08-181-629A-3	Sequence 3, Appli
11	17	81.0	5496	US-08-181-629A-2	Sequence 2, Appli
12	16.2	77.1	491	US-09-020-956-52	Sequence 52, Appli
13	16.2	77.1	491	US-09-030-607-52	Sequence 52, Appli
14	16.2	77.1	491	US-09-439-313-52	Sequence 52, Appli
15	16.2	77.1	508	US-08-327-451E-23	Sequence 23, Appli
16	16.2	77.1	508	US-08-458-109-23	Sequence 23, Appli
17	16.2	77.1	910	US-09-191-608-2	Sequence 2, Appli
18	16.2	77.1	953	US-08-197-793-1	Sequence 1, Appli
19	16.2	77.1	953	US-08-636-176-1	Sequence 1, Appli
20	16.2	77.1	953	PCT-US95-01618-1	Sequence 1, Appli
21	16.2	77.1	1083	US-09-247-373B-35	Sequence 35, Appli
22	16.2	77.1	1543	US-08-991-946A-4	Sequence 4, Appli
23	16.2	77.1	2906	US-08-554-612C-49	Sequence 49, Appli
24	16.2	77.1	5467	US-08-605-106-7	Sequence 7, Appli
25	16.2	77.1	7070	US-08-619-554-3	Sequence 3, Appli
26	16.2	77.1	35100	US-08-306-691B-19	Sequence 19, Appli
27	16.2	77.1	35100	PCT-US93-06251-19	Sequence 19, Appli

c 28	16	76.2	4092	4	US-09-306-595C-5	Sequence 5, Appli
c 29	15.8	75.2	181	2	US-08-256-790-5	Sequence 5, Appli
c 30	15.8	75.2	515	4	US-09-439-313-472	Sequence 472, App
c 31	15.8	75.2	767	1	US-07-697-275-1	Sequence 1, Appli
c 32	15.8	75.2	1750	4	US-09-262-856A-7	Sequence 7, Appli
c 33	15.8	75.2	2550	2	US-08-884-072-2	Sequence 2, Appli
c 34	15.8	75.2	2550	4	US-09-212-168-2	Sequence 2, Appli
c 35	15.8	75.2	2816	4	US-09-171-337A-1	Sequence 1, Appli
c 36	15.8	75.2	4527	2	US-08-944-449-8	Sequence 8, Appli
c 37	15.8	75.2	5935	4	US-09-178-973B-17	Sequence 17, Appli
c 38	15.8	75.2	5935	4	US-09-354-243B-29	Sequence 29, Appli
c 39	15.4	73.3	1533	1	US-07-721-761A-32	Sequence 32, Appli
c 40	15.4	73.3	1533	1	US-07-978-687-32	Sequence 32, Appli
c 41	15.4	73.3	1533	1	US-08-471-791-12	Sequence 12, Appli
c 42	15.4	73.3	1533	5	PCT-US91-01746-12	Sequence 12, Appli
c 43	15.4	73.3	1533	5	PCT-US91-05801-32	Sequence 32, Appli
c 44	15.4	73.3	1675	1	US-07-688-352C-29	Sequence 29, Appli
c 45	15.4	73.3	1675	2	US-08-474-379C-29	Sequence 29, Appli

ALIGNMENTS

RESULT 1
US-09-012-366-7
; Sequence 7, Application US/09012366
; Patent No. 6034072
; GENERAL INFORMATION:
; APPLICANT: Robert Ralston
; APPLICANT: Susanne Muller
; APPLICANT: Russ Mumper
; APPLICANT: William Munger
; APPLICANT: Maria Bruno
; TITLE OF INVENTION: IL-2 GENE EXPRESSION AND
; TITLE OF INVENTION: DELIVERY SYSTEMS AND USES
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/012,366
; FILING DATE: January 23, 1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/039,709
; FILING DATE: February 10, 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Berkman, Charles S.
; REGISTRATION NUMBER: 38,077
; REFERENCE/DOCKET NUMBER: 230/214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 30 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-012-366-7

Query Match 100.0%; Score 21; DB 3; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.7;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTTCACAGG 21
Db 10 TTCTTTTCTCTTCACAGG 30

RESULT 2

US-09-099-041A-7/c
Sequence 7, Application US/09099041A

Patent No. 6340576
GENERAL INFORMATION:
APPLICANT: Bertin, John
TITLE OF INVENTION: NOVEL MOLECULES OF THE CARD-RELATED
TITLE OF INVENTION: PROTEIN FAMILY AND USES THEREOF
FILE REFERENCE: 07334-076001
CURRENT APPLICATION NUMBER: US/09/099,041A
CURRENT FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 09/019,942
PRIOR FILING DATE: 1998-02-06
NUMBER OF SEQ ID NOS: 37
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 7
LENGTH: 3382
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: CDS
LOCATION: (245)...(3103)
US-09-099-041A-7

Query Match 87.6%; Score 18.4; DB 4; Length 3382;
Best Local Similarity 95.0%; Pred. No. 26;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTTCACAG 20
Db 3371 TTCTTTTCTCTTCACAG 3352

RESULT 3

US-08-605-106-4
Sequence 4, Application US/08605106

Patent No. 5910631
GENERAL INFORMATION:
APPLICANT: Topfer, R.
APPLICANT: Martini, N.
APPLICANT: Schell, J.
TITLE OF INVENTION: MEDIUM CHAIN-SPECIFIC THIOESTERS
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Schwegman, Lundberg, Woessner & Kluth, P.A.
STREET: P.O. Box 2938
CITY: Minneapolis
STATE: MN
COUNTRY: USA
ZIP: 55402
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/605,106
FILING DATE: 23-SEPT-1996
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/EP94/02935
FILING DATE: 01-MAR-1996

ATTORNEY/AGENT INFORMATION:
NAME: Woessner, Warren D
REGISTRATION NUMBER: 30,440
REFERENCE/DOCKET NUMBER: 235,001US1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 612-373-6900
TELEFAX: 612-339-3061
TELEX:
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 4098 Base pairs
TYPE: nucleic acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: : DNS (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Cuphea lanceolata
IMMEDIATE SOURCE:
LIBRARY: genomic Lambda FIX II
CLONE: ClTEg1
FEATURE:
NAME/KEY: CDS
LOCATION: join(1797..2294, 2658..2791, 2898..3011, 3132
LOCATION: ..3303, 3391..3459, 3672..3941)
FEATURE:
NAME/KEY: Startcodon
LOCATION: 1797..1799
FEATURE:
NAME/KEY: exon II
LOCATION: 1787..2294
FEATURE:
NAME/KEY: intron II
LOCATION: 2295..2657
FEATURE:
NAME/KEY: exon III
LOCATION: 2658..2791
FEATURE:
NAME/KEY: intron III
LOCATION: 2792..2897
FEATURE:
NAME/KEY: exon IV
LOCATION: 2898..3011
FEATURE:
NAME/KEY: intron IV
LOCATION: 3012..3131
FEATURE:
NAME/KEY: exon V
LOCATION: 3132..3303
FEATURE:
NAME/KEY: intron V
LOCATION: 3304..3390
FEATURE:
NAME/KEY: exon VI
LOCATION: 3391..3459
FEATURE:
NAME/KEY: intron VI
LOCATION: 3460..3671
FEATURE:
NAME/KEY: exon VII
LOCATION: 3672..3941
FEATURE:
NAME/KEY: Stopcodon
LOCATION: 3942..3944
US-08-605-106-4

Query Match 84.8%; Score 17.8; DB 2; Length 4098;
Best Local Similarity 90.5%; Pred. No. 46;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTTCACAGG 21

SEQUENCE CHARACTERISTICS:

; SEQUENCE CHARACTERISTICS:

RESULT 7

US-08-477-451-9/C
; Sequence 9, Application US/08477451
; Patent No. 5928865
; GENERAL INFORMATION:
; APPLICANT: Covacci, Antonello
; TITLE OF INVENTION: Helicobacter Pylori Cagi Region
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Chiron Corporation
; STREET: 4560 Horton Street
; CITY: Emeryville
; STATE: CA
; COUNTRY: USA
; ZIP: 94608-2916
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/477,451
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: McClung, Barbara G.
; REGISTRATION NUMBER: 33,113
; REFERENCE/DOCKET NUMBER: 0335.002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 510-601-2708
; TELEFAX: 510-655-3542
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 5599 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-477-451-9

Query Match 82.9%; Score 17.4; DB 2; Length 5599;
Best Local Similarity 94.7%; Pred. No. 68;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTCTCA 19
|||||

Db 1695 TTCTTTTCTCTCTCA 1677

RESULT 8
US-08-477-451-13
; Sequence 13, Application US/08477451
; Patent No. 5928865
; GENERAL INFORMATION:
; APPLICANT: Covacci, Antonello
; TITLE OF INVENTION: Helicobacter Pylori Cagi Region
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Chiron Corporation
; STREET: 4560 Horton Street
; CITY: Emeryville
; STATE: CA
; COUNTRY: USA
; ZIP: 94608-2916
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/477,451
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:
; NAME: McClung, Barbara G.
; REGISTRATION NUMBER: 33,113
; REFERENCE/DOCKET NUMBER: 0335.002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 510-601-2708
; TELEFAX: 510-655-3542
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 5599 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-477-451-13

Query Match 82.9%; Score 17.4; DB 2; Length 5599;
Best Local Similarity 94.7%; Pred. No. 68;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTCTCA 19
|||||

Db 3905 TTCTTTTCTCTCTCA 3923

RESULT 9
US-08-477-451-25/C
; Sequence 25, Application US/08477451
; Patent No. 5928865
; GENERAL INFORMATION:
; APPLICANT: Covacci, Antonello
; TITLE OF INVENTION: Helicobacter Pylori Cagi Region
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Chiron Corporation
; STREET: 4560 Horton Street
; CITY: Emeryville
; STATE: CA
; COUNTRY: USA
; ZIP: 94608-2916
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/477,451
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: McClung, Barbara G.
; REGISTRATION NUMBER: 33,113
; REFERENCE/DOCKET NUMBER: 0335.002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 510-601-2708
; TELEFAX: 510-655-3542
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19932 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-477-451-25

Query Match 82.9%; Score 17.4; DB 2; Length 19932;
Best Local Similarity 94.7%; Pred. No. 74;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTCTCA 19
|||||

Db 5252 TTCCTTTTCTCTCTCA 5234

```
RESULT 10
US-08-181-629A-3/C
; Sequence 3, Application US/08181629A
; Patent No. 5472872
; GENERAL INFORMATION:
; APPLICANT: Swaminathan, Neela
; APPLICANT: Van Etten, James
; APPLICANT: Mead, David
; APPLICANT: Skowron, Piotr
; TITLE OF INVENTION: Recombinant CviJI Restriction Endonuclease
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/181,629A
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 31504
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1225 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: join(1...33, 55..1128)
; US-08-181-629A-3

Query Match 81.0%; Score 17; DB 1; Length 1225;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTCCTTTTCTCTCTCA 17
Db 139 TTCCTTTTCTCTCTCA 123

RESULT 11
US-08-181-629A-2/C
; Sequence 2, Application US/08181629A
; Patent No. 5472872
; GENERAL INFORMATION:
; APPLICANT: Swaminathan, Neela
; APPLICANT: Van Etten, James
; APPLICANT: Mead, David
; APPLICANT: Skowron, Piotr
; TITLE OF INVENTION: Recombinant CviJI Restriction Endonuclease
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
```

```
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/181,629A
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 31504
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 5496 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-181-629A-2

Query Match 81.0%; Score 17; DB 1; Length 5496;
Best Local Similarity 100.0%; Pred. No. 97;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTCCTTTTCTCTCTCA 17
Db 1207 TTCCTTTTCTCTCTCA 1191

RESULT 12
US-09-020-956-52
; Sequence 52, Application US/09020956
; Patent No. 6261562
; GENERAL INFORMATION:
; APPLICANT: Xu, Jiangchun
; APPLICANT: Dillin, Davin C.
; TITLE OF INVENTION: COMPOUNDS FOR IMMUNOTHERAPY OF PROSTATE CANCER AND METHODS
; NUMBER OF SEQUENCES: 178
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/020,956
; FILING DATE: 09-FEB-1998
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Maki, David J.
; REGISTRATION NUMBER: 31,392
; REFERENCE/DOCKET NUMBER: 210121.427C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
```

; INFORMATION FOR SEQ ID NO: 52;
; SEQUENCE CHARACTERISTICS:
; LENGTH: 491 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; US-09-020-956-52

Query Match 77.1%; Score 16.2; DB 4; Length 491;
Best Local Similarity 85.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCTTTTCTCTTCACAGG 21
|||||
Db 387 TTCTTTTCTCTTCACAGG 407

RESULT 13
US-09-030-607-52
; Sequence 52, Application US/09030607
; Patent No. 6262245

; GENERAL INFORMATION:
; APPLICANT: Xu, Jiangchun
; APPLICANT: Dillon, Davin C.
; TITLE OF INVENTION: COMPOUNDS FOR IMMUNOTHERAPY OF PROSTATE CANCER AND METHODS FO
; NUMBER OF SEQUENCES: 224
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: SEED AND BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98104

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/030, 607
; FILING DATE: 25-FEB-1998

; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Maki, David J.
; REGISTRATION NUMBER: 31,392
; REFERENCE/DOCKET NUMBER: 210121.427C3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031

; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 491 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; US-09-030-607-52

Query Match 77.1%; Score 16.2; DB 4; Length 491;
Best Local Similarity 85.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCTTTTCTCTTCACAGG 21
|||||
Db 387 TTCTTTTCTCTTCACAGG 407

RESULT 14
US-09-439-313-52
; Sequence 52, Application US/09439313
; Patent No. 6329505
; GENERAL INFORMATION:
; APPLICANT: Xu, Jiangchun
; APPLICANT: Dillon, Davin C.
; APPLICANT: Mitcham, Jennifer L.
; APPLICANT: Harlocker, Susan Louise
; APPLICANT: Jiang Yuqui
; APPLICANT: Reed, Steven G.
; APPLICANT: Kalos, Michael
; APPLICANT: Fanger, Gary
; APPLICANT: Retter, Mark
; APPLICANT: Solk, John
; APPLICANT: Day, Craig
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THERAPY AND
; TITLE OF INVENTION: DIAGNOSIS OF PROSTATE CANCER
; FILE REFERENCE: 210121.427C9
; CURRENT APPLICATION NUMBER: US/09/439,313
; CURRENT FILING DATE: 1999-11-12
; NUMBER OF SEQ ID NOS: 575
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 52
; LENGTH: 491
; TYPE: DNA
; ORGANISM: Homo sapien
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(491)
; OTHER INFORMATION: n = A,T,C or G
US-09-439-313-52

Query Match 77.1%; Score 16.2; DB 4; Length 491;
Best Local Similarity 85.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCTTTTCTCTTCACAGG 21
|||||
Db 387 ttcttttttttttttacagg 407

RESULT 15
US-08-327-451E-23/C
; Sequence 23, Application US/08327451E
; Patent No. 5910630
; GENERAL INFORMATION:
; APPLICANT: Davies, Maelor
; APPLICANT: Hawkins, Deborah
; APPLICANT: Nelsen, Janet
; APPLICANT: Lassner, Michael
; TITLE OF INVENTION: PLANT LYSOPHOSPHATIDIC
; TITLE OF INVENTION: ACID ACYLTRANSFERASES
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Calgene, Inc.
; STREET: 1920 Fifth Street
; CITY: Davis
; STATE: CA
; COUNTRY: USA
; ZIP: 95616
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 MB
; COMPUTER: IBM PC
; OPERATING SYSTEM: Windows NT 4.0
; SOFTWARE: Microsoft Word For Windows 7.0a
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/327,451E
; FILING DATE: 21-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/254,404

; FILING DATE: 06-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/231,196
; FILING DATE: 21-APR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/224,625
; FILING DATE: 06-APR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Carl J. Schwedler
; REGISTRATION NUMBER: 36,924
; REFERENCE/DOCKET NUMBER: CGNE 106-3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (530) 753-6313
; TELEFAX: (530) 753-1510
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 508 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to mRNA
US-08-327-451E-23

Query Match 77.1%; Score 16.2; DB 2; Length 508;
Best Local Similarity 85.7%; Pred. NO. 1.7e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 TTCTTTTTCCTTCACAGG 21
Db 496 TTCTTTTTCCTTCACAGG 476

Search completed: July 21, 2002, 09:47:21
Job time: 11952 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run On: July 21, 2002, 09:11:05 ; Search time 3274.61 Seconds
(without alignments)
86.556 Million cell updates/sec

Title: US-09-754-014-10_COPY_25_45
Perfect score: 21
Sequence: 1 TTCTTTTTCCTTCACAGG 21

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 13736207 seqs, 6748477542 residues

Total number of hits satisfying chosen parameters: 27472414

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST:
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hic:*
9: gb_est1:*
10: gb_est2:*
11: gb_hic:*
12: gb_gss:*
13: em_gss_hum:*
14: em_gss_inv:*
15: em_gss_pln:*
16: em_gss_vrt:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
C 1	19.4	92.4	537	10	BI219527	BI219527 602936604
C 2	19.4	92.4	691	10	BG499610	BG499610 602546774
C 3	18.4	87.6	242	9	BB015899	BB015899 BB015899
4	18.4	87.6	301	9	BB540713	BB540713 BB540713
5	18.4	87.6	327	9	BB125849	BB125849 BB125849
C 6	18.4	87.6	335	9	AA063675	AA063675 T3357 MVA
7	18.4	87.6	341	12	AQ0908298	AQ0908298 GSSTC0505
8	18.4	87.6	349	12	BM057848	BM057848 RPT-24-3
9	18.4	87.6	407	9	AW493746	AW493746 UI-M-BH3-
C 10	18.4	87.6	511	10	BG140084	BG140084 EST480526
C 11	18.4	87.6	522	9	AA677704	AA677704 zj72h09.s
C 12	18.4	87.6	561	10	BM217071	BM217071 C0890E05-
C 13	18.4	87.6	577	10	BM030926	BM030926 495476 MA
C 14	18.4	87.6	593	9	AI671885	AI671885 wb41b12.x
C 15	18.4	87.6	679	12	AG055132	AG055132 Pan trogl
C 16	18.4	87.6	855	12	CNS05FV8	AL335501 Tetraodon
17	18	85.7	289	9	BB365025	BB365025 BB365025

18	18	85.7	456	12	B35225	B35225 HS-1027-A2-
C 19	18	85.7	520	10	BG659544	BG659544 TgESTY2a2
C 20	18	85.7	652	10	BG709019	BG709019 602675169
C 21	18	85.7	907	12	CNS04AC9	AL281682 Tetraodon
C 22	18	85.7	931	9	BE039837	BE039837 OC08612 O
23	18	85.7	1014	9	AL540909	AL540909 AL540909
C 24	17.8	84.8	193	10	BI424873	BI424873 sah49h02.
C 25	17.8	84.8	243	10	BF023701	BF023701 EtesTea52
26	17.8	84.8	271	9	AV079879	AV079879 AV079879
27	17.8	84.8	276	10	BE993065	BE993065 UI-M-B21-
C 28	17.8	84.8	332	10	BM446523	BM446523 1118H11.a
C 29	17.8	84.8	340	9	BB104566	BB104566 BB104566
C 30	17.8	84.8	347	10	BI402376	BI402376 MI-P-CP0-
C 31	17.8	84.8	353	12	BH289808	BH289808 CH230-202
C 32	17.8	84.8	357	9	BE106435	BE106435 UI-R-B01-
C 33	17.8	84.8	372	9	AI136137	AI136137 UI-R-C2p-
C 34	17.8	84.8	393	10	BG541755	BG541755 602569639
35	17.8	84.8	409	9	AW785838	AW785838 117303 MA
36	17.8	84.8	419	9	AW514225	AW514225 hd24a09.x
37	17.8	84.8	453	12	AQ077923	AQ077923 CIT-HSP-2
C 38	17.8	84.8	458	12	AQ803358	AQ803358 HS_3139.A
C 39	17.8	84.8	469	10	BF532479	BF532479 602074528
40	17.8	84.8	477	12	AZ102514	AZ102514 RPT-23-2
41	17.8	84.8	477	12	BH340152	BH340152 CH230-41E
42	17.8	84.8	479	12	AQ208834	AQ208834 HS_3056_B
C 43	17.8	84.8	507	12	AZ714340	AZ714340 RPT-24-1
C 44	17.8	84.8	531	12	AZ868125	AZ868125 2M0179B17
45	17.8	84.8	534	12	AZ144116	AZ144116 SP_0042_B

ALIGNMENTS

BI219527 602936604F1 NCI_CGAP_L19 Mus musculus cDNA clone IMAGE:5099929 5',
mRNA sequence.

ACCESSION BI219527
VERSION BI219527.1 GI:14672971
KEYWORDS EST.
SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE 1 (bases 1 to 537)
AUTHORS NIH-MGC <http://mgs.nci.nih.gov/>.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov

Tissue Procurement: Jeffrey E. Green, M.D.
CDNA Library Preparation: Life Technologies, Inc.
CDNA Sequencing by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:
<http://image.llnl.gov>

Plate: LLAM11240 row: g column: 02
High quality sequence stop: 485.
Location/Qualifiers
1. .537

FEATURES

source
/organism="Mus musculus"
/strain="FVB/N"
/db_xref="taxon:10090"
/clone="IMAGE:5099929"
/clone_lib="NCI_CGAP_L19"
/lab_host="DH10B (T1 phage-resistant)"
/note="Organ: liver; Vector: pCMV-SPORT6; Site:1: NotI;
Site:2: SalI; Cloned unidirectionally. Primer: Oligo dT.
Average insert size 1.9 kb. Constructed by Life Technologies. Note: this is a NCI_CGAP Library."
108 a 145 c 123 t

BASE COUNT

ORIGIN

Query Match 92.4%; Score 19.4; DB 10; Length 537;
 Best Local Similarity 95.2%; Pred. No. 1.9e+04;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TTTCTTTTCTCTTCACAGG 21
 Db 534 TTTCTTTTCTCTTAACAGG 514

RESULT 2

BG499610/c
 LOCUS
 DEFINITION 602546774F1 NIH_MGC_60 Homo sapiens cDNA clone IMAGE:4669003 5', mRNA linear EST 27-MAR-2001
 mRNA sequence.

ACCESSION BG499610
 VERSION BG499610.1 GI:13461127
 KEYWORDS EST.
 SOURCE human.

ORGANISM

Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1 (bases 1 to 691)
 NIH-MGC http://mgc.nci.nih.gov/.
 National Institutes of Health, Mammalian Gene Collection (MGC)
 Unpublished (1999)
 Contact: Robert Strausberg, Ph.D.

AUTHORS

Email: cgapbs-remail.nih.gov
 Tissue Procurement: DCTD/DTP
 cDNA Library Preparation: CLONTECH Laboratories, Inc.
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
 DNA Sequencing by: Incyte Genomics, Inc.

JOURNAL

Clone distribution: MGC clone distribution information can be
 found through the I.M.A.G.E. Consortium/LLNL at:
 http://image.llnl.gov

Plate: L1CMI480 row: c column: 20

High quality sequence stop: 211.

FEATURES

source

1..691
 Location/Qualifiers
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:4669003"
 /clone_lib="NIH_MGC_60"
 /tissue_type="adenocarcinoma"
 /lab_host="DH10B (T1 phage-resistant)"
 /note="Organ: prostate; Vector: pDNR-LIB (Clontech);
 Site_1: SfII (ggccctcgcc); Site_2: SfII (ggccattatggcc
); Double-stranded cDNA was prepared from cell line RNA.
 5' and 3' adaptors were used in cloning as follows: 5'
 adaptor sequence: 5'-CACGCCATTATGGCC-3' and 3' adaptor
 sequence: 5'-ATTCTAGAGCGGCGGCGCCGACATG-dT(30)BN-3',
 (where B = A, C, or G and N = A, C, G, or T). Average
 insert size 1.5 kb (range 0.9-4.0 kb). 14/15 colonies
 contained inserts by PCR. This library was enriched for
 full-length clones and was constructed by Clontech
 Laboratories (Palo Alto, CA). Note: this is a NIH_MGC
 Library."

BASE COUNT 304 a 103 c 220 g 61 t 3 others
 ORIGIN

Query Match 92.4%; Score 19.4; DB 10; Length 691;
 Best Local Similarity 95.2%; Pred. No. 1.7e+04;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TTTCTTTTCTCTTCACAGG 21
 Db 256 TTTCTTTTCTCTTCACAGG 236

RESULT 3

BB015899

LOCUS

BB015899 RIKEN full-length enriched, adult male testis (DH10B) Mus
 musculus cDNA clone 4930556M05 3', mRNA sequence.

ACCESSION

BB015899

VERSION

BB015899.1 GI:8186874

KEYWORDS

house mouse.

SOURCE

Mus musculus

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

1 (bases 1 to 242)
 Konno, H., Aizawa, K., Akahira, S., Akiyama, J., Arakawa, T., Carninci
 P., Endo, T., Fukuda, S., Fukunishi, Y., Hara, A., Hayatsu, N.,
 Hirozane, T., Hori, F., Ishii, Y., Ishikawa, J., Ishikawa, T., Itoh, M.,
 Izawa, M., Kadota, K., Kagawa, I., Kai, C., Kawai, J., Kikuchi, N.,
 Kiyosawa, H., Kojima, Y., Kondo, S., Koya, S., Kurihara, C., Kusakabe, M.,
 Matsuyama, T., Miki, R., Mizuno, Y., Nakamura, M., Oda, H., Okazaki, Y.,
 Ono, T., Owa, C., Saito, H., Sakai, C., Sato, K., Shibata, K., Shibata, Y.,
 Shigemoto, Y., Shinagawa, A., Shiraki, T., Sogabe, Y., Sugahara, Y.,
 Suzuki, H., Suzuki, H., Tagawa, A., Takahashi, F., Tominaga, N., Toya
 T., Tsunoda, Y., Watabiki, A., Watanabe, S., Yamamura, T., Yamanaka, I.,
 Yano, R., Yasunishi, A., Yokota, T., Yoshida, K., Yoshiki, A., Yoshino

AUTHORS

M., Muramatsu, M. and Hayashizaki, Y.

TITLE

RIKEN Mouse ESTs (Konno, H., et al.)

JOURNAL

Unpublished (2000)

COMMENT

Contact: Yoshihide Hayashizaki
 Laboratory for Genome Exploration Research Group, RIKEN Genomic
 Sciences Center(GSC), Yokohama Institute
 The Institute of Physical and Chemical Research (RIKEN)
 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
 Tel: 81-45-503-9222

Fax: 81-45-503-9216

Email: genome-resgsc.riken.go.jp,

URL: http://genome.gsc.riken.go.jp/

Carninci, P., Nishiyama, Y., Westover, A., Itoh, M., Nagaoka, S., Sasaki

N., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.

Thermostabilization and thermoactivation of thermolabile enzymes by

trehalose and its application for the synthesis of full length

cDNA. Proc. Natl. Acad. Sci. U.S.A. 95 (2), 520-524 (1998)

Itoh, M., Kitsuai, T., Akiyama, J., Shibata, K., Izawa, M., Kawai, J.,

Tomaru, Y., Carninci, P., Shibata, Y., Ozawa, Y., Muramatsu, M., Okazaki

Y. and Hayashizaki, Y.

Automated filtration-based high-throughput plasmid preparation

system. Genome Res. 9 (5), 463-470 (1999)

Carninci, P. and Hayashizaki, Y.

High-efficiency full-length cDNA cloning. Methods Enzymol. 303,

19-44 (1999)

Please visit our web site (<http://genome.rtc.riken.go.jp>) for

further details.

FEATURES

source

Location/Qualifiers
 1..242
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="4930556M05"
 /clone_lib="RIKEN full-length enriched, adult male testis
 (DH10B)"
 /sex="male"
 /tissue_type="testis"
 /dev_stage="adult"
 /lab_host="DH10B"
 /note="Site_1: SalI; Site_2: BamHI; cDNA library was
 prepared and sequenced in Mouse Genome Encyclopedia
 Project of Genome Exploration Research Group in Riken
 Genomic Sciences Center and Genome Science Laboratory in
 RIKEN. Division of Experimental Animal Research in Riken
 contributed to prepare mouse tissues. 1st strand cDNA was
 primed with a primer [5'
 GAGAGAGAAGGATCCAGAGCTCTTTTCTTTTNN 3'], cDNA was
 prepared by using trehalose thermo-activated reverse
 transcriptase and subsequently enriched for full-length by
 cap-trapper. Second strand cDNA was prepared with the

primer adapter of sequence [5'
GAGAGAGATTCTCGAGTTAAATTAATTCCTCCCGCCCCCCC 3']. cDNA
was cloned into the XhoI and BamHI sites. Vector: a
modified pBluescript KS(+) after bulk excision from Lambda
FLC I. Cloning sites, 5' end: SalI; 3' end: BamHI."

BASE COUNT 78 a 45 c 33 g 86 t
ORIGIN

Query Match 87.6%; Score 18.4; DB 9; Length 242;
Best Local Similarity 95.0%; Pred. No. 4.8e+04;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TCTCTTTTCTCTTCACAG 20
|||||
Db 96 TCTCTTTTCTCTTCACAG 115

RESULT 4
BB540713 301 bp mRNA linear EST 31-JUL-2000
LOCUS BB540713 RIKEN full-length enriched, 0 day neonate eyeball Mus
DEFINITION musculus cDNA clone E130107M24 3', mRNA sequence.
ACCESSION BB540713
VERSION BB540713.1 GI:9611936
KEYWORDS EST.
SOURCE house mouse.
ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 301)
Konno, H., Aizawa, K., Akahira, S., Fukunishi, Y., Hara, A., Hayatsu, N.,
P., Endo, T., Fukuda, S., Ishii, Y., Ishikawa, J., Itoh, M.,
Izawa, M., Kadota, K., Kagawa, I., Kai, C., Kawai, J., Kikuchi, N.,
Kiyosawa, H., Kojima, Y., Kondo, S., Koya, S., Kurihara, C., Kusakabe, M.,
Matsuyama, T., Miki, R., Mizuno, Y., Nakamura, M., Oda, H., Okazaki, Y.,
Ono, T., Owa, C., Saito, H., Sakai, C., Sato, K., Shibata, K., Shibata, Y.,
Shigemoto, Y., Shinagawa, A., Shiraki, T., Sogabe, Y., Sugahara, Y.,
Suzuki, H., Suzuki, H., Tagawa, A., Takahashi, F., Tominaga, N., Toya, T., Tsunoda, Y., Watahiki, A., Watanabe, S., Yamamura, T., Yamanaka, I.,
Yano, R., Yasunishi, A., Yokota, T., Yoshida, K., Yoshiki, A., Yoshino, M., Muramatsu, M. and Hayashizaki, Y.
RIKEN Mouse ESTs (Konno, H., et al.)

Unpublished (2000)
Contact: Yoshihide Hayashizaki
Laboratory for Genome Exploration Research Group, RIKEN Genomic
Sciences Center (GSC), Yokohama Institute
The Institute of Physical and Chemical Research (RIKEN)
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
Tel: 81-45-503-9222
Fax: 81-45-503-9216
Email: genome-res@sc.riken.go.jp,
URL: http://genome.gsc.riken.go.jp/
Carninci, P., Nishiyama, Y., Westover, A., Itoh, M., Nagaoka, S., Sasaki, N., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.
Thermolabile enzymes and thermoactivation of the synthesis of full length
thermolabile enzymes and thermoactivation of the synthesis of full length
cDNA. Proc. Natl. Acad. Sci. U.S.A. 95 (2), 520-524 (1998)
Itoh, M., Kusunagi, T., Akiyama, J., Shibata, K., Izawa, M., Kawai, J.,
Tomaru, Y., Carninci, P., Shibata, Y., Ozawa, Y., Muramatsu, M., Okazaki, Y., and Hayashizaki, Y.
Automated filtration-based high-throughput plasmid preparation
system. Genome Res. 9 (5), 463-470 (1999)
Carninci, P. and Hayashizaki, Y.
High-efficiency full-length cDNA cloning. Methods Enzymol. 303,
19-44 (1999)
Please visit our web site (http://genome.rtc.riken.go.jp) for
further details.

FEATURES
Source
1..301
Location/Qualifiers
/organism="Mus musculus"
/db_xref="taxon:10090"

/clone="E130107M24"
eyeball"
/tissue_type="eyeball"
/dev_stage="0 day neonate"
/lab_host="DH10B"
/note="Site_1: SalI; Site_2: BamHI; cDNA library was
prepared and sequenced in Mouse Genome Encyclopedia
Project of Genome Exploration Research Group in Riken
Genomic Sciences Center and Genome Science Laboratory in
RIKEN. Division of Experimental Animal Research in Riken
contributed to prepare mouse tissues. 1st strand cDNA was
primed with a primer [5'
GAGAGAGAGCGCGCAACTCGAGTTTCTCTTTTCTCTTTT 3'], cDNA was
prepared by using trehalose thermo-activated reverse
transcriptase and subsequently enriched for full-length by
cap-trapper. Second strand cDNA was prepared with the
primer adapter of sequence [5'
GAGAGAGAGATTCTCGAGTTAAATTAATTCCTCCCGCCCCCCC 3']. cDNA
was cleaved with BamHI and XhoI. Vector: a modified
pBluescript KS(+) after bulk excision from Lambda FLC I."

BASE COUNT 55 a 105 c 60 g 81 t
ORIGIN

Query Match 87.6%; Score 18.4; DB 9; Length 301;
Best Local Similarity 95.0%; Pred. No. 4.4e+04;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 TCTTTTCTCTTCACAG 21
|||||
Db 177 TCTTTTCTCTTCACAG 196

RESULT 5
BB125849 327 bp mRNA linear EST 28-JUN-2000
LOCUS BB125849 RIKEN full-length enriched, 16 days neonate cerebellum Mus
DEFINITION musculus cDNA clone 9630009E03 3', mRNA sequence.
ACCESSION BB125849
VERSION BB125849.1 GI:8780181
KEYWORDS EST.
SOURCE house mouse.
ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 327)
Konno, H., Aizawa, K., Akahira, S., Akiyama, J., Arakawa, T., Carninci, P., Endo, T., Fukuda, S., Fukunishi, Y., Hara, A., Hayatsu, N.,
Hirozane, T., Hori, F., Ishii, Y., Ishikawa, J., Ishikawa, T., Itoh, M.,
Izawa, M., Kadota, K., Kagawa, I., Kai, C., Kawai, J., Kikuchi, N.,
Kiyosawa, H., Kojima, Y., Kondo, S., Koya, S., Kurihara, C., Kusakabe, M.,
Matsuyama, T., Miki, R., Mizuno, Y., Nakamura, M., Oda, H., Okazaki, Y.,
Ono, T., Owa, C., Saito, H., Sakai, C., Sato, K., Shibata, K., Shibata, Y.,
Shigemoto, Y., Shinagawa, A., Shiraki, T., Sogabe, Y., Sugahara, Y.,
Suzuki, H., Suzuki, H., Tagawa, A., Takahashi, F., Tominaga, N., Toya, T., Tsunoda, Y., Watahiki, A., Watanabe, S., Yamamura, T., Yamanaka, I.,
Yano, R., Yasunishi, A., Yokota, T., Yoshida, K., Yoshiki, A., Yoshino, M., Muramatsu, M. and Hayashizaki, Y.
RIKEN Mouse ESTs (Konno, H., et al.)

Unpublished (2000)
Contact: Yoshihide Hayashizaki
Laboratory for Genome Exploration Research Group, RIKEN Genomic
Sciences Center (GSC), Yokohama Institute
The Institute of Physical and Chemical Research (RIKEN)
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
Tel: 81-45-503-9222
Fax: 81-45-503-9216
Email: genome-res@sc.riken.go.jp,
URL: http://genome.gsc.riken.go.jp/
Carninci, P., Nishiyama, Y., Westover, A., Itoh, M., Nagaoka, S., Sasaki, N., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.
Thermolabile enzymes and thermoactivation of the synthesis of full length
thermolabile enzymes and thermoactivation of the synthesis of full length
cDNA. Proc. Natl. Acad. Sci. U.S.A. 95 (2), 520-524 (1998)
Itoh, M., Kusunagi, T., Akiyama, J., Shibata, K., Izawa, M., Kawai, J.,
Tomaru, Y., Carninci, P., Shibata, Y., Ozawa, Y., Muramatsu, M., Okazaki, Y., and Hayashizaki, Y.
Automated filtration-based high-throughput plasmid preparation
system. Genome Res. 9 (5), 463-470 (1999)
Carninci, P. and Hayashizaki, Y.
High-efficiency full-length cDNA cloning. Methods Enzymol. 303,
19-44 (1999)
Please visit our web site (http://genome.rtc.riken.go.jp) for
further details.

trehalose and its application for the synthesis of full length cDNA. Proc. Natl. Acad. Sci. U.S.A. 95 (2), 520-524 (1998)
 Itoh, M., Kitsuai, T., Akiyama, J., Shibata, K., Izawa, M., Kawai, J., Tomaru, Y., Carninci, P., Shibata, Y., Ozawa, Y., Muramatsu, M., Okazaki, Y. and Hayashizaki, Y.
 Automated filtration-based high-throughput plasmid preparation system. Genome Res. 9 (5), 463-470 (1999)
 Carninci, P. and Hayashizaki, Y.
 High-efficiency full-length cDNA cloning. Methods Enzymol. 303, 19-44 (1999)
 Please visit our web site (<http://genome.rtc.riken.go.jp>) for further details.

FEATURES source

Location/Qualifiers
 1. .327
 /organism="Mus musculus"
 /db_xref="taxon:10090"
 /clone_lib="RIKEN full-length enriched, 16 days neonate cerebellum"
 /tissue_type="cerebellum"
 /dev_stage="16 days neonate"
 /lab_host="DH10B"
 /note="Site_1: Sali; Site_2: BamHI; cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues. 1st strand cDNA was primed with a primer [5' GAGAGAGAGATCCCAAGAGCTCTTTTTTTTTTNN 3'], cDNA was prepared by using trehalose thermo-activated reverse transcriptase and subsequently enriched for full-length by cap-trapper. cDNA went through one round of normalization to Rot = 20.0 and subtraction to Rot = 370.0. Second strand cDNA was prepared with the primer adapter of sequence [5' GAGAGAGATCTCGATTAAATTAATCCCCCCCCCCCC 3']. cDNA was cleaved with XhoI and BamHI. Vector: a modified pBluescript KS(+) after bulk excision from Lambda FLC I."

BASE COUNT 92 a 52 c 49 g 134 t
 ORIGIN

Query Match 87.6%; Score 18.4; DB 9; Length 327;
 Best Local Similarity 95.0%; Pred. No. 4.3e+04;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 TCTTTTCTCTCTCACAGG 21
 |||||
 Db 19 TCTTTTCTCTCTCCAGG 38

RESULT 6 AA063675/c

LOCUS T3357 MVAT4 bloodstream form of serodeme WRATat1.1 Trypanosoma brucei rhodesiense cDNA 5', mRNA sequence.
 DEFINITION
 ACCESSION AA063675
 VERSION
 KEYWORDS EST.
 SOURCE Trypanosoma brucei rhodesiense.
 ORGANISM Eukaryota; Euzlenozoa; Kinetoplastida; Trypanosomatidae; Trypanosoma.

REFERENCE 1 (bases 1 to 335)
 AUTHORS Djikeng, A., Donelson, J.E. and Majiwa, P.A.O.
 TITLE Generation of expressed sequence tags as physical landmarks in the genome of Trypanosoma brucei

JOURNAL Unpublished (1996)
 COMMENT Contact: Majiwa PAO
 Molecular Biology Unit
 International Livestock Research Institute
 P.O. Box 30709, Nairobi, Kenya

Tel: 254-2 630743
 Fax: 254-2 631499
 Email: p.majiwa@cnet.com
 Seq primer: T3 primer.

FEATURES source

Location/Qualifiers
 1. .335
 /organism="Trypanosoma brucei rhodesiense"
 /db_xref="taxon:31286"
 /clone_lib="MVAT4 bloodstream form of serodeme WRATat1.1"
 /note="Vector: Lambda ZAP II (Stratagene); Site_1: EcoRI; Site_2: XhoI; the mRNA was purified from a cloned population of bloodstream trypanosomes reexpressing the MVAT4 metacyclic variant surface glycoprotein (VSG). A unidirectional oligo dT-primed EcoRI/XhoI cDNA library was constructed in lambda ZAP II (Stratagene)."

BASE COUNT 115 a 92 c 56 g 72 t
 ORIGIN

Query Match 87.6%; Score 18.4; DB 9; Length 335;
 Best Local Similarity 95.0%; Pred. No. 4.2e+04;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TTCTTTTCTCTCTCACAG 20
 |||||
 Db 223 TTTTCTTCTCTCTCACAG 204

RESULT 7 AQ908298

LOCUS GSSTc05056 Trypanosoma cruzi random genomic library Trypanosoma cruzi genomic clone G26J5, DNA sequence.
 DEFINITION
 ACCESSION AQ908298
 VERSION
 KEYWORDS GSS.
 SOURCE Trypanosoma cruzi.
 ORGANISM Eukaryota; Euzlenozoa; Kinetoplastida; Trypanosomatidae; Trypanosoma; Schizotrypanum.

REFERENCE 1 (bases 1 to 341)
 AUTHORS Aguero, F., Verdun, R., Frasch, A.C.C. and Sanchez, D.O.
 TITLE A random sequencing approach for the analysis of the trypanosoma cruzi genome: general structure, large gene and repetitive DNA families, and gene discovery

JOURNAL Genome Res. 10 (12), 1996-2005 (2000)
 MEDLINE 2058489
 COMMENT On Sep 14, 2000 this sequence version replaced gi:9370869.

Contact: Sanchez D.O.
 Instituto de Investigaciones Biocnolcgicas (Univ. Nac. de Gral San Martin)
 Av. Gral Paz entre Albarcellos y Constituyentes, INTI edificio 24 CP(1650) San Martin, Prov. de BS AS, Argentina
 Tel: 54-11-4580-7255 ext 309
 Fax: 54-11-4752-9639
 Email: dsanchez@ib.unsam.edu.ar

Sequences were basecalled with phred and vector was masked with crossmatch (see <http://genome.washington.edu>). Sequences were then trimmed from both ends to remove low quality bases and masked vector.
 Seq primer: T7
 Class: shotgun.

FEATURES source

Location/Qualifiers
 1. .341
 /organism="Trypanosoma cruzi"
 /strain="CL-Brener"
 /db_xref="taxon:5693"
 /clone="G26J5"
 /clone_lib="Trypanosoma cruzi random genomic library"
 /cell_type="epimastigote"
 /note="Vector: pBS(-) (Stratagene); T. cruzi DNA was randomly sheared using a nebulizer and the 1 to 2 Kb range was gel purified and cloned into the dephosphorylated

BASE COUNT 108 a 76 c 52 g 105 t
 ORIGIN HincII site of the vector"

Query Match 87.6%; Score 18.4; DB 12; Length 341;
 Best Local Similarity 95.0%; Pred. NO. 4.2e+04;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TTCTTTTTCCTTCACAG 20
 |||
 DB 148 TTTTTCCTTCACAG 167

RESULT 8
 LOCUS BH057848
 DEFINITION RPCI-24-354M18.TJ RPCI-24 Mus musculus genomic clone RPCI-24-354M18
 , DNA sequence.

ACCESSION BH057848
 VERSION BH057848.1 GI:14866229
 KEYWORDS GSS.

SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 349)

AUTHORS Zhao,S., Niehman,W., Malek,J., Shatsman,S., Akinret,B., Levins,M.,
 Tsegaye,G., Geer,K., Krol,M., Shvartsbeyn,A., Gebregorgis,E.,
 Russell,D., de Jong,P. and Fraser,C.N.

TITLE Mouse BAC End Sequences from Library RPCI-24
 JOURNAL Unpublished (1999)
 COMMENT Other GSSs: RPCI-24-354M18.TV

Contact: Shaying Zhao
 Department of Eukaryotic Genomics
 The Institute for Genomic Research
 9712 Medical Center Dr., Rockville, MD 20850, USA
 Tel: 301 838 0200
 Fax: 301 838 0208

Email: szhao@tigr.org
 Clones are derived from the mouse BAC library RPCI-24. For BAC
 library availability, please contact Pieter de Jong
 (pdejong@mail.cho.org). Clones may be purchased from BACPAC
 Resources (<http://www.choi.org/bacpac/orderingframe.htm>). BAC end
 page: http://www.tigr.org/tdb/bac_ends/mouse/bac_end_intro.html
 Plate: 354 row: M column: 18
 Seq primer: SP6
 Class: BAC ends.

FEATURES

Location/Qualifiers
 1..349
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="RPCI-24-354M18"
 /clone_lib="RPCI-24"
 /sex="Male"
 /cell_type="Spleen/Brain"

/note="Vector: pTARBAC1; Site_1: BamHI; Site_2: BamHI;
 RPCI-24 Mouse BAC Library produced by Pieter de Jong. The
 library was cloned in the pTARBAC1 cloning vector at the
 BamHI sites using MboI partially digested male C57BL/6J
 DNA."

BASE COUNT 89 a 89 c 68 g 103 t
 ORIGIN

Query Match 87.6%; Score 18.4; DB 12; Length 349;
 Best Local Similarity 95.0%; Pred. NO. 4.2e+04;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TTCTTTTTCCTTCACAG 20
 |||
 DB 250 TTTTTCCTTCACAG 269

RESULT 9
 LOCUS AW493746

DEFINITION UI-M-BH3-auo-g-01-0-UI.s1 NIH_BMAP_M_S4 Mus musculus cDNA clone
 UI-M-BH3-auo-g-01-0-UI 3', mRNA sequence.

ACCESSION AW493746
 VERSION AW493746.1 GI:7064027
 KEYWORDS EST.

SOURCE house mouse.
 ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 407)

AUTHORS Bonaldo,M.F., Lennon,G. and Soares,M.B.
 TITLE Normalization and subtraction: two approaches to facilitate gene
 discovery

JOURNAL Genome Res. 6 (9), 791-806 (1996)
 MEDLINE 9704477
 COMMENT

Contact: Chin, H
 National Institute of Mental Health
 6001 Executive Blvd. Room 7N-7190, MSC 9643, Bethesda, MD
 20892-9643, USA
 Tel: 301 443 1706
 Fax: 301 443 9890

Email: mEST@mail.nih.gov

The sequence contained an oligo-dT track that was present in the
 oligonucleotide that was used to prime the synthesis of first
 strand cDNA and therefore this may represent a bonafide poly A
 tail. The sequence tag present in the cDNA between the NotI site
 and the oligo-dT track served to identify it as a clone from the
 normalized hypothalamus library cDNA Library Preparation: M.B.
 Soares Lab Clone distribution: Researchers may obtain BMAP CDNA
 clones from RESEARCH GENETICS. It should be noted that Bento Soares
 is generating a small number of additional specialized
 non-redundant arrays of BMAP cDNAs whose availability will be
 considered under appropriate and limited collaborative arrangements
 Seq primer: M13 Forward
 POLYA=Yes.

FEATURES

Location/Qualifiers
 1..407
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UI-M-BH3-auo-g-01-0-UI"
 /clone_lib="NIH_BMAP_M_S4"
 /dev_stage="27-32 days"

/lab_host="DH10B (Life Technologies)"
 /note="Vector: pT7T3D-Pac (Pharmacia) with a modified
 polylinker; Site_1: Not I; Site_2: Eco RI; The
 NIH_BMAP_M_S4 library is a subtracted library of a series,
 ultimately derived from a mixture of individually tagged
 normalized libraries from ten regions of the mouse brain
 (cerebellum, brain stems, olfactory bulbs, hypothalamus,
 cortex, amygdala, basal ganglia, pineal gland, striatum,
 hippocampus) after a series of subtractions to reduce the
 representation of cDNAs from which ESTs had already been
 generated. The following serially subtracted libraries
 were generated in this process: NIH_BMAP_M_S4,
 NIH_BMAP_M_S3.3, NIH_BMAP_M_S3.2, NIH_BMAP_M_S3.1,
 NIH_BMAP_M_S2, NIH_BMAP_M_S1. The subtracted library
 (NIH_BMAP_M_S4) was constructed as follows: PCR amplified
 cDNA inserts from NIH_BMAP_M_S3.3, NIH_BMAP_M_S3.2, and
 NIH_BMAP_M_S3.1 clones from which 3' ESTs had been derived
 was used as a driver in a hybridization with a pool of
 the NIH_BMAP_M_S3.3, NIH_BMAP_M_S3.2, and NIH_BMAP_M_S3.1
 libraries in the form of single-stranded circles. The
 remaining single-stranded circles (subtracted library)
 was purified by hydroxyapatite column chromatography,
 converted to double-stranded circles and electroporated
 into DH10B bacteria (Life Technologies) to generate the
 NIH_BMAP_M_S4 library. This procedure has been previously

described (Bonaldo, Lennon and Soares, Genome Research
6:791-806, 1996)
TAG_LTB-NIH_BMAP_M.S4
TAG_TISSUE=hypothalamus
TAG_SEQ-CGCA

BASE COUNT 94 a 102 c 70 g 141 t
ORIGIN

Query Match 87.6%; Score 18.4; DB 9; Length 407;
Best Local Similarity 95.0%; Pred. No. 3.9e+04;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTCTCACAG 20
|||||
Db 6 TTTTCTTCTCTCTCACAG 25

RESULT 10
BG140084/c
LOCUS
DEFINITION EST480526 wild tomato pollen Lycopersicon pennellii cDNA clone
CLPP16119 5' sequence, mRNA sequence.
BG140084

ACCESSION BG140084.1 GI:12640272
VERSION
KEYWORDS EST.

SOURCE Lycopersicon pennellii.
ORGANISM Lycopersicon pennellii
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Asteridae; euasterids I; Solanales; Solanaceae; Solanum;
Lycopersicon.

REFERENCE 1 (bases 1 to 511)
AUTHORS van der Hoeven, R., Bezzerides, J., Sun, H., Cho, J., Utterback, T.,
Hansen, C., Ronning, C. and Tanksley, S.
TITLE Generation of ESTs from wild tomato (L. pennellii) pollen
JOURNAL Unpublished (2001)
COMMENT Contact: CUGI

Clemson University
Clemson University
100 Jordan Hall, Clemson, SC 29634, USA
Email: <http://www.genome.clemson.edu/orders/index.html>.

FEATURES
source
1..511
Location/Qualifiers
/organism="Lycopersicon pennellii"
/cultivar="TA56"
/db_xref="taxon:28526"

/clone="clPp16119"
/lab_host="wild tomato pollen"
/tissue_type="pollen"
/dev_stage="pollen collected from open flowers"
/lab_host="SOLR"
/note="Vector: pBluescript SK(-); Site_1: EcoRI; Site_2:
XhoI; Pollen was collected from open flowers from
L.pennellii TA56, and stored at -80 C until library
construction."

BASE COUNT 156 a 77 c 125 g 153 t
ORIGIN

Query Match 87.6%; Score 18.4; DB 10; Length 511;
Best Local Similarity 95.0%; Pred. No. 3.6e+04;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTCTCACAG 20
|||||
Db 432 TTTCTTCTCTCTCTCACAG 413

RESULT 11
AA677704/c
LOCUS
DEFINITION zj72h09.s1 Soares_fetal_liver_spleen_INFLS_S1 Homo sapiens cDNA

clone IMAGE:460481 3', mRNA sequence.
AA677704
VERSION AA677704.1 GI:2658226
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 522)

REFERENCE Hillier, L., Allen, M., Bowles, L., Dubuque, T., Geisel, G., Jost, S.,
Krizman, D., Kucaba, T., Lacy, M., Le, N., Lennon, G., Marra, M., Martin,
J., Moore, B., Scheinberg, K., Steptoe, M., Tan, F., Theising, B.,
White, Y., Wylie, T., Waterston, R. and Wilson, R.
TITLE WashU-NCI human EST Project
JOURNAL Unpublished (1997)
COMMENT Contact: Wilson RK

Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu

This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
Seq primer: -40ml3 fwd. ET from Amersham
High quality sequence stop: 468.

FEATURES
Location/Qualifiers
1..522
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:460481"
/clone_lib="Soares_fetal_liver_spleen_INFLS_S1"
/sex="male"
/dev_stage="20 week-post conception fetus"
/lab_host="DH10B (ampicillin resistant)"

/note="Organ: Liver and Spleen; Vector: p7T3D (Pharmacia)
with a modified polylinker; Site_1: Pac I; Site_2: Eco RI;
This is a subtracted version of the original Soares fetal
liver spleen INFLS library. 1st strand cDNA was primed
with a Pac I - oligo(dT) primer [5',
AACTGCAAGAATTAATAAGATCTTTTCTTTTCTTTT 3'],
double-stranded cDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Pac I and cloned into the Pac I
and Eco RI sites of the modified p7T3 vector. Library
went through one round of normalization. Library
constructed by Bento Soares and M.Fatima Bonaldo."

BASE COUNT 186 a 100 c 109 g 127 t
ORIGIN

Query Match 87.6%; Score 18.4; DB 9; Length 522;
Best Local Similarity 95.0%; Pred. No. 3.5e+04;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTCTCACAG 20
|||||
Db 472 TTCTTTTCTCTCTCACAG 453

RESULT 12
BM217071

LOCUS
DEFINITION C0890E05-3 NIA Mouse Blastocyst cDNA Library (Long) Mus musculus
cDNA clone C0890E05 3', mRNA sequence.

ACCESSION BM217071
VERSION BM217071.1 GI:17776109
KEYWORDS EST.
SOURCE house mouse.

ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 561)
REFERENCE Piao, Y., Kargul, G.J., Dudekula, D.B., Qian, Y., Tanaka, T., Luo, A. and
Ko, M.S.H.

TITLE JOURNAL COMMENT

Systematic Analyses of NIA Mouse Blastocyst cDNA Library (Long)
Unpublished (2001)
Contact: Dawood B. Dudekula
Laboratory of Genetics
National Institute on Aging/National Institutes of Health
333 Cassell Drive, Suite 4000, Baltimore, MD 21224-6820, USA
Email: cda@igsun.grc.nia.nih.gov
Plate: C0890 row: E column: 05
Seq primer: -21M13 Forward
High quality sequence stop: 561
POLYA-Yes.

FEATURES

source Location/Qualifiers

1. .561
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="niaEST:C0890E05-3"
/db_xref="taxon:10090"
/clone="C0890E05"
/clone_lib="NIA Mouse Blastocyst cDNA Library (Long)"
/tissue_type="Blastocyst"
/dev_stage="3.5-dpc"
/lab_host="DH10B"
/note="Vector: pSPORT1 (Invitrogen); Site_1: Sali; Site_2: NotI; Mouse cDNA project by the Laboratory of Genetics, National Institute on Aging (NIA), Intramural Research Program, NIH (<http://igsun.grc.nia.nih.gov/cDNA>). This is a long-transcript enriched cDNA library (Ref. Genome Res. 11: 1553-1558 (2001). [PMID: 11544199]). Total RNAs were extracted from a pool of 20 Blastocysts. Double-stranded cDNAs were synthesized with an Oligo(dT) primer [Invitrogen]:
5'-pgactagtcttagatcgcgagcgccgccttttttttttt-3' from 0.2 ug of total RNA, treated with T4 DNA polymerase, and purified by ethanol-precipitation. The cDNAs were ligated to lone-linker L1-Sal4, purified by phenol/chloroform, and separated from free linkers by Centricon 100. Then, the cDNAs were amplified by long-range high fidelity PCR using Ex Taq polymerase (Takara) with a primer Sal4-S. The products were purified by phenol/chloroform and Centricon 100. The cDNAs were digested with Sali and NotI enzymes and cloned into Sali/NotI site of pSPORT1 plasmid vector. The DH10B E. coli host was transformed with the ligation mixture by the standard chemical method. The average insert size is about 2.2 kb. The library was constructed by Yulan Piao (NIA)."

BASE COUNT 145 a 127 c 127 g 162 t
ORIGIN

Query Match 87.6%; Score 18.4; DB 10; Length 561;
Best Local Similarity 95.0%; Pred. No. 3.4e+04;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TTCTTTTCTCTCTCACAG 20
||||||| |||||||

Db 114 TTCTTTTCTCTCTCACAG 133

RESULT 13

LOCUS BM030926/c
DEFINITION 495476 MARC 2BOV Bos taurus cDNA 5', mRNA sequence.
ACCESSION BM030926
VERSION BM030926.1 GI:16744496
KEYWORDS EST.
SOURCE cow.

ORGANISM

Bos taurus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;
Bovidae; Bovinae; Bos.
1 (bases 1 to 577)

REFERENCE

AUTHORS Smith,T.P.L., Grosse,W.M., Freking,B.A., Roberts,A.J., Stone,R.T., Casas,E., Wray,J.E., White,J., Cho,J., Fahrenkrug,S.C., Bennett

TITLE

JOURNAL
MEDLINE
COMMENT

,G.L., Heaton,M.P., Laegreid,W.W., Rohrer,G.A., Chitko-McKown,C.G., Perte,G., Holt,I., Karamycheva,S., Liang,F., Quackenbush,J. and Keele,J.W.
Sequence evaluation of four pooled-tissue normalized bovine cDNA libraries and construction of a gene index for cattle
Genome Res. 11 (4), 626-630 (2001)
21180013
Contact: Smith TPL
USDA, ARS, US Meat Animal Research Center
PO Box 166, Clay Center, NE 68933-0166, USA
Tel: 402 762 4366
Fax: 402 762 4390
Email: smith@mail.marc.usda.gov
Single pass sequencing. Bases called and alt_trimmed with phred v0.980904.e. Vector identified by cross_match with the -minscore 18 and -minmatch 12 options.

PCR Primers

FORWARD: AGGAACAGCTATGACCAT
BACKWARD: GTTTTCCCAGTCACGACG
Plate: 122 row: D column: 15
Seq primer: ATTTAGGTGACACTATAG.

FEATURES

source

1. .577
Location/Qualifiers
/organism="Bos taurus"
/db_xref="taxon:9913"
/clone_lib="MARC 2BOV"
/tissue_type="pooled"
/lab_host="DH10B"

/note="Vector: pCMV SPORT6; Site_1: XbaI; Site_2: XhoI;
Library made from pooled tissue from testis, thymus, semitendinosus muscle, longissimus muscle, pancreas, adrenal, and endometrium."

BASE COUNT 145 a 121 c 144 g 167 t
ORIGIN

Query Match 87.6%; Score 18.4; DB 10; Length 577;
Best Local Similarity 95.0%; Pred. No. 3.4e+04;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 TCTTTTCTCTCTCACAGG 21
||||||| |||||||

Db 141 TCTTTTCTCTCTCACAGG 122

RESULT 14

LOCUS AI671885/c
DEFINITION wb41b12.x1 NCI-CGAP_GC6 Homo sapiens cDNA clone IMAGE:2308223 3', mRNA sequence.
ACCESSION AI671885
VERSION AI671885.1 GI:4851616
KEYWORDS EST.
SOURCE human.

ORGANISM

Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 593)

NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.

National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index

Unpublished (1997)

Contact: Robert Strausberg, Ph.D.

Email: cgapbs-r@mail.nih.gov

Tissue Procurement: Christopher A. Moskaluk, M.D., Ph.D., Michael R. Emmert-Buck, M.D., Ph.D.

cDNA Library Preparation: M. Bento Soares, Ph.D., M. Fatima Bonaldo, Ph.D.

cDNA Library Arrayed by: Greg Lennon, Ph.D.

DNA Sequencing by: Washington University Genome Sequencing Center

Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www-bio.llnl.gov/bbrp/image/image.html

Insert Length: 744 Std Error: 0.00
Seq primer: -40UP from Gibco
High quality sequence stop: 450.

FEATURES

source

Location/Qualifiers
1. .593
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2308223"
/clone_lib="NCI_CGAP_GC6"
/tissue_type="pooled germ cell tumors"
/lab_host="DH10B"

/note="vector: pT73D-Pac (Pharmacia) with a modified polylinker; Site_1: Not I; Site_2: Eco RI; Plasmid DNA from the normalized library NCI_CGAP_GC4 was prepared, and ss circles were made in vitro. Following HAP purification, this DNA was used as tracer in a subtractive hybridization reaction. The driver was PCR-amplified cDNAs from a pool of 5,000 clones made from the same library (cloneIDs 1257096-1258631, 1469064-1470983, and 1475592-1476743). Subtraction by Bento Soares and M. Fatima Bonaldo. "

BASE COUNT
ORIGIN

213 a 109 c 122 g 148 t 1 others

Query Match 87.6%; Score 18.4; DB 9; Length 593;
Best Local Similarity 95.0%; Pred. No. 3.4e+04;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TTCTTTTCTCTCTTCACAG 20

||||| |||||||||

Db 477 TTCTTTTCTCTCTTCACAG 458

RESULT 15

AG055132/c

LOCUS AG055132 679 bp DNA linear GSS 02-NOV-2001
DEFINITION Pan troglodytes DNA, clone: PTB-041A09.R, genomic survey sequence.

ACCESSION AG055132

VERSION AG055132.1 GI:16592575

KEYWORDS GSS; GSS (genome survey sequence).

SOURCE Pan troglodytes male lymphoblast DNA, clone_lib:PTB Chimpanzee Male BAC Library clone:PTB-041A09.R.

ORGANISM

Pan troglodytes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.

REFERENCE

AUTHORS

1 (sites)
Fujiyama,A., Hattori,M., Toyoda,A., Taylor,T.D., Yada,T.,

Totoki,Y., Watanabe,H. and Sakaki,Y.

TITLE BAC end sequences of Library PTB

JOURNAL Unpublished

AUTHORS

2 (bases 1 to 679)
Fujiyama,A., Hattori,M., Toyoda,A., Taylor,T.D., Yada,T.,

Totoki,Y., Watanabe,H. and Sakaki,Y.

TITLE Direct Submission

JOURNAL

Submitted (02-AUG-2001) Asao Fujiyama, The Institute of Physical and Chemical Research (RIKEN), Genomic Sciences Center (GSC);
1-7-22 Suehiro-chou,Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
(E-mail:chimpsesgsc.riken.go.jp, URL:http://hgp.gsc.riken.go.jp/,
Tel:81-45-503-9111, Fax:81-45-503-9170)

Clones are derived from the chimpanzee BAC library PTB This BAC end was generated during the R&D process and may have higher chance of clone tracking errors.

PRIMERS

Sequencing: M13Rev

LIBRARY

Vector : PKS145

R.Site 1 : SacI

R.Site 2 : SacI.

Location/Qualifiers

1. .679

/organism="Pan troglodytes"

/db_xref="taxon:9598"

/clone="PTB-041A09.R"

FEATURES

source

/sex="male"
/cell_type="lymphoblast"
/clone_lib="PTB Chimpanzee Male BAC Library"
BASE COUNT 147 a 170 c 163 g 198 t 1 others
ORIGIN

Query Match 87.6%; Score 18.4; DB 12; Length 679;
Best Local Similarity 95.0%; Pred. No. 3.2e+04;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 TCTTTTCTCTCTTCACAGG 21

||||| |||||||||

Db 245 TCTTTTCTCTCTTCACAGG 226

Search completed: July 21, 2002, 09:11:09
Job time: 10385 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 21, 2002, 06:20:09 ; Search time 2038.31 Seconds
(without alignments)
92.400 Million cell updates/sec

Title: US-09-754-014-10_COPY_1_9

Perfect score: 9

Sequence: 1 CAGGTAAGT 9

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 1797656 seqs, 10463268293 residues

Total number of hits satisfying chosen parameters: 3595312

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl.*

1: gb_ba.*

2: gb_htg.*

3: gb_in.*

4: gb_om.*

5: gb_ov.*

6: gb_pat.*

7: gb_ph.*

8: gb_pl.*

9: gb_pr.*

10: gb_ro.*

11: gb_sts.*

12: gb_sy.*

13: gb_un.*

14: gb_vi.*

15: em_ba.*

16: em_fun.*

17: em_hum.*

18: em_in.*

19: em_mu.*

20: em_om.*

21: em_or.*

22: em_ov.*

23: em_pat.*

24: em_ph.*

25: em_pl.*

26: em_ro.*

27: em_sts.*

28: em_un.*

29: em_vi.*

30: em_htg_hum.*

31: em_htg_inv.*

32: em_htg_other.*

33: em_htgo_inv.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
------------	-------	-------------	--------	----	-------------

ALIGNMENTS

RESULT 1

AX152396/c

LOCUS

DEFINITION

AX152396

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

source

BASE COUNT

ORIGIN

linear PAT 22-JUN-2001

10 bp DNA

Sequence 311 from Patent WO0138577.

AX152396

AX152396.1 GI:14534047

human.

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 10)

Velculescu, V.E., Vogelstein, B. and Kinzler, K.W.

Human transcriptomes

Patent: WO 0138577-A 311 31-MAY-2001;

The Johns Hopkins University (US)

Location/Qualifiers

1. 10

/organism="Homo sapiens"

/db_xref="taxon:9606"

2 a 4 c 1 g 3 t

Query Match 100.0%; Score 9; DB 6; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6.5e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
 |||||
 Db 9 CAGGTAAGT 1

RESULT 2

AX018745
 LOCUS AX018745 13 bp DNA linear PAT 07-SEP-2000
 DEFINITION Sequence 3 from Patent WO9943848.
 ACCESSION AX018745
 VERSION AX018745.1 GI:10042868
 KEYWORDS
 SOURCE synthetic construct.
 ORGANISM synthetic construct.
 REFERENCE 1 (bases 1 to 13)
 AUTHORS Ong, C.J. and Jirik, F.R.
 TITLE Protein interaction and transcription factor trap
 JOURNAL Patent: WO 9943848-A 3 02-SEP-1999;
 ONG CHRISTOPHER J (CA); UNIV BRITISH COLUMBIA (CA); JIRIK FRANK R (CA)

FEATURES
 source Location/Qualifiers
 1..13
 /organism="synthetic construct"
 /db_xref="taxon:32630"
 /note="Oligomer containing a splice donor sequence"

BASE COUNT 4 a 2 c 4 g 3 t
 ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 13;
 Best Local Similarity 100.0%; Pred. No. 6.3e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
 |||||
 Db 5 CAGGTAAGT 13

RESULT 3

AX018746/c
 LOCUS AX018746 13 bp DNA linear PAT 07-SEP-2000
 DEFINITION Sequence 4 from Patent WO9943848.
 ACCESSION AX018746
 VERSION AX018746.1 GI:10042869
 KEYWORDS
 SOURCE synthetic construct.
 ORGANISM synthetic construct.
 REFERENCE 1 (bases 1 to 13)
 AUTHORS Ong, C.J. and Jirik, F.R.
 TITLE Protein interaction and transcription factor trap
 JOURNAL Patent: WO 9943848-A 4 02-SEP-1999;
 ONG CHRISTOPHER J (CA); UNIV BRITISH COLUMBIA (CA); JIRIK FRANK R (CA)

FEATURES
 source Location/Qualifiers
 1..13
 /organism="synthetic construct"
 /db_xref="taxon:32630"
 /note="Oligomer for adjusting a reading frame for ligation"

BASE COUNT 3 a 4 c 1 g 5 t
 ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 13;
 Best Local Similarity 100.0%; Pred. No. 6.3e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
 |||||
 Db 13 CAGGTAAGT 5

RESULT 4

A63967/c
 LOCUS A63967 14 bp DNA linear PAT 29-MAR-1999
 DEFINITION Sequence 11 from Patent EP0784094.
 ACCESSION A63967
 VERSION A63967.1 GI:3717488
 KEYWORDS
 SOURCE unidentified.
 ORGANISM unidentified.
 REFERENCE 1 (bases 1 to 14)
 AUTHORS Bozzoni, I.
 TITLE Ribozyme-snrRNA chimeric molecules having a catalytic activity for nuclear RNAs
 JOURNAL Patent: EP 0784094-A 11 16-JUL-1997;
 UNIV ROMA (IT)

FEATURES
 source Location/Qualifiers
 1..14
 /organism="unidentified"
 /db_xref="taxon:32644"
 BASE COUNT 3 a 4 c 3 g 4 t
 ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 14;
 Best Local Similarity 100.0%; Pred. No. 6.3e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
 |||||
 Db 12 CAGGTAAGT 4

RESULT 5

AR091477/c
 LOCUS AR091477 14 bp DNA linear PAT 07-SEP-2000
 DEFINITION Sequence 11 from patent US 5994124.
 ACCESSION AR091477
 VERSION AR091477.1 GI:10018232
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 14)
 AUTHORS Bozzoni, I.
 TITLE Ribozyme-snrRNA chimeric molecules having a catalytic activity for nuclear RNAs
 JOURNAL Patent: US 5994124-A 11 30-NOV-1999;
 FEATURES
 source Location/Qualifiers
 1..14
 /organism="unknown"
 BASE COUNT 3 a 4 c 3 g 4 t
 ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 14;
 Best Local Similarity 100.0%; Pred. No. 6.3e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
 |||||
 Db 12 CAGGTAAGT 4

RESULT 6

AX018747
 LOCUS AX018747 14 bp DNA linear PAT 07-SEP-2000

DEFINITION Sequence 5 from Patent WO9943848.
ACCESSION AX018747
VERSION AX018747.1 GI:10042870
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequence.

REFERENCE 1 (bases 1 to 14)
AUTHORS Ong, C.J. and Jirik, F.R.
TITLE Protein interaction and transcription factor trap
JOURNAL Patent: WO 9943848-A 5 02-SEP-1999;
ONG CHRISTOPHER J (CA); UNIV BRITISH COLUMBIA (CA); JIRIK FRANK R (CA)

FEATURES
source
Location/Qualifiers
1..14
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Oligomer containing a splice donor sequence"

BASE COUNT 4 a 3 c 4 g 3 t

Query Match 100.0%; Score 9; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.3e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
|||||

Db 6 CAGGTAAGT 14

RESULT 7
AX018748/c
LOCUS AX018748 14 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 6 from Patent WO9943848.
ACCESSION AX018748
VERSION AX018748.1 GI:10042871
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequence.

REFERENCE 1 (bases 1 to 14)
AUTHORS Ong, C.J. and Jirik, F.R.
TITLE Protein interaction and transcription factor trap
JOURNAL Patent: WO 9943848-A 6 02-SEP-1999;
ONG CHRISTOPHER J (CA); UNIV BRITISH COLUMBIA (CA); JIRIK FRANK R (CA)

FEATURES
source
Location/Qualifiers
1..14
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Oligomer for adjusting a reading frame for ligation"

BASE COUNT 3 a 4 c 2 g 5 t

Query Match 100.0%; Score 9; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.3e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
|||||

Db 13 CAGGTAAGT 5

RESULT 8
AX018749
LOCUS AX018749 15 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 7 from Patent WO9943848.
ACCESSION AX018749
VERSION AX018749.1 GI:10042872
KEYWORDS

SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequence.
REFERENCE 1 (bases 1 to 15)
AUTHORS Ong, C.J. and Jirik, F.R.
TITLE Protein interaction and transcription factor trap
JOURNAL Patent: WO 9943848-A 7 02-SEP-1999;
ONG CHRISTOPHER J (CA); UNIV BRITISH COLUMBIA (CA); JIRIK FRANK R (CA)

FEATURES
source
Location/Qualifiers
1..15
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Oligomer containing a splice donor sequence"

BASE COUNT 4 a 4 c 4 g 3 t

Query Match 100.0%; Score 9; DB 6; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.2e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
|||||

Db 7 CAGGTAAGT 15

RESULT 9
AX018750/c
LOCUS AX018750 15 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 8 from Patent WO9943848.
ACCESSION AX018750
VERSION AX018750.1 GI:10042873
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequence.
REFERENCE 1 (bases 1 to 15)
AUTHORS Ong, C.J. and Jirik, F.R.
TITLE Protein interaction and transcription factor trap
JOURNAL Patent: WO 9943848-A 8 02-SEP-1999;
ONG CHRISTOPHER J (CA); UNIV BRITISH COLUMBIA (CA); JIRIK FRANK R (CA)

FEATURES
source
Location/Qualifiers
1..15
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Oligomer for adjusting a reading frame for ligation"

BASE COUNT 3 a 4 c 3 g 5 t

Query Match 100.0%; Score 9; DB 6; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.2e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
|||||

Db 13 CAGGTAAGT 5

RESULT 10
AR075705
LOCUS AR075705 20 bp DNA linear PAT 30-AUG-2000
DEFINITION Sequence 4 from patent US 5958692.
ACCESSION AR075705
VERSION AR075705.1 GI:10002451
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)

AUTHORS Cotton, R.G.H., Youil, R. and Kemper, B.W.
 TITLE Detection of mutation by resolvease cleavage
 JOURNAL Patent: US 5958692-A 4 28-SEP-1999;
 FEATURES Location/Qualifiers
 1. .20

BASE COUNT 5 a 4 c 7 g 4 t
 ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 20;
 Best Local Similarity 100.0%; Pred. No. 6e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
 | | | | | | | |
 Db 2 CAGGTAAGT 10

RESULT 11
 ARI39514
 LOCUS ARI39514 20 bp DNA linear PAT 16-JUN-2001
 DEFINITION Sequence 31 from patent US 6207383.
 ACCESSION ARI39514
 VERSION ARI39514.1 GI:14482010
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Keating, M.T. and Splawski, I.
 TITLE Mutations in and genomic structure of HERG--a long QT syndrome gene
 JOURNAL Patent: US 6207383-A 31 27-MAR-2001;
 FEATURES Location/Qualifiers
 1. .20

BASE COUNT 4 a 6 c 6 g 4 t
 ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 20;
 Best Local Similarity 100.0%; Pred. No. 6e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
 | | | | | | | |
 Db 8 CAGGTAAGT 16

RESULT 12
 AX069132
 LOCUS AX069132 20 bp DNA linear PAT 25-JAN-2001
 DEFINITION Sequence 50 from Patent WO0102604.
 ACCESSION AX069132
 VERSION AX069132.1 GI:12579014
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 20)
 AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 TITLE Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 JOURNAL Tournier-Lasserre, E., Laberge-Le, S. and Labauge, P.
 Use of the krt1 gene in anglogenesis
 Patent: WO 0102604-A 50 11-JAN-2001;
 INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
 (FR)

FEATURES Location/Qualifiers
 1. .20
 source /organism="Homo sapiens"
 /db_xref="taxon:9606"
 BASE COUNT 10 a 3 c 3 g 4 t
 ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 20;
 Best Local Similarity 100.0%; Pred. No. 6e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
 | | | | | | | |
 Db 8 CAGGTAAGT 16

RESULT 13
 AX259809
 LOCUS AX259809 20 bp DNA linear PAT 26-OCT-2001
 DEFINITION Sequence 36 from Patent WO0172822.
 ACCESSION AX259809
 VERSION AX259809.1 GI:16508883
 KEYWORDS
 SOURCE human.

ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (sites)
 AUTHORS Hugot, J.P., Thomas, G., Zouali, M., Lesage, S. and Chamaillard, M.
 TITLE Genes involved in intestinal inflammatory diseases and use thereof
 JOURNAL Patent: WO 0172822-A 36 04-OCT-2001;
 FEATURES Location/Qualifiers
 1. .20

BASE COUNT 6 a 3 c 6 g 5 t
 ORIGIN /organism="Homo sapiens"
 /db_xref="taxon:9606"

Query Match 100.0%; Score 9; DB 6; Length 20;
 Best Local Similarity 100.0%; Pred. No. 6e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
 | | | | | | | |
 Db 10 CAGGTAAGT 18

RESULT 14
 EI5758
 LOCUS EI5758 20 bp DNA linear PAT 28-JUL-1999
 DEFINITION PCR primer for human Slit cDNA.
 ACCESSION EI5758
 VERSION EI5758.1 GI:5710441
 KEYWORDS JP 1998087699-A/5.
 SOURCE unidentified.
 ORGANISM unclassified.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Ito, A. and Sakano, S.
 TITLE SLIT-LIKE POLYPEPTIDE
 JOURNAL Patent: JP 1998087699-A 5 07-APR-1998;
 COMMENT ASahi Chem Ind Co Ltd
 OS None
 OC Artificial sequences.
 PN JP 1998087699-A/5
 PD 07-APR-1998
 PF 15-JUL-1997 JP 1997205351
 PR 16-JUL-1996 JP 96P 186219
 PI ITO AKIRA, SAKANO SEIJI
 PC C07K14/47, A61K38/00, C07K16/18, C12N5/10, C12N15/09, C12N15/02, PC
 C12P21/02.

PC C12P21/08, (C12P21/02, C12R1:91);
 CC strandedness: Single;
 CC topology: Linear;
 FH key Location/Qualifiers
 FT source 1. .20

FT /organism='Artificial sequences'.
Location/Qualifiers

source
1. .20
/organism="unidentified"
/db_xref="taxon:32644"

BASE COUNT 5 a 4 c 6 g 5 t
ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 20;
Best Local Similarity 100.0%; Pred. No. 6e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
|||||
Db 8 CAGGTAAGT 16

RESULT 15

E21777
LOCUS E21777 Novel slit-like polypeptide. 20 bp DNA linear PAT 07-FEB-2001
DEFINITION
ACCESSION E21777
VERSION E21777.1 GI:13023697

KEYWORDS JP 1999018777-A/8.
SOURCE unidentified.

ORGANISM
unclassified.
1 (bases 1 to 20)

REFERENCE
AUTHORS Akira,I.S.S.S.

TITLE Novel slit-like polypeptide

JOURNAL Patent: JP 1999018777-A 8 26-JAN-1999;

COMMENT ASahi CHEM IND CO LTD

OS Unidentified

PN JP 1999018777-A/8

PD 26-JAN-1999

PF 09-JUL-1997 JP 1997183683

PR

PI AKIRA ITO,SEIJI SAKANO

PC C12N15/09,A61K38/00,A61K38/00,A61K38/00,C07H21/04,C07K14/47,

C07K16/18

PC C12N5/10,C12P21/02/(C12N15/09,C12R1:91),(C12N5/10,C12R1:91),

PC (C12P21/02,C12R1:91),C12N15/00,A61K37/02,A61K37/02,A61K37/02,

C12N5/00,

PC (C12N15/00,C12R1:91),(C12N5/00,C12R1:91)

CC Strandedness: Single;

CC Topology: Linear;

FH Key Location/Qualifiers

FT source

1. .20

Location/Qualifiers
/organism="Unidentified".

FEATURES

source
1. .20

/organism="unidentified"

/db_xref="taxon:32644"

BASE COUNT 5 a 4 c 6 g 5 t

ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 20;
Best Local Similarity 100.0%; Pred. No. 6e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
|||||
Db 8 CAGGTAAGT 16

Search completed: July 21, 2002, 09:45:13
Job time: 12304 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 21, 2002, 08:08:59 ; Search time 467.25 Seconds
(without alignments)
33.071 Million cell updates/sec

Title: US-09-754-014-10_COPY_1_9
Perfect score: 9
Sequence: 1 CAGGTAAGT 9
Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :			
N_Geneseq_032802:*			
1:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*		
2:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*		
3:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*		
4:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*		
5:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*		
6:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*		
7:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*		
8:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*		
9:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*		
10:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*		
11:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*		
12:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*		
13:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*		
14:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*		
15:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*		
16:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*		
17:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*		
18:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*		
19:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*		
20:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*		
21:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*		
22:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*		
23:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*		
24:	/SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*		

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	9	100.0	9	AAV43548	Insertion sequence
2	9	100.0	10	AAZ81555	Metastatic breast
3	9	100.0	10	AAZ82988	Metastatic breast
4	9	100.0	10	AAZ85454	Metastatic breast
5	9	100.0	10	AAH43531	SD sequence. Synt
6	9	100.0	10	AAH63471	Human ubiquitously
7	9	100.0	11	AAH23795	Murine histidine d
8	9	100.0	13	AAZ11271	Splice donor site
9	9	100.0	14	AAZ11272	Splice donor site

10	9	100.0	15	20	AAZ40412	5' splice site seq
11	9	100.0	15	20	AAZ11273	Splice donor site
c 12	9	100.0	17	18	AAZ71417	Human KDR VEGF rec
c 13	9	100.0	17	18	AAZ71418	Human KDR VEGF rec
c 14	9	100.0	17	21	AAZ36045	Human genomic SNP
c 15	9	100.0	19	21	AAZ72504	Single nucleotide
16	9	100.0	20	16	AAZ00608	21-hydroxylase B g
17	9	100.0	20	19	AAV16969	Oligonucleotide se
18	9	100.0	20	20	AAZ89172	Seq ID No: 26 of J
19	9	100.0	20	20	AAZ19950	Human slit 1 PCR a
20	9	100.0	20	20	AAZ14987	PCR primer used to
21	9	100.0	20	20	AAV80054	Human PMW2 exon 1/
22	9	100.0	20	21	AAZ74093	Human biallelic ma
c 23	9	100.0	20	21	AAZ74129	Human biallelic ma
c 24	9	100.0	20	21	AAZ68759	Human FUT3 antisen
25	9	100.0	20	21	AAZ93668	Antisense oligonuc
26	9	100.0	20	21	AAZ93669	Antisense oligonuc
27	9	100.0	20	21	AAZ93670	Antisense oligonuc
28	9	100.0	20	21	AAZ93671	Antisense oligonuc
29	9	100.0	20	21	AAZ93672	Antisense oligonuc
30	9	100.0	20	21	AAZ93673	Antisense oligonuc
31	9	100.0	20	21	AAZ07629	Antisense oligonuc
32	9	100.0	20	21	AAZ61274	HERG gene exon 3/1
33	9	100.0	20	22	AAI65624	5' splice donor of
34	9	100.0	20	22	AAZ3121	Primer for microsa
35	9	100.0	20	22	AAZ31140	Human ERbeta gene,
36	9	100.0	20	22	AAZ08768	Human ERbeta gene,
37	9	100.0	20	22	AAZ08859	Human PD-ABC form
38	9	100.0	20	22	AAZ27713	Human bcl-x splice
39	9	100.0	20	22	AAZ27714	Human bcl-x splice
40	9	100.0	20	22	AAZ27715	Human bcl-x splice
41	9	100.0	20	22	AAZ27716	Human bcl-x splice
42	9	100.0	20	22	AAZ27717	Human bcl-x splice
43	9	100.0	20	22	AAZ27718	Human bcl-x splice
44	9	100.0	20	22	AAZ27718	Human bcl-x splice
45	9	100.0	20	22	AAZ24987	Nucleotide sequenc
			20	24	ABA89794	Human oestrogen re

ALIGNMENTS

RESULT 1
AAV43548
ID AAV43548 standard; DNA; 9 BP.
XX
AC AAV43548;
XX
DT 16-SEP-1998 (first entry)
XX
DE Insertion sequence 1 used for creating a tagged gene.
DE
KW Tagged gene; tagged transcript; hybrid intron; protein tag;
KW protein isolation; recombination; subcellular structure analysis;
KW transcriptional regulation; viral infection; ss.
XX
OS Synthetic.
OS Unidentified.
PN WO9820031-A1.
XX
PD 14-MAY-1998.
XX
PF 07-NOV-1997; 97WO-US20150.
XX
PR 08-NOV-1996; 96US-0705404.
XX
PA (JARV/) JARVIK J W.
XX
PI Jarvik JW;
XX
DR WPI; 1998-286861/25.
XX
PT Tagging genes, transcripts and proteins - using tag-creating DNA

PT inserted into intron of gene to create 2 hybrid introns separated by
 XX new-exon encoding protein tag
 PS Claim 1; Page 33; 66pp; English.
 XX
 CC This sequence is used in the method of invention for tagging genes,
 CC transcripts and proteins in cells in a single recombinational event. The
 CC method comprises producing a tagged gene by inserting a DNA sequence
 CC into an intron of a gene by selecting a DNA sequence having a 5' portion
 CC free of any nucleotide sequence selected from AAV43548 to AAV43551, a
 CC nucleotide sequence selected from AAV43552 to AAV43560 and nucleotide
 CC sequences identical to a known splice branch site in a known gene,
 CC sequences identical in length to a known spacer region between splice
 CC branch and acceptor sites in a known gene, sequences identical to a known
 CC splice acceptor site in a known gene, sequence identical to a known
 CC splice donor site in a known gene, an open reading frame (ORF) 3N-1
 CC nucleotides in length, the ORF encoding a known peptide tag recognisable
 CC by a known reaction characteristic of the known peptide tag and sequences
 CC selected from CAGG and TAGG. The DNA sequence is inserted into the intron
 CC within the gene to create a tagged gene, and the tagged gene is incubated
 CC within a cell so as to maintain intact or to introduce the tagged gene
 CC within the genome of the cell. The method is used for isolating proteins,
 CC RNA and genes, for analysis of subcellular structures, cellular responses
 CC and transcriptional regulation, for the study of viral infection and for
 CC diagnosis of disease.
 XX
 SQ Sequence 9 BP; 3 A; 1 C; 3 G; 2 T; 0 other;

Query Match 100.0%; Score 9; DB 19; Length 9;
 Best Local Similarity 100.0%; Pred. NO. 1.9e+08;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
 |||||
 Db 1 caggtaatg 9

RESULT 2
 AAZ81555/c
 ID AAZ81555 standard; DNA; 10 BP.

XX AC AAZ81555;

XX DT 07-APR-2000 (first entry)

XX DE Metastatic breast tumour cell upregulated transcript tag #789.

XX KW Human; metastatic breast tumour tissue; breast cancer; tag; primer;

XX KW non-metastatic breast tumour tissue; gene therapy; anticancer;

XX KW antimetastatic; vaccine; diagnosis; ss.

XX OS Homo sapiens.

XX PN WO9965928-A2.

XX PD 23-DEC-1999.

XX PF 18-JUN-1999; 99WO-US13647.

XX PR 19-JUN-1998; 98US-0089853.

XX PR 19-JUN-1998; 98US-0089997.

XX PR 19-JUN-1998; 98US-0090039.

XX PR 19-JUN-1998; 98US-0090040.

XX PR 19-JUN-1998; 98US-0090041.

XX PA (GENZ) GENZYME CORP.

XX PA (ROBE/) ROBERTS B L.

XX PA (SHAN/) SHANKARA S.

XX PI Roberts BL, Shankara S;

XX DR WPI; 2000-106079/09.

XX

PT Isolated polynucleotides differentially expressed between metastatic
 XX and non-metastatic breast cancer cells, useful for diagnosis,
 PT prevention and treatment of cancer -

XX PS Claim 1; Page 79; 219pp; English.

XX CC

CC AAZ80767 to AAZ83941 represent tags corresponding to distinct
 CC transcripts that are preferentially transcribed in the metastatic breast
 CC tumour tissue (i.e. are upregulated in metastatic breast tumour cells).

CC CC AAZ83942 to AAZ86677 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the primary or non-metastatic
 CC breast tumour tissue (i.e. are downregulated in metastatic breast tumour
 CC cells). These transcripts can be used for diagnosis, prognosis,

CC monitoring and treatment of breast cancer, particularly where metastatic.
 CC Diagnosis is by standard immunoassays or hybridisation/amplification
 CC reactions. Compounds that modulate expression of the transcripts are

CC potentially useful for treatment of (metastatic) breast cancer, while
 CC promoters from the transcripts are used to direct expression, in selected
 CC cell types, of e.g. therapeutic genes (also ribozymes or antisense

CC sequences), particularly an antigen-encoded sequence for use in gene or
 CC cell-based vaccines. Polypeptides encoded by the transcripts are also
 CC useful in vaccines; for diagnosing breast cancer and for raising

CC specific antibodies (Ab). Ab are used to detect the polypeptides or as
 CC therapeutic agents. Host cells that produce the polypeptides can be used
 CC to expand and isolate populations of educated, antigen-specific immune

CC effector cells, e.g. cytotoxic T lymphocytes, and these used for
 CC adoptive immunotherapy.

XX

SQ Sequence 10 BP; 2 A; 3 C; 2 G; 3 T; 0 other;

Query Match 100.0%; Score 9; DB 21; Length 10;

Best Local Similarity 100.0%; Pred. No. 8.3e+03;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9

|||||

Db 9 CAGGTAAGT 1

RESULT 3

AAZ82988/c

ID AAZ82988 standard; DNA; 10 BP.

XX AC AAZ82988;

XX DT 07-APR-2000 (first entry)

XX DE Metastatic breast tumour cell upregulated transcript tag #2222.

XX KW Human; metastatic breast tumour tissue; breast cancer; tag; primer;

XX KW non-metastatic breast tumour tissue; gene therapy; anticancer;

XX KW antimetastatic; vaccine; diagnosis; ss.

XX OS Homo sapiens.

XX PN WO9965928-A2.

XX PD 23-DEC-1999.

XX PF 18-JUN-1999; 99WO-US13647.

XX PR 19-JUN-1998; 98US-0089853.

XX PR 19-JUN-1998; 98US-0089997.

XX PR 19-JUN-1998; 98US-0090039.

XX PR 19-JUN-1998; 98US-0090040.

XX PR 19-JUN-1998; 98US-0090041.

XX PA (GENZ) GENZYME CORP.

XX PA (ROBE/) ROBERTS B L.

XX PA (SHAN/) SHANKARA S.

PI Roberts BL, Shankara S;
XX WPI; 2000-106079/09.
XX
XX Isolated polynucleotides differentially expressed between metastatic
XX and non-metastatic breast cancer cells, useful for diagnosis,
PT prevention and treatment of cancer -
PT
XX
XX Claim 1; Page 119; 219pp; English.
PS
XX AAZ80767 to AAZ83941 represent tags corresponding to distinct
CC transcripts that are preferentially transcribed in the metastatic breast
CC tumour tissue (i.e. are upregulated in metastatic breast tumour cells).
CC AAZ83942 to AAZ86677 represent tags corresponding to distinct transcripts
CC that are preferentially transcribed in the primary or non-metastatic
CC breast tumour tissue (i.e. are downregulated in metastatic breast tumour
CC cells). These transcripts can be used for diagnosis, prognosis,
CC monitoring and treatment of breast cancer, particularly where metastatic.
CC Diagnosis is by standard immunoassays or hybridisation/amplification
CC reactions. Compounds that modulate expression of the transcripts are
CC potentially useful for treatment of (metastatic) breast cancer, while
CC promoters from the transcripts are used to direct expression, in selected
CC cell types, of e.g. therapeutic genes (also ribozymes or antisense
CC sequences), particularly an antigen-encoded sequence for use in gene or
CC cell-based vaccines. Polypeptides encoded by the transcripts are also
CC useful in vaccines. Polypeptides encoded by the transcripts are also
CC specific antibodies (Ab). Ab are used to detect the polypeptides or as
CC therapeutic agents. Host cells that produce the polypeptides can be used
CC to expand and isolate populations of educated, antigen-specific immune
CC effector cells, e.g. cytotoxic T lymphocytes, and these used for
CC adoptive immunotherapy.
XX
XX Sequence 10 BP; 2 A; 3 C; 1 G; 4 T; 0 other;
SQ

Query Match 100.0%; Score 9; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 8.3e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
Db 9 CAGGTAAGT 1
|||||||

RESULT 4
AAZ85454/c
ID AAZ85454 standard; DNA; 10 BP.
XX
XX AC AAZ85454;
XX
XX DT 07-APR-2000 (first entry)
XX
XX DE Metastatic breast tumour cell downregulated transcript tag #4688.
XX
XX KW Human; metastatic breast tumour tissue; breast cancer; tag; primer;
KW non-metastatic breast tumour tissue; gene therapy; anticancer;
KW antimetastatic; vaccine; diagnosis; ss.
XX
XX OS Homo sapiens.
XX
XX PN W09565928-A2.
XX
XX PD 23-DEC-1999.
XX
XX PF 18-JUN-1999; 99WO-US13647.
XX
XX PR 19-JUN-1998; 98US-0089853.
XX PR 19-JUN-1998; 98US-0089997.
XX PR 19-JUN-1998; 98US-0090039.
XX PR 19-JUN-1998; 98US-0090040.
XX PR 19-JUN-1998; 98US-0090041.
XX
XX PF (GENZ) GENZYME CORP.

PA (ROBE/) ROBERTS B L.
PA (SHAN/) SHANKARA S.
XX
XX Roberts BL, Shankara S;
XX
XX WPI; 2000-106079/09.
XX
XX Isolated polynucleotides differentially expressed between metastatic
XX and non-metastatic breast cancer cells, useful for diagnosis,
PT prevention and treatment of cancer -
PT
XX
XX Claim 1; Page 184; 219pp; English.
PS
XX AAZ80767 to AAZ83941 represent tags corresponding to distinct
CC transcripts that are preferentially transcribed in the metastatic breast
CC tumour tissue (i.e. are upregulated in metastatic breast tumour cells).
CC AAZ83942 to AAZ86677 represent tags corresponding to distinct transcripts
CC that are preferentially transcribed in the primary or non-metastatic
CC breast tumour tissue (i.e. are downregulated in metastatic breast tumour
CC cells). These transcripts can be used for diagnosis, prognosis,
CC monitoring and treatment of breast cancer, particularly where metastatic.
CC Diagnosis is by standard immunoassays or hybridisation/amplification
CC reactions. Compounds that modulate expression of the transcripts are
CC potentially useful for treatment of (metastatic) breast cancer, while
CC promoters from the transcripts are used to direct expression, in selected
CC cell types, of e.g. therapeutic genes (also ribozymes or antisense
CC sequences), particularly an antigen-encoded sequence for use in gene or
CC cell-based vaccines. Polypeptides encoded by the transcripts are also
CC useful in vaccines. Polypeptides encoded by the transcripts are also
CC specific antibodies (Ab). Ab are used to detect the polypeptides or as
CC therapeutic agents. Host cells that produce the polypeptides can be used
CC to expand and isolate populations of educated, antigen-specific immune
CC effector cells, e.g. cytotoxic T lymphocytes, and these used for
CC adoptive immunotherapy.
XX
XX Sequence 10 BP; 2 A; 3 C; 2 G; 3 T; 0 other;
SQ

Query Match 100.0%; Score 9; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 8.3e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
Db 10 CAGGTAAGT 2
|||||||

RESULT 5
AAH43531/c
ID AAH43531 standard; DNA; 10 BP.
XX
XX AC AAH43531;
XX
XX DT 13-DEC-2001 (first entry)
XX
XX DE SD sequence.
XX
XX KW Mouse; heat shock antigen; HSA; human; rat; signal transducer; CD24;
KW fusion protein; inhibition; autoreactive T cell; aTC; primer; PCR;
KW autoimmune disease; multiple sclerosis; rheumatoid arthritis;
KW systemic lupus erythematosus; psoriasis; diabetes; allergy; amplify;
KW transplant rejection; transgenic mouse; polymerase chain reaction; ss.
XX
XX OS Synthetic.
XX
XX PN W0200172325-A1.
XX
XX PD 04-OCT-2001.
XX
XX PF 29-MAR-2001; 2001WO-US40390.
XX
XX PR 29-MAR-2000; 2000US-192814P.
XX

PA (OHIS) UNIV OHIO STATE RES FOUND.
PI Liu Y, Zheng P, Bai X;
XX WPI; 2001-611581/70.
XX Inhibiting tissue destruction by autoreactive T cells, useful for
PT treating autoimmune diseases, by administering a heat-shock
PT antigen/CD24 polypeptide or its antibody -
XX Example 2; Page 17; 34pp; English.
XX The sequences given in AAH4325-34 are primers which were used in
CC the production of a fusion gene which comprises a nucleotide
CC sequence encoding the mouse heat shock antigen (HSA) fused to the
CC cDNA sequence of human IgG1 Fc. The resulting fusion protein
CC may be used in the method of the invention for inhibiting
CC destruction of tissue initiated by autoreactive T cells (aTC). The
CC method is especially used to treat subjects suspected of having
CC autoimmune diseases, particularly multiple sclerosis, rheumatoid
CC arthritis, systemic lupus erythematosus, psoriasis, diabetes and
CC allergy, also transplant rejection. Transgenic mice that express
CC human CD24 on their T cells are useful as models for testing drugs
CC for use against autoimmune diseases.
XX Sequence 10 BP; 2 A; 3 C; 1 G; 4 T; 0 other;
SQ

Query Match 100.0%; Score 9; DB 22; Length 10;
Best Local Similarity 100.0%; Pred. No. 8.3e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CAGGTAAGT 9
DB 9 CAGGTAAGT 1
|||||

RESULT 6
AAH63471/C
ID AAH63471 standard; cDNA; 10 BP.
XX
AC AAH63471;
XX 20-SEP-2001 (first entry)
XX Human ubiquitously expressed transcriptome sequence SEQ ID NO: 311.
XX Human; transcriptome; gene expression pattern; cancer; drug screening;
KW cancer diagnosis; cell specific gene expression; ss.
XX Homo sapiens.
XX WO200138577-A2.
XX 31-MAY-2001.
XX 21-NOV-2000; 2000WO-US31922.
XX 24-NOV-1999; 99US-0448480.
XX (UJYO) UNIV JOHNS HOPKINS.
PI Velculescu VE, Vogelstein B, Kinzler KW;
XX WPI; 2001-367706/38.
XX New isolated polynucleotides, useful for identifying specific cell
PT type, such as cancer cell, comprises transcriptomes expressed in
PT particular cell types -
XX Claim 13; Page 46; 94pp; English.
XX The present invention describes a method of identifying the type of cell

CC in a sample, involving determining which of the sequences
CC AAH63161-AAH64724 is expressed by the cell. The transcriptomes described
CC in the invention are cell-type specific, cancer specific or ubiquitously
CC expressed in humans. They can also be used to screen for drugs, reduce
CC cancer specific gene expression, standardise expression and restore the
CC function of a diseased cell or tissue. The present sequence is one of
CC the transcriptomes described in the exemplification of the invention.
XX Sequence 10 BP; 2 A; 4 C; 1 G; 3 T; 0 other;
SQ

Query Match 100.0%; Score 9; DB 22; Length 10;
Best Local Similarity 100.0%; Pred. No. 8.3e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CAGGTAAGT 9
DB 9 CAGGTAAGT 1
|||||

RESULT 7
AAH23795
ID AAH23795 standard; DNA; 11 BP.
XX
AC AAH23795;
XX 16-AUG-2001 (first entry)
XX Murine histidine decarboxylase exon/intron boundary #9.
XX Murine; histidine decarboxylase; enzyme; mouse chromosome 2; histamine;
KW ds.
XX Mus sp.
XX WO200132892-A1.
XX 10-MAY-2001.
XX 01-NOV-2000; 2000WO-JP07689.
XX 02-NOV-1999; 99JP-0312559.
XX (NISC-) JAPAN SCI & TECHNOLOGY CORP.
XX Ohtsu H;
XX WPI; 2001-308746/32.
XX Polynucleotide encoding histidine decarboxylase located on mouse
PT chromosome 2 for producing histamine defective animal models -
XX Claim 2; Fig 1; 27pp; Japanese.
XX The present invention relates to an isolated and purified polynucleotide
CC located on mouse chromosome 2, encoding histidine decarboxylase,
CC comprising exons 1 to 12 to a total length of approximately 24kb. The
CC present sequence is an exon/intron boundary from the histidine
CC decarboxylase polynucleotide sequence of the present invention.
CC Recombinant vectors containing the polynucleotide with at least one
CC exon substituted by a drug resistance gene, preferably neomycin
CC resistance are also claimed. The polynucleotide is used to produce
CC histamine defective animal models for studying histamine related
CC disorders in humans and to produce treatments for them.
XX Sequence 11 BP; 4 A; 1 C; 3 G; 3 T; 0 other;
SQ

Query Match 100.0%; Score 9; DB 22; Length 11;
Best Local Similarity 100.0%; Pred. No. 8.3e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CAGGTAAGT 9

Db 3 caggttaagt 11
|||||||
RESULT 8
AAZ11271
ID AAZ11271 standard; DNA; 13 BP.
XX AC AAZ11271;
XX DT 15-NOV-1999 (first entry)
XX DE Splice donor site #1 for VP16 gene trap vector.
XX KW Splice donor; VP16 gene trap vector; protein-cell interaction; detection;
XX KW protein-protein interaction; transcriptional activator domain; ds.
XX OS Synthetic.
FH Key Location/Qualifiers
FT misc_feature 1..4
FT /*tag= a
FT /label= sticky_end
FT /note= "the 5' end of the complementary strand overhangs
FT the 3' end of this strand by the sequence
FT 5'-TCAAT-3'."
XX PN WO9943848-A1.
XX PD 02-SEP-1999.
XX PF 25-FEB-1999; 99WO-CA00173.
XX PR 25-FEB-1998; 98CA-2224475.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Jirik FR, Ong CJ;
XX WPI; 1999-540605/45.
XX New protein interaction and transcription factor trap used for
XX identification of unknown genes encoding transcriptional activator
XX domains
XX Example 1; Page 25; 40pp; English.
XX This sequence represents a splice donor site that can be used in a VP16
XX gene trap vector used in the method of the invention. The method is for
XX detecting interaction between an endogenous protein of a cell and a test
XX protein. The cell contains a first DNA sequence encoding a reporter under
XX transcriptional control of a transcriptional regulatory element, and a
XX second DNA sequence that is expressed by the cell and which encodes a
XX first hybrid protein comprising a first transcriptional regulatory
XX protein moiety (TRP) selected from a DNA-binding domain that recognises a
XX binding site on the transcriptional regulatory element controlling
XX transcriptional of the first DNA sequence and, a transcriptional
XX activator functional in the cell; and a test protein. The method
XX comprises: (a) placing into the cell a DNA construct comprising one or
XX more mRNA splice sites, and a third DNA sequence encoding a second TRP
XX which, when combined with the first TRP, will reconstitute a
XX TRP capable of binding to and activating the transcriptional regulatory
XX element controlling transcription of the first DNA sequence; and
XX (b) determining whether the reporter is expressed by the cell, as an
XX indicator of expression of a second hybrid protein comprising the second
XX TRP and an endogenous protein of the cell capable of interaction with the
XX test protein. The method is used for the identification and
XX characterisation of unknown genes according to protein-protein
XX interactions or for identification of genes encoding transcriptional
XX activator domains.
SQ Sequence 13 BP; 4 A; 2 C; 4 G; 3 T; 0 other;

Query Match 100.0%; Score 9; DB 20; Length 13;
Best Local Similarity 100.0%; Pred. No. 8.3e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CAGGTAAGT 9
Db 5 caggttaagt 13
|||||||
RESULT 9
AAZ11272
ID AAZ11272 standard; DNA; 14 BP.
XX AC AAZ11272;
XX DT 15-NOV-1999 (first entry)
XX DE Splice donor site #2 for VP16 gene trap vector.
XX KW Splice donor; VP16 gene trap vector; protein-cell interaction; detection;
XX KW protein-protein interaction; transcriptional activator domain; ds.
XX OS Synthetic.
FH Key Location/Qualifiers
FT misc_feature 1..4
FT /*tag= a
FT /label= sticky_end
FT /note= "the 5' end of the complementary strand overhangs
FT the 3' end of this strand by the sequence
FT 5'-TCAAT-3'."
XX PN WO9943848-A1.
XX PD 02-SEP-1999.
XX PF 25-FEB-1999; 99WO-CA00173.
XX PR 25-FEB-1998; 98CA-2224475.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Jirik FR, Ong CJ;
XX WPI; 1999-540605/45.
XX New protein interaction and transcription factor trap used for
XX identification of unknown genes encoding transcriptional activator
XX domains
XX Example 1; Page 25; 40pp; English.
XX This sequence represents a splice donor site that can be used in a VP16
XX gene trap vector used in the method of the invention. The method is for
XX detecting interaction between an endogenous protein of a cell and a test
XX protein. The cell contains a first DNA sequence encoding a reporter under
XX transcriptional control of a transcriptional regulatory element, and a
XX second DNA sequence that is expressed by the cell and which encodes a
XX first hybrid protein comprising a first transcriptional regulatory
XX protein moiety (TRP) selected from a DNA-binding domain that recognises a
XX binding site on the transcriptional regulatory element controlling
XX transcriptional of the first DNA sequence and, a transcriptional
XX activator functional in the cell; and a test protein. The method
XX comprises: (a) placing into the cell a DNA construct comprising one or
XX more mRNA splice sites, and a third DNA sequence encoding a second TRP
XX which, when combined with the first TRP, will reconstitute a
XX TRP capable of binding to and activating the transcriptional regulatory
XX element controlling transcription of the first DNA sequence; and
XX (b) determining whether the reporter is expressed by the cell, as an
XX indicator of expression of a second hybrid protein comprising the second
XX TRP and an endogenous protein of the cell capable of interaction with the
XX test protein. The method is used for the identification and

CC Characterisation of unknown genes according to protein-protein
CC interactions or for identification of genes encoding transcriptional
CC activator domains.

XX Sequence 14 BP; 4 A; 3 C; 4 G; 3 T; 0 other;

Query Match 100.0%; Score 9; DB 20; Length 14;
Best Local Similarity 100.0%; Pred. No. 8.2e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
|||||
Db 6 caggttaagt 14

RESULT 10
AAZ40412
ID AAZ40412 standard; DNA; 15 BP.

XX AC AAZ40412;

XX 15-FEB-2000 (first entry)

XX 5' splice site sequence for interferon-alpha plasmid.

XX Wild type; human; Interferon-alpha; plasmid; cytomegalovirus; CMV;
XX promoter; growth hormone; untranslated region; UTR; mammal; disease;
XX cancer; intron; ss.

XX Synthetic.

XX WO9947678-A2.

XX 23-SEP-1999.

XX 12-MAR-1999; 99WO-US05394.

XX 19-MAR-1998; 98US-0078654.

XX (GENE-) GENEMEDICINE INC.

XX Nordstrom J, Pericle F, Rolland A, Ralston R;

XX WPI; 1999-562116/47.

XX New plasmids containing an interferon-alpha coding sequence, used for
XX the treatment of a mammalian condition or disease, particularly cancer

XX Disclosure; Page 31; 137pp; English.

XX The invention relates to a novel plasmid comprising a cytomegalovirus
XX (CMV) promoter transcriptionally linked with an interferon alpha
XX (IFN-alpha) coding sequence, and a growth hormone 3'-untranslated
XX region (UTR). Sequences AAZ40412 and AAZ40413 represent synthetic 5' and
XX 3' splice donor and acceptor sites respectively for generating a
XX synthetic intron to be inserted into the plasmid of the invention. The
XX plasmids can be used for treating a mammalian condition or disease,
XX particularly cancer.

XX Sequence 15 BP; 3 A; 3 C; 4 G; 5 T; 0 other;

Query Match 100.0%; Score 9; DB 20; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.2e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
|||||
Db 1 caggttaagt 9

RESULT 11

AAZ11273
ID AAZ11273 standard; DNA; 15 BP.

XX AC AAZ11273;

XX 15-NOV-1999 (first entry)

XX Splice donor site #3 for Vp16 gene trap vector.

XX Splice donor; Vp16 gene trap vector; protein-cell interaction; detection;
XX protein-protein interaction; transcriptional activator domain; ds.

XX Synthetic.

XX Key Location/Qualifiers
XX misc_feature 1..4
XX /tag= a
XX /label= sticky_end
XX /note= "the 5' end of the complementary strand overhangs
XX the 3' end of this strand by the sequence
XX 5'-TCAT-3'"

XX WO9943848-A1.

XX 02-SEP-1999.

XX 25-FEB-1999; 99WO-CA00173.

XX 25-FEB-1998; 98CA-2224475.

XX (UYBR-) UNIV BRITISH COLUMBIA.

XX Jirik FR, Ong CJ;

XX WPI; 1999-540605/45.

XX New protein interaction and transcription factor trap used for
XX identification of unknown genes encoding transcriptional activator
XX domains

XX Example 1; Page 25; 40pp; English.

XX This sequence represents a splice donor site that can be used in a Vp16
XX gene trap vector used in the method of the invention. The method is for
XX detecting interaction between an endogenous protein of a cell and a test
XX protein. The cell contains a first DNA sequence encoding a reporter under
XX transcriptional control of a transcriptional regulatory element, and a
XX second DNA sequence that is expressed by the cell and which encodes a
XX protein moiety (TRP) selected from a first transcriptional regulatory
XX binding site on the transcriptional regulatory domain that recognises a
XX transcriptional of the first DNA sequence and, a transcriptional
XX activator functional in the cell; and a test protein. The method
XX comprises: (a) placing into the cell a DNA construct comprising one or
XX more mRNA splice sites, and a third DNA sequence encoding a second TRP
XX which, when combined with the first TRP, will reconstitute a
XX TRP capable of binding to and activating the transcriptional regulatory
XX element controlling transcription of the first DNA sequence; and
XX (b) determining whether the reporter is expressed by the cell, as an
XX indicator of expression of a second hybrid protein comprising the second
XX TRP and an endogenous protein of the cell capable of interaction with the
XX test protein. The method is used for the identification and
XX characterisation of unknown genes according to protein-protein
XX interactions or for identification of genes encoding transcriptional
XX activator domains.

XX Sequence 15 BP; 4 A; 4 C; 4 G; 3 T; 0 other;

Query Match 100.0%; Score 9; DB 20; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.2e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
 DT 7 caggttaagt 15
 DB

RESULT 12

AAAX71417/C
 ID AAX71417 standard; RNA; 17 BP.

AC AAX71417;

DT 28-JUL-1999 (first entry)

DE Human KDR VEGF receptor hammerhead ribozyme substrate #429.

XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
 KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.

OS Homo sapiens.

PN WO9715662-A2.

XX 01-MAY-1997.

PD 25-OCT-1996; 96WO-US17480.

PF 11-JAN-1996; 96US-0584040.

PR 26-OCT-1995; 95US-0005974.

XX (CHIR) CHIRON CORP.

PA (RIBO-) RIBOZYME PHARM INC.

PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

DR WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient

XX Claim 4; Page 110; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.

XX Sequence 17 BP; 3 A; 5 C; 4 G; 5 U; 0 other;

Query Match 100.0%; Score 9; DB 18; Length 17;
 Best Local Similarity 100.0%; Pred. No. 8.2e+03;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9

DB 14 CAGGTAAGT 6

RESULT 13

AAAX71418/C
 ID AAX71418 standard; RNA; 17 BP.

XX

AC AAX71418;

DT 28-JUL-1999 (first entry)

DE Human KDR VEGF receptor hammerhead ribozyme substrate #430.

XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
 KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.

OS Homo sapiens.

PN WO9715662-A2.

XX 01-MAY-1997.

XX 25-OCT-1996; 96WO-US17480.

PF 11-JAN-1996; 96US-0584040.

PR 26-OCT-1995; 95US-0005974.

XX (CHIR) CHIRON CORP.

PA (RIBO-) RIBOZYME PHARM INC.

PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

DR WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient

XX Claim 4; Page 110; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.

XX Sequence 17 BP; 4 A; 5 C; 4 G; 4 U; 0 other;

Query Match 100.0%; Score 9; DB 18; Length 17;
 Best Local Similarity 100.0%; Pred. No. 8.2e+03;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9

DB 13 CAGGTAAGT 5

RESULT 14

AAA36045
 ID AAA36045 standard; DNA; 17 BP.

XX AAA36045;

XX 26-JUL-2000 (first entry)

DE Human genomic SNP allele specific oligonucleotide SEQ ID NO:102.

XX Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
 KW allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
 KW genomic classification; identification; DNA fingerprinting;
 KW tumour characterisation; hybridisation; ss.

```
XX OS Homo sapiens.
XX PN WO200018960-A2.
XX PD 06-APR-2000.
XX PF 24-SEP-1999; 99WO-US22283.
XX PR 25-SEP-1998; 98US-0101757.
XX PA (MASI ) MASSACHUSETTS INST TECHNOLOGY.
XX PI Landers JE, Jordan B, Housman DE, Charest A;
XX DR WPI: 2000-293181/25.
XX PT Detection of single nucleotide polymorphisms in genomes by preparation
XX PR and analysis of reduced complexity genomes, useful for genotyping,
XX PT fingerprinting and determining allele frequency of SNPs -
XX PS Disclosure; Page 56; 111pp; English.
XX CC A method has been developed for detecting the presence or absence of a
XX CC single nucleotide polymorphism (SNP) allele in a genomic sample. The
XX CC method comprises preparing a reduced complexity genome (RCG) from the
XX CC genomic sample and analysing the RCG for the presence or absence of a
XX CC SNP allele. The method can be used to characterise a tumour, to generate
XX CC a genomic pattern for an individual genome or to generate a genomic
XX CC classification code for a genome. The method can be used to assess
XX CC whether a subject is at risk for developing a disease or to identify a
XX CC set of SNP alleles associated with a disease. The method can also be
XX CC used to perform linkage analysis. AAA35944 to AAA35947 represent
XX CC sequences used in the exemplification of the present invention. AAA35948
XX CC to AAA36032 represent nucleotide sequences containing SNPs.
XX SQ Sequence 17 BP; 5 A; 2 C; 6 G; 4 T; 0 other;

Query Match 100.0%; Score 9; DB 21; Length 17;
Best Local Similarity 100.0%; Pred. No. 8.2e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
Db ||||||||
6 caggtaagt 14

RESULT 15
AAC72504/c
ID AAC72504 standard; DNA; 19 BP.
XX AC AAC72504;
XX DT 09-FEB-2001 (first entry)
XX DE Single nucleotide polymorphism PCR primer #1556.
XX KW Single nucleotide polymorphism; SNP; human; genetic disease;
XX KW disease susceptibility; cardiovascular system; endocrine system;
XX KW neurological system; forensic testing; paternity testing; PCR primer; ss.
XX OS Homo sapiens.
XX PN WO200058519-A2.
XX PD 05-OCT-2000.
XX PF 30-MAR-2000; 2000WO-US08440.
XX PR 31-MAR-1999; 99US-0127248.
XX PA (WHED ) WHITEHEAD INST BIOMEDICAL RES.
```

(AFFY-) AFFYMETRIX INC.

Altshuler D, Cargill M, Daley GQ, Ireland JS, Lander ES;
Lipshutz RJ, Patil N, Sklar P;

WPI: 2000-611722/58.

Nucleic acid selected from one of 106 genes comprising single
nucleotide polymorphisms, allele-specific oligonucleotides to the genes
are useful for phenotypic correlations, forensics, paternity testing,
medicine and genetic analysis -

Claim 8; Fig 5; 214pp; English.

The present invention is concerned with a number of human single
nucleotide polymorphisms (SNPs) which the inventors identified in human
genes. These SNPs can be used in disease diagnosis and prediction of an
individual's susceptibility to disease, in forensic and paternity testing
and in genetic mapping. In particular, the SNPs of the invention can be
used to diagnose susceptibility to diseases of the cardiovascular,
endocrine and neurological systems, such as coronary artery disease,
schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
diseases.

Sequence 19 BP; 4 A; 4 C; 6 G; 5 T; 0 other;

Query Match 100.0%; Score 9; DB 21; Length 19;
Best Local Similarity 100.0%; Pred. No. 8.2e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9

Db ||||||||
15 CAGGTAAGT 7

Search completed: July 21, 2002, 09:55:18
Job time: 6379 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 21, 2002, 06:28:09 ; Search time 112.48 Seconds
(without alignments)
19.654 Million cell updates/sec

Title: US-09-754-014-10_COPY_1_9

Perfect score: 9

Sequence: 1 CAGGTAAGT 9

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 383533 seqs, 122816752 residues

Total number of hits satisfying chosen parameters: 767066

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued_Patents_NA.*

1: /cgn2_6/ptodata/2/ina/5A_COMB.seq.*

2: /cgn2_6/ptodata/2/ina/5B_COMB.seq.*

3: /cgn2_6/ptodata/2/ina/6A_COMB.seq.*

4: /cgn2_6/ptodata/2/ina/6B_COMB.seq.*

5: /cgn2_6/ptodata/2/ina/PTUS_COMB.seq.*

6: /cgn2_6/ptodata/2/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	9	100.0	9	5	PCT-US92-10024-1
2	9	100.0	14	2	US-08-781-620B-11
3	9	100.0	15	3	US-09-012-366-6
4	9	100.0	17	4	US-08-584-040-4167
5	9	100.0	17	4	US-08-584-040-4168
6	9	100.0	20	1	US-08-714-626-4
7	9	100.0	20	2	US-08-922-169-4
8	9	100.0	20	4	US-09-226-012-31
9	9	100.0	20	4	US-09-323-743-57
10	9	100.0	20	4	US-09-323-743-58
11	9	100.0	20	4	US-09-323-743-59
12	9	100.0	20	4	US-09-323-743-60
13	9	100.0	20	4	US-09-323-743-61
14	9	100.0	20	4	US-09-323-743-62
15	9	100.0	20	4	US-09-556-031-10
16	9	100.0	20	5	PCT-US95-04852-4
17	9	100.0	21	2	US-08-256-426B-274
18	9	100.0	23	4	US-09-098-628-50
19	9	100.0	23	4	US-09-098-628-62
20	9	100.0	28	2	US-08-859-998-1010
21	9	100.0	28	4	US-09-225-928-1010
22	9	100.0	30	1	US-08-123-702-34
23	9	100.0	39	1	US-08-257-073-21
24	9	100.0	39	1	US-08-184-009-143
25	9	100.0	39	2	US-08-458-356-143
26	9	100.0	39	2	US-08-658-665-152
27	9	100.0	39	4	US-08-796-101-128

28	9	100.0	39	4	US-08-460-736-143	Sequence 143, App	
29	9	100.0	39	4	US-09-085-273-152	Sequence 152, App	
30	9	100.0	41	4	US-09-238-356-2	Sequence 2, Appl	
c	31	9	100.0	42	2	US-08-792-075-5	Sequence 5, Appl
32	9	100.0	45	2	US-08-454-557C-54	Sequence 54, Appl	
33	9	100.0	45	2	US-08-340-426D-54	Sequence 54, Appl	
34	9	100.0	45	2	US-08-450-673C-54	Sequence 54, Appl	
35	9	100.0	45	5	PCT-US95-17111A-54	Sequence 54, Appl	
c	36	9	100.0	47	1	US-08-147-696E-23	Sequence 23, Appl
37	9	100.0	47	1	US-08-147-696E-27	Sequence 27, Appl	
c	38	9	100.0	47	1	US-08-484-334-23	Sequence 23, Appl
c	39	9	100.0	47	1	US-08-484-334-27	Sequence 27, Appl
c	40	9	100.0	47	3	US-09-013-092-23	Sequence 23, Appl
c	41	9	100.0	47	3	US-09-013-092-27	Sequence 27, Appl
c	42	9	100.0	47	3	US-09-280-999-23	Sequence 23, Appl
c	43	9	100.0	47	3	US-09-280-999-27	Sequence 27, Appl
c	44	9	100.0	47	4	US-08-952-793-195	Sequence 195, App
c	45	9	100.0	47	5	PCT-US96-09455A-195	Sequence 195, App

ALIGNMENTS

RESULT 1

PCT-US92-10024-1

; Sequence 1, Application PC/TUS9210024

; GENERAL INFORMATION:

; APPLICANT: Chang, Tse Wen

; TITLE OF INVENTION: ANTI-SENSE OLIGONUCLEOTIDES FOR ISOTYPE-SPECIFIC

; NUMBER OF SEQUENCES: 38

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Tanox Biosystems, Inc.

; STREET: 10301 Stella Link Rd.

; CITY: Houston

; STATE: Texas

; COUNTRY: USA

; ZIP: 77025

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette, 3.5 inch

; COMPUTER: IBM PS/2

; OPERATING SYSTEM: DOS 3.30

; SOFTWARE: Wordperfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: PCT/US92/10024

; FILING DATE: 19921118

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US/07/794,395

; FILING DATE: 11/18/91

; ATTORNEY/AGENT INFORMATION:

; NAME: Mirabel, Eric P.

; REGISTRATION NUMBER: 31,211

; REFERENCE/DOCKET NUMBER: TNX91-6-PCT

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (713) 664-2288

; TELEFAX: (713) 664-8914

; INFORMATION FOR SEQ ID NO: 1:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 9 nucleotides

; TYPE: NUCLEIC ACID

; STRANDEDNESS: double-stranded

; TOPOLOGY: linear

; PCT-US92-10024-1

Query Match 100.0%; Score 9; DB 5; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.6e-07;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9

|||||||

DB 1 CAGGTAAGT 9

[illegible]

;
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-4167

Query Match 100.0%; Score 9; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 8.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
|||||

Db 14 CAGGTAAGT 6

RESULT 5

US-08-584-040-4168/C

; Sequence 4168, Application US/08584040

; Patent No. 6346398

; GENERAL INFORMATION:

; APPLICANT: Pavco, Pamela

; APPLICANT: McSwiggen, James

; APPLICANT: Stinchcomb, Dan T.

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE

; TITLE OF INVENTION: TREATMENT OF DISEASES OR

; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS

; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL

; TITLE OF INVENTION: GROWTH FACTOR

; NUMBER OF SEQUENCES: 8502

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Suite 4700

; STATE: Los Angeles

; COUNTRY: California

; ZIP: U.S.A.

; ZIP: 90071-2066

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: Word Perfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/584.040

; FILING DATE: January 11, 1996

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 60/005,974

; FILING DATE: October 26, 1995

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 218/064

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 4168:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-584-040-4168

Query Match 100.0%; Score 9; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 8.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
|||||

Db 13 CAGGTAAGT 5

RESULT 6

US-08-714-626-4

; Sequence 4, Application US/08714626

; Patent No. 5698400

; GENERAL INFORMATION:

; APPLICANT: Cotton, Richard G.H.

; APPLICANT: Youll, Rima

; APPLICANT: Kemper, Borries W.

; TITLE OF INVENTION: Detection of Mutation by

; TITLE OF INVENTION: Resolvase Cleavage

; NUMBER OF SEQUENCES: 8

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Fish & Richardson

; STREET: 225 Franklin Street

; CITY: Boston

; STATE: Massachusetts

; COUNTRY: U.S.A.

; ZIP: 02110-2804

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; COMPUTER: IBM PS/2 Model 502 or 55SX

; OPERATING SYSTEM: MS-DOS (Version 5.0)

; SOFTWARE: Wordperfect (Version 5.1)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/714,626

; FILING DATE:

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US/08/232,530

; FILING DATE:

; ATTORNEY/AGENT INFORMATION:

; NAME: Clark, Paul T.

; REGISTRATION NUMBER: 30,162

; REFERENCE/DOCKET NUMBER: 06253/002001

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (617) 542-5070

; TELEFAX: (617) 542-8906

; TELEX: 200154

; INFORMATION FOR SEQ ID NO: 4:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 20

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-714-626-4

Query Match 100.0%; Score 9; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 8.5e+02;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9

|||||

Db 2 CAGGTAAGT 10

RESULT 7

US-08-922-169-4

; Sequence 4, Application US/08922169

; Patent No. 5958692

; GENERAL INFORMATION:

; APPLICANT: Cotton, Richard G.H.

; APPLICANT: Youll, Rima

; APPLICANT: Kemper, Borries W.

; TITLE OF INVENTION: Detection of Mutation by

; TITLE OF INVENTION: Resolvase Cleavage

; NUMBER OF SEQUENCES: 8

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Fish & Richardson

; STREET: 225 Franklin Street

```
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 502 or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/922,169
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/232,530
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 06253/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-922-169-4

Query Match 100.0%; Score 9; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
Db 2 CAGGTAAGT 10

RESULT 8
US-09-226-012-31
; Sequence 31, Application US/09226012
; Patent No. 6207383
; GENERAL INFORMATION:
; APPLICANT: Keating, Mark T.
; APPLICANT: Splawski, Igor
; TITLE OF INVENTION: MUTATIONS IN AND GENOMIC STRUCTURE OF HERG - A LONG QT
; FILE REFERENCE: 2323-136
; CURRENT APPLICATION NUMBER: US/09/226,012
; CURRENT FILING DATE: 1999-01-06
; EARLIER APPLICATION NUMBER: 09/122,847
; EARLIER FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-226-012-31

Query Match 100.0%; Score 9; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
Db 8 CAGGTAAGT 16

; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 502 or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/922,169
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/232,530
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 06253/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-922-169-4

Query Match 100.0%; Score 9; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
Db 2 CAGGTAAGT 10

RESULT 9
US-09-323-743-57
; Sequence 57, Application US/09323743
; Patent No. 6214986
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett P.
; APPLICANT: Nickoloff, Brian J.
; APPLICANT: Zhang, QingQing
; TITLE OF INVENTION: Antisense Modulation of bcl-x Expression
; FILE REFERENCE: ISPH-0368
; CURRENT APPLICATION NUMBER: US/09/323,743
; CURRENT FILING DATE: 1999-06-01
; EARLIER APPLICATION NUMBER: 09/277,020
; EARLIER FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 09/167,921
; EARLIER FILING DATE: 1998-10-07
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
; US-09-323-743-57

Query Match 100.0%; Score 9; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
Db 2 CAGGTAAGT 10

RESULT 10
US-09-323-743-58
; Sequence 58, Application US/09323743
; Patent No. 6214986
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett P.
; APPLICANT: Nickoloff, Brian J.
; APPLICANT: Zhang, QingQing
; TITLE OF INVENTION: Antisense Modulation of bcl-x Expression
; FILE REFERENCE: ISPH-0368
; CURRENT APPLICATION NUMBER: US/09/323,743
; CURRENT FILING DATE: 1999-06-01
; EARLIER APPLICATION NUMBER: 09/277,020
; EARLIER FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 09/167,921
; EARLIER FILING DATE: 1998-10-07
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
; US-09-323-743-58

Query Match 100.0%; Score 9; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGGTAAGT 9
```

```
Db      4 caggtaaagt 12      |||||
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 11
US-09-323-743-59
; Sequence 59, Application US/09323743
; Patent No. 6214986
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett P.
; APPLICANT: Zhang, QingQing
; TITLE OF INVENTION: Antisense Modulation of bcl-x Expression
; FILE REFERENCE: ISPH-0368
; CURRENT APPLICATION NUMBER: US/09/323,743
; CURRENT FILING DATE: 1999-06-01
; EARLIER APPLICATION NUMBER: 09/277,020
; EARLIER FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 09/167,921
; EARLIER FILING DATE: 1998-10-07
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-323-743-59

Query Match      100.0%; Score 9; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 CAGGTAAGT 9
      |||||
Db      6 caggtaaagt 14

RESULT 12
US-09-323-743-60
; Sequence 60, Application US/09323743
; Patent No. 6214986
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett P.
; APPLICANT: Nickoloff, Brian J.
; APPLICANT: Zhang, QingQing
; TITLE OF INVENTION: Antisense Modulation of bcl-x Expression
; FILE REFERENCE: ISPH-0368
; CURRENT APPLICATION NUMBER: US/09/323,743
; CURRENT FILING DATE: 1999-06-01
; EARLIER APPLICATION NUMBER: 09/277,020
; EARLIER FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 09/167,921
; EARLIER FILING DATE: 1998-10-07
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-323-743-60

Query Match      100.0%; Score 9; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 CAGGTAAGT 9
      |||||
Db      6 caggtaaagt 14

RESULT 13
US-09-323-743-61
; Sequence 61, Application US/09323743
; Patent No. 6214986
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett P.
; APPLICANT: Nickoloff, Brian J.
; APPLICANT: Zhang, QingQing
; TITLE OF INVENTION: Antisense Modulation of bcl-x Expression
; FILE REFERENCE: ISPH-0368
; CURRENT APPLICATION NUMBER: US/09/323,743
; CURRENT FILING DATE: 1999-06-01
; EARLIER APPLICATION NUMBER: 09/277,020
; EARLIER FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 09/167,921
; EARLIER FILING DATE: 1998-10-07
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-323-743-61

Query Match      100.0%; Score 9; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 CAGGTAAGT 9
      |||||
Db      10 caggtaaagt 18

RESULT 14
US-09-323-743-62
; Sequence 62, Application US/09323743
; Patent No. 6214986
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett P.
; APPLICANT: Nickoloff, Brian J.
; APPLICANT: Zhang, QingQing
; TITLE OF INVENTION: Antisense Modulation of bcl-x Expression
; FILE REFERENCE: ISPH-0368
; CURRENT APPLICATION NUMBER: US/09/323,743
; CURRENT FILING DATE: 1999-06-01
; EARLIER APPLICATION NUMBER: 09/277,020
; EARLIER FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 09/167,921
; EARLIER FILING DATE: 1998-10-07
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-323-743-62

Query Match      100.0%; Score 9; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 CAGGTAAGT 9
      |||||
Db      10 caggtaaagt 18
```

Query Match 100.0%; Score 9; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 8.5e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
 Db 12 caggtaagt 20

RESULT 15
 US-09-556-031-10/c
 ; Sequence 10, Application US/09556031
 ; Patent No. 6350868
 ; GENERAL INFORMATION:
 ; APPLICANT: Weston, Brent W.
 ; APPLICANT: Hiller, Kara B.
 ; TITLE OF INVENTION: Antisense Fucosyltransferase Sequences and Methods of
 ; FILE REFERENCE: Use Thereof
 ; CURRENT APPLICATION NUMBER: US/09/556,031
 ; CURRENT FILING DATE: 2000-04-20
 ; PRIOR APPLICATION NUMBER: 60/131,068
 ; PRIOR FILING DATE: 1999-04-26
 ; NUMBER OF SEQ ID NOS: 24
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 10
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence:antisense
 ; OTHER INFORMATION: oligonucleotide
 US-09-556-031-10

Query Match 100.0%; Score 9; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 8.5e+02;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
 Db 13 CAGGTAAGT 5

Search completed: July 21, 2002, 09:47:18
 Job time: 11949 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 21, 2002, 06:18:04 ; Search time 3274.61 Seconds
(without alignments)
37.095 Million cell updates/sec

Title: US-09-754-014-10_COPY_1_9

Perfect score: 9

Sequence: 1 CAGGTAAGT 9

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 13736207 seqs, 6748477542 residues

Total number of hits satisfying chosen parameters: 27472414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

EST:*

- 1: em_estba:*
- 2: em_esthum:*
- 3: em_estin:*
- 4: em_estmu:*
- 5: em_estov:*
- 6: em_estpl:*
- 7: em_estro:*
- 8: em_htc:*
- 9: gb_est1:*
- 10: gb_est2:*
- 11: gb_htc:*
- 12: gb_gss:*
- 13: em_gss_hum:*
- 14: em_gss_inv:*
- 15: em_gss_pln:*
- 16: em_gss_vrt:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
c 1	9	100.0	24	12	AZ478673
c 2	9	100.0	25	12	AZ868376
c 3	9	100.0	29	12	AZ596214
c 4	9	100.0	34	10	H40658
c 5	9	100.0	37	9	AA961266
c 6	9	100.0	38	12	AZ461182
c 7	9	100.0	41	9	AW059896
c 8	9	100.0	50	9	AU102848
c 9	9	100.0	50	9	AU102849
c 10	9	100.0	50	9	AU102850
c 11	9	100.0	50	9	AU103835
c 12	9	100.0	51	10	BI824201
c 13	9	100.0	51	10	D19969
c 14	9	100.0	51	10	BE978061
c 15	9	100.0	54	12	AZ346887
c 16	9	100.0	55	12	AZ919892
17	9	100.0	60	12	B04047

18	9	100.0	61	10	BG271723
19	9	100.0	61	12	BH626214
20	9	100.0	63	12	AQ026164
c 21	9	100.0	65	12	AZ773615
c 22	9	100.0	66	12	B04318
c 23	9	100.0	67	12	CNS03MSX
c 24	9	100.0	68	9	AA138566
c 25	9	100.0	70	9	AA028449
c 26	9	100.0	70	9	AI014447
c 27	9	100.0	71	12	AZ317589
c 28	9	100.0	71	12	AZ633786
c 29	9	100.0	71	12	AG025331
c 30	9	100.0	74	9	AW611631
c 31	9	100.0	76	12	BH234085
c 32	9	100.0	77	9	AV833086
c 33	9	100.0	77	12	AZ495680
c 34	9	100.0	79	9	AA490024
c 35	9	100.0	79	12	FR0024865
c 36	9	100.0	81	12	BH234141
c 37	9	100.0	82	9	AI311824
c 38	9	100.0	82	9	AI353568
c 39	9	100.0	83	12	AZ776655
c 40	9	100.0	84	9	AA835987
c 41	9	100.0	85	9	AI789299
c 42	9	100.0	86	9	AI353306
c 43	9	100.0	86	10	W63933
c 44	9	100.0	87	9	AA231789
45	9	100.0	89	10	N88337

ALIGNMENTS

RESULT 1
AZ478673/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
FEATURES

AZ478673 24 bp DNA linear GSS 04-OCT-2000
IM0298J20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0298J20 R, DNA sequence.
AZ478673
AZ478673.1 GI:10637794
GSS.
house mouse.
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 24)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0298 row: J column: 20
Seq primer: CACACAGGAACACGATGACC
Class: plasmid ends
High quality sequence stop: 24.
Location/Qualifiers
1..24
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0298J20"
/clone_lib="Mouse 10kb plasmid UUGC1M library"

```

/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gil14732114[gb]AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
BASE COUNT      6 a      3 g      7 t
ORIGIN

```

```

Query Match      100.0%; Score 9; DB 12; Length 24;
Best Local Similarity 100.0%; Pred. No. 6.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 CAGGTAAGT 9
    |||||
Db 14 CAGGTAAGT 6

```

RESULT 2

```

AZ868376
LOCUS      25 bp      DNA      linear      GSS 21-FEB-2001
DEFINITION 2M0180N05F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
Clone UUGC2M0180N05 F, DNA sequence.

```

```

AZ868376
ACCESSION  A2868376
VERSION     GI:13071628
KEYWORDS    GSS.
SOURCE      house mouse.

```

```

ORGANISM    Mus musculus

```

```

REFERENCE   1
AUTHORS     Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
            ,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
            and Wright,D.,Weiss,R.
TITLE       Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
JOURNAL     Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000 Std Error: 0.00
            Plate: 0180 row: N column: 05
            Seq primer: CGTTGTAAACGACGCCAGT
            Class: plasmid ends
            High quality sequence stop: 25.

```

```

FEATURES             source

```

```

1..25
    /organism="Mus musculus"
    /strain="C57BL/6J"
    /db_xref="taxon:10090"
    /clone="UUGC2M0180N05"

```

```

/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gil14732114[gb]AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
BASE COUNT      8 a      3 c      8 g      6 t
ORIGIN

```

```

Query Match      100.0%; Score 9; DB 12; Length 25;
Best Local Similarity 100.0%; Pred. No. 6.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 CAGGTAAGT 9
    |||||
Db 4 CAGGTAAGT 12

```

RESULT 3

```

AZ596214/c
LOCUS      29 bp      DNA      linear      GSS 13-DEC-2000
DEFINITION 1M0409A21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
Clone UUGC1M0409A21 F, DNA sequence.

```

```

AZ596214
ACCESSION  A2596214
VERSION     GI:11718404
KEYWORDS    GSS.
SOURCE      house mouse.

```

```

ORGANISM    Mus musculus

```

```

REFERENCE   1
AUTHORS     Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
            ,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
            and Wright,D.,Weiss,R.
TITLE       Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
JOURNAL     Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000 Std Error: 0.00
            Plate: 0409 row: A column: 21
            Seq primer: CGTTGTAAACGACGCCAGT
            Class: plasmid ends
            High quality sequence stop: 29.

```

```

FEATURES             source

```

```

1..29
    /organism="Mus musculus"
    /strain="C57BL/6J"
    /db_xref="taxon:10090"

```

```

/clone="UUG1M0409A21"
/clone_lib="Mouse 10kb plasmid UUG1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMDA2 (gi14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid RI. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
BASE COUNT      6 a 11 c 6 g 6 t
ORIGIN

Query Match      100.0%; Score 9; DB 12; Length 29;
Best Local Similarity 100.0%; Pred. No. 6.6e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
    |||||
Db 22 CAGGTAAGT 14

RESULT 4
H40658/c
LOCUS
DEFINITION
H40658 34 bp mRNA linear EST 31-JUL-1995
IMAGE:174613 5' similar to SP:SSRB-CANFA P23438 SIGNAL SEQUENCE
RECEPTOR BETA SUBUNIT PRECURSOR ;, mRNA sequence.
ACCESSION H40658
VERSION H40658.1 GI:916710
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 34)
Hillier, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M., Holman, M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M., Parsons, J., Rifkin, L., Rohlfing, T., Soares, M., Tan, F., Trevaskis, E., Waterston, R., Williamson, A., Wohlmann, P. and Wilson, R.
The Washo-Merck EST Project
Unpublished (1995)
Contact: Wilson RK
Washington University School of Medicine
444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Insert size: 781
High quality sequence starts: 1
High quality sequence stops: 1
Source: IMAGE Consortium, LNL
This clone is available royalty-free through LNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
Trace considered overall poor quality
Possible reversed clone: similarity on wrong strand
Insert Length: 781 Std Error: 0.00
Seq primer: M3Rev
High quality sequence stop: 1.

```

```

FEATURES
source
Location/Qualifiers
1..34
/organism="Homo sapiens"
/db_xref="CDB:3836648"
/db_xref="taxon:9606"
/clone="IMAGE:174613"
/clone_lib="Soares adult brain N2b5HB55Y"
/sex="Male"
/dev_stage="55-year old"
/lab_host="DH10B (ampicillin resistant)"
/notes="Organ: brain; Vector: pT73D (Pharmacia) with a modified polylinker; Site: Not I; Site_2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer [5' TGTTACCAATCTGAAGTGGAGCGCGCGCTTTTTTTTTTTT 3'], double-stranded cDNA was size selected, ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of a modified pT73 vector (Pharmacia). Library went through one round of normalization to a Cot = 53. Library constructed by Bento Soares and M. Fatima Bonaldo. The adult brain RNA was provided by Dr. Donald H. Gilden. Tissue was acquired 17-18 hours after death which occurred in consequence of a ruptured aortic aneurysm. RNA was prepared from a pool of tissues representing the following areas of the brain: frontal, parietal, temporal and occipital cortex from the left and right hemispheres, subcortical white matter, basal ganglia, thalamus, cerebellum, midbrain, pons and medulla."
BASE COUNT      9 a 12 c 5 g 8 t
ORIGIN

Query Match      100.0%; Score 9; DB 10; Length 34;
Best Local Similarity 100.0%; Pred. No. 6.6e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGGTAAGT 9
    |||||
Db 31 CAGGTAAGT 23

RESULT 5
AA961266
LOCUS
DEFINITION
AA961266 37 bp mRNA linear EST 23-JUN-1998
IMAGE:1564496 3' similar to SW:YGF4.YEAST P53173 HYPOTHETICAL 15.9
KD PROTEIN IN OLE1-DUPL INTERGENIC REGION. ;, mRNA sequence.
ACCESSION AA961266
VERSION AA961266.1 GI:3127283
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 37)
NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Email: cgapsb@remail.nih.gov
This clone is available royalty-free through LNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
Trace considered overall poor quality
Insert Length: 681 Std Error: 0.00
Seq primer: -40ml3 fwd. Et from Amersham
High quality sequence stop: 1.
Location/Qualifiers
1..37
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:1564496"
/clone_lib="Soares_NFL_T_GBC_S1"
FEATURES
source

```

/lab_host="DH10B"
/note="Organ: pooled; Vector: pF73D-Pac (Pharmacia) with a modified polylinker; Site_1: Not I; Site_2: Eco RI; Equal amounts of plasmid DNA from three normalized libraries (fetal lung NBHL19W, testis NHT, and B-cell NCI-CGAP-GCB1) were mixed, and ss circles were made in vitro. Following HAP purification, this DNA was used as tracer in a subtractive hybridization reaction. The driver was PCR-amplified cDNAs from pools of 5,000 clones made from the same 3 libraries. The pools consisted of I.M.A.G.E. clones 297480-302087, 682632-687239, 726408-728711, and 729096-731399. Subtraction by Bento Soares and M. Fatima Bonaldo."
BASE COUNT 14 a 4 c 11 g 8 t
ORIGIN

Query Match 100.0%; Score 9; DB 9; Length 37;
Best Local Similarity 100.0%; Pred. No. 6.7e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CAGGTAAGT 9
|||||
Db 16 CAGGTAAGT 24

RESULT 6
AZ461182/c
LOCUS
DEFINITION
A2461182 38 bp DNA linear GSS 04-OCT-2000
clone UUGC1M0266M21 R, DNA sequence.
ACCESSION
VERSION
A2461182.1 GI:10619307
KEYWORDS
SOURCE
house mouse.
ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1 (bases 1 to 38)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly ,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
84112, USA
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0266 row: M column: 21
Seq primer: CACACAGGAACAGCATGACC
Class: plasmid ends
High quality sequence stop: 38.
Location/Qualifiers
1..38
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0266M21"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a

FEATURES
source
1..38
Location/Qualifiers
/organism="Mus musculus"
/db_xref="taxon:10090"
/clone="UUGC1M0266M21"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a

0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
BASE COUNT 11 a 13 c 2 g 12 t
ORIGIN

Query Match 100.0%; Score 9; DB 12; Length 38;
Best Local Similarity 100.0%; Pred. No. 6.7e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CAGGTAAGT 9
|||||
Db 17 CAGGTAAGT 9

RESULT 7
AW059896
LOCUS
DEFINITION
30_comp15-s30 UPC15 Homo sapiens cDNA similar to CYTOCHROME C OXIDASE POLYPEPTIDE VIB, mRNA sequence.
ACCESSION
VERSION
AW059896.1 GI:6652218
KEYWORDS
SOURCE
human.
ORGANISM

Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 41)
Brenner,S., Williams,S.R., Vermaess,E.H., Storck,T., Moon,K., McCallum,C., Mao,J.I., Kirchner,J.J., Eieir,S., DuBridge,R.B., Burcham,F. and Albrecht,G.
In vitro cloning of complex mixtures of DNA on microbeads: Physical separation of differentially expressed cDNAs
Proc. Natl. Acad. Sci. U.S.A. 97 (4), 1665-1670 (2000)
20144098
Contact: Burcham TS
LYNX Therapeutics, Inc.
25861 Industrial Blvd., Hayward, CA 94545, USA
Tel: 510 670 9338
Fax: 510 670 9302
Email: timb@lynxgen.com
Sequence obtained from LYNX Therapeutics Megasort technology. High quality sequence stop: 41.
Location/Qualifiers
1..41
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="UPC15"
/cell_type="monocytic leukemia"
/cell_line="THP-1 (TIB-202)"
/note="Vector: PCR2.1; Cloning of PCR products from micro-beads carrying 3' end of up-regulated cDNA. THP-1 cells induced with 100 nM PMA in DMSO."
BASE COUNT 12 a 5 c 9 g 15 t
ORIGIN

Query Match 100.0%; Score 9; DB 9; Length 41;
Best Local Similarity 100.0%; Pred. No. 6.7e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;


```
Db 23 CAGGTAAGT 15

RESULT 14
BE978061/c
LOCUS
DEFINITION
bs73c08.y1 Drosophila melanogaster adult testis library Drosophila
melanogaster cDNA clone bs73c08 5', mRNA sequence.
ACCESSION
BE978061
VERSION
BE978061.1 GI:10609159
KEYWORDS
EST.
SOURCE
fruit fly.
ORGANISM
Drosophila melanogaster
Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;
Pterygota; Neoptera; Endopterygota; Diptera; Brachycera;
Muscomorpha; Ephydroidea; Drosophilidae; Drosophila.
1 (bases 1 to 51)
Andrews, J., Bouffard, G. and Oliver, B.
Drosophila melanogaster testis expressed sequence tags
Unpublished (1999)
Contact: Brian Oliver
Laboratory of Cellular and Developmental Biology
NIDDK, National Institutes of Health
6 Center Drive MSC 2715, Bldg 6, Rm B1-13, Bethesda, MD 20892 USA
Fax: (301) 496 5239
Email: oliver@helix.nih.gov,
http://www.niddk.nih.gov/intram/people/boliver.htm
Tissue isolation and library construction performed at the National
Institute of Diabetes and Digestive and Kidney Diseases, NIH (see
http://www.niddk.nih.gov/intram/people/boliver.htm). DNA sequencing
and analyses performed by National Institutes of Health Intramural
Sequencing Center (NISC; see http://www.nisc.nih.gov).
Plate: 73 row: c column: 08
Seq primer: M13RP1 reverse primer (ABI).
Location/Qualifiers
1..51
/organism="Drosophila melanogaster"
/strain="y[*] w[67cl]/Y"
/db_xref="taxon:7227"
/clone="bs73c08"
/clone_lib="Drosophila melanogaster adult testis library"
/sex="male"
/dev_stage="1-5 day adult"
/lab_host="SOLR (Stratagene)"
/Note="Organ: testis; Vector: pBluescript SK (Stratagene);
Site 1: EcoR I; Site 2: Xho I; Testes dissected from 1-5
day adult y[*] w[67cl]/Y males raised at 25oc. RNA
isolated using Trizol (Life Technologies) and a single
round of Poly(A)+ selection using Oligotex (Qiagen). cDNA
library constructed using Stratagene ZAP-cDNA synthesis
kit. Oligo dt-primed, size fractionated -1-6 kb, and
directionally cloned at EcoRI and XhoI in Uni-ZAP XR.
Following a single round of amplification pBluescript SK
phagemids were mass excised. A distribution channel for
clones is being sought, but not currently available.
Requests for clones cannot be honored."
BASE COUNT 12 a 11 c 12 g 16 t
ORIGIN
Query Match 100.0%; Score 9; DB 10; Length 51;
Best Local Similarity 100.0%; Pred. No. 6.9e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CAGGTAAGT 9
|||||
Db 41 CAGGTAAGT 33

RESULT 15
AZ346887/c
LOCUS
DEFINITION
1M0082P17F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
ACCESSION
AZ346887
VERSION
AZ346887.1 GI:10426124
KEYWORDS
GSS.
SOURCE
house mouse.
ORGANISM
Mus musculus
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1 (bases 1 to 54)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly
, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A.
and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: dunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0082 row: P column: 17
Seq primer: CGTTGTAAACGACGCGCCAGT
Class: plasmid ends
High quality sequence stop: 54.
Location/Qualifiers
1..54
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0082P17"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, P-"
/Note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptored DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 (gil4732114[gb|AF129072.1], a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptored mouse DNA was annealed to
adaptored vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
BASE COUNT 11 a 13 c 14 g 16 t
ORIGIN
Query Match 100.0%; Score 9; DB 12; Length 54;
Best Local Similarity 100.0%; Pred. No. 6.9e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CAGGTAAGT 9
|||||
Db 42 CAGGTAAGT 34

Search completed: July 21, 2002, 09:11:03
Job time: 10379 sec
```

